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 Abstract 
Microbial natural products are a fundamental source of new chemical entities and are well represented 
as a substantial component of today’s pharmaceutical and agrochemical compendium. Despite the 
past problems of microbial biodiversity with the excessive rediscovery of known metabolites, recent 
advances in the genome sequencing have revealed the hidden potential of microorganisms to produce 
more diverse secondary metabolites than ever imagined. This thesis is focused on the application of 
approaches for the exploration of silent secondary metabolism of microorganisms obtained from 
sheep faeces. This includes the high-throughput cultivation and extraction of microbes under various 
cultivation media and conditions (called MATRIX), followed by advanced mass spectrometry 
(UHPLC-QTOF-MS/MS) and Global Natural Product Social (GNPS) molecular networking based 
dereplication strategies. Microbial co-cultivation based activation of silent secondary metabolites was 
also investigated to explore the microbial chemical diversity. Targeted microbial metabolites were 
then purified using different chromatographic techniques such as solid phase fractionation, 
preparative and semi-preparative HPLC. In addition, different spectroscopic methods (UV-vis, 
HRMS, [a]D, 1D and 2D NMR), total synthesis, chemical derivatization (C3 Marfey’s analysis) were 
adopted for structure elucidation and characterization of isolated microbial metabolites.  
 
Chapter 1 highlights the opportunities of microbial natural products and the strategies to explore the 
hidden capacities of microbial secondary metabolism. This chapter reviews some commonly used 
strategies reported in the recent literature, including (i) chemical dereplication, (ii) exploring 
microbes from unusual sources, (iii) variation in the culture and media conditions, (iv) microbial co-
cultivation and (v) bioassay-guided isolation of metabolites. 
 
Chapter 2 summarizes the assemble of a microbial library from sheep faecal samples supplied from 
sheep farms in NSW, Australia; and assembly of a microbial crude extract library obtained from the 
solid vs liquid cultivation of isolated microbes. It also describes prioritization of isolates by the 
chemical and biological profiling of microbial crude extracts including the co-cultivation and 
bioassay-guided isolation methods. This chapter briefly discusses one example of bioassay-guided 
approach through the isolation and characterization of bioactive metabolites.  
 
Chapter 3 describes the MATRIX cultivation and identification of suitable culture conditions for the 
production of metabolites by fungus, Talaromyces sp. CMB-NF091. Scaled-up cultivation on ISP2 
agar medium afforded the isolation and identification of a novel cyclic hexapeptide, talaropyrolide 
A, which exhibits an unusual binary conformation. The structure was assigned on the basis of detailed 
spectroscopic analysis (1D and 2D NMR, HRESIMS) and chemical derivatization (C3 Marfey’s 
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analysis). The binary conformation was confirmed by analysing the NMR spectroscopic data in 
different solvents and comparing with the synthetic model compounds. The isolated peptide was 
evaluated for antimicrobial properties against MDR strains and showed bacteriostatic activity against 
methicillin resistant Staphylococcus aureus (MRSA) and vancomycin resistant Enterococcus faecalis 
(VRE). The compound was also tested for cytotoxicity properties against cancer cell lines and showed 
no cytotoxic activity. 
 
Chapter 4 discusses the isolation and characterization of eight new chlorinated depsidone analogues, 
spiromastixones P-W, along with four known depsidones, from a sheep faeces derived fungus, 
Spiromastix sp. CMB-NB162. The anti-microbial and cytotoxic potential of the isolated depsidones 
are also described. 
 
Chapter 5 illustrates the effects of varying culture conditions (MATRIX) on the secondary 
metabolism of fungus Spiromastix sp. CMB-NB162 and GNPS molecular networking based 
identification and purification of new cyclic tetrapeptides, spiromastides A-E. Chemical 
derivatization (C3 Marfey’s analysis) of the cyclic tetrapeptides was used to confirm the absolute 
configuration of the amino acid residues.  
 
Chapter 6 investigates the application of microbial co-cultivation based activation of silent secondary 
metabolisms. Co-cultivation of fungus Purpureocillium sp. CMB-NF122 with co-isolated 
Streptomyces sp. CMB-NB198 resulted in the activation of antibacterial alternariol. Another co-
cultivation of a co-isolated fungus Penicillium sp. CMB-NF125 with the same Streptomyces sp. 
CMB-NB198 resulted up-regulation in the production of a fungal mycotoxin trypacidin by the fungus, 
and a new congener of the hazimycin class, pre-hazimycin (2-2¢-N-N-diformyl-dityrosine-diamide) 
by the Streptomyces CMB-NB198. The detailed study was performed to understand the basic 
mechanism of activation/upregulation of the metabolites involved in the co-cultivation.  
 
Chapter 7 describes the total synthesis and structure rearrangement of anthranilic acid derived 
hydrazone natural products, first reported as penipacids A-E, isolated from a marine derived fungus 
Penicillium paneum. This chapter draws attention to the chemically reactive nature of hydrazides and 
their potential to form hydrazone artefacts during extraction and handling.  
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1 Chapter 1: Introduction 
1.1 Natural products as a source of drugs and drug leads 
Natural products have been a major source of pharmaceutical and agrochemical discovery throughout 
the history.1,2 Approximately, 50% of approved small-molecule drugs in last two decades have 
originated from natural products, including unaltered natural compounds, semi-synthetic derivatives 
of natural products and synthetic natural mimics derived from natural product template of 
pharmacophore.3,4 Despite being challenged by combinatorial chemistry coupled with high-
throughput screening, which can generate and screen large libraries of synthetically diverse chemistry 
in a short time, natural products continue to offer competitive advantages.2 The value of natural 
products lies on the variety of functional and stereochemical centres, higher bond saturation and lower 
hydrophobicity, which is considered to be pharmacologically favourable in drug discovery.3 Natural 
products and their analogues are also meaningful to illustrate the structure-activity relationships and 
key to optimize the pharmaceutical products of clinically relevant entities.5 
 
1.2 Microbial natural products  
Amongst the various resources for the discovery of natural products, microorganisms are considered 
as one of the prolific sources of exceptionally diverse secondary metabolites. Taking into 
consideration that microbes live in a complex eco-system, are involved in, and have evolved from, 
complex ecological interactions between organisms and the environment. Therefore, microbial 
secondary metabolites have been optimized to interact with biological macromolecules, making them 
inherently bioavailable and ideal for the development of new therapeutics.3-5 As a result, microbial 
natural products based drug discovery provides comparatively high quality hits. Moreover, the 
remarkable capacity of microorganisms to survive in diverse ecological environments, from terrestrial 
to marine habitats, added additional chemical diversity to microbial secondary metabolites. The 
production of metabolites by direct in situ fermentation also provide access to reliable and scalable 
supply, inclusive of analogues to support structure-activity relationship studies.6 
 
1.3 Fungi, a major source of natural products 
Microbial secondary metabolites, especially from filamentous fungi, have been used for decades as 
one of the most successful sources of drugs to treat diseases.7 Though the first systemic study on 
fungal secondary metabolism was reported in 1922 by Harold Raistrick,8 the serendipitous discovery 
of penicillin (1.01) from the filamentous fungus, Penicillium notatum, by Alexander Fleming in 1929, 
and its broad spectrum therapeutic use, promoted the intensive investigation on fungal natural product 
discovery.3 Since then, the search for bioactive fungal secondary metabolites has continued unabated 
and offered thousands of structurally and functionally diverse metabolites. Most of these metabolites 
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showed potent and highly selective biological properties and are widely used in medicine for the 
treatment of a range of many diseases (Figure 1.1).9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The fungal sources for new metabolites have been extended from saprophytic terrestrial strains to 
marine habitats and living plants with their endophytes. By far, the most fungal metabolites reported 
are produced by ascomycetes (e.g. Penicillium and Aspergillus sp.), with other from basidiomycetes 
and zygomycetes.7 A total of ~120,000 fungal species have been recognized from diverse ecological 
spaces, contributing to biosynthetically diverse secondary metabolites. However, phylogenetic 
identification and in situ detection of individual microbial cells without cultivation revealed 
multispecies enrichment of microorganisms in soil samples.10,11 Current estimations suggest that the 
global fungal biome includes 1.5 million fungal strains.12 That suggests the inability to systematic 
cultivation of  most naturally occurring fungus and only a small portion of fungal chemical diversity 
has been studied for secondary metabolite production. 
 
1.4 Challenges and opportunities to hustle fungal biodiscovery 
Despite the historical impact of fungal natural products as a valuable source of drugs and drug leads, 
fungal biodiscovery has historically been confronted by various challenges, leading to a decline in 
the discovery of new chemical scaffolds. In recent years, fungal biodiscovery have been challenged 
by excessive re-discovery of known metabolites as well as the underestimation of the capacity of 
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fungal secondary metabolism. The main reasons contributing to these challenges are inability to 
culture all microbial isolates from the environmental samples and traditional approaches to harness 
the biosynthetic potential of fungi.1 Nevertheless, the demand for new bioactive compounds capable 
of treating resistant pathogenic microbial and viral infections, as well as neoplastic diseases, is urgent 
and compelling.6-8  
 
It is well known that the biosynthesis genes encoding for fungal secondary metabolites are mostly 
organized in large gene clusters. Such gene clusters code for core enzymes belonging to well-defined 
families, include polyketide synthases (PKSs), non-ribosomal peptide synthases (NRPSs) and 
dimethylallyltryptophan synthases (DMATSs).12 However, these secondary metabolite gene clusters 
are controlled by a complex regulatory system, composed of multiple proteins and complexes. These 
regulatory proteins are known to be responsive to various physiological and environmental stimuli, 
such as carbon and nitrogen sources, ambient temperature, light, pH, air composition, iron availability 
and biotic factors.13 Therefore, understanding the metabolic and regulatory mechanisms that can 
activate these genes, is vital for the discovery and exploitation of fungal secondary metabolism.14 
Opportunely, recent advances across the fields of microbial genomics and analytical techniques 
revealed the presence of “silent/cryptic” biosynthetic gene clusters (BGCs).2,15-17 These gene clusters 
remain cryptic under standard laboratory conditions. As a result, it is now accepted that microbes 
have far greater potential to produce unique secondary metabolites than previously imagined.  
 
For example, a genome analysis of Aspergillus nidulans, revealed a genetic capacity to produce over 
53-putative secondary metabolites. This capacity was not been represented by the secondary 
metabolites isolated from this fungus to date, with metabolites from only 5/27 NRPS gene clusters 
characterized so far.18 Recent studies demonstrated that a well-known secondary metabolite producer, 
Aspergillus flavus, had a genome size of 36.8 Mbp, harboring about 35 PKS and 24-NRPS 
biosynthetic gene clusters (BGCs), while A. fumigatus was predicted to have 14 PKS and 14-NPRS 
gene clusters.19  
 
Along with the in silico gene cluster analysis, several genetic engineering based approaches, such as 
specific pathways overexpression and stimulation of specific transcription factors, awaking of silent 
gene clusters by chromatin modification, have proved successful for discovering unique/silent fungal 
metabolites.20 For example, a 2006 study by Bok et al.14 reported that the modulation of LaeA in the 
transcriptional secondary metabolite cluster of A. nidulans, characterized an antitumor compound 
terrequinone A, (1.06), which was unidentified before in this fungus. Another study by Clevenger et 
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al. 21 demonstrated the expression of biosynthetic gene clusters of A. nidulans by heterologous gene 
expression and identified 15 new metabolites including a new macrolactone, valactamide A (1.07).  
 
 
 
 
 
 
 
 
A 2015 study by Albright et al. also reported the genetic and chemical reductions in histone 
deacetylase activity of A. nidulans, resulted the upregulated production of fellutamide B (1.08) with 
other two antibiotics.22 Scherlach et al. revealed that deletion of N-acetyltransferase B gene (nnaB) 
in A. nidulans resulted in slow growing mutant strain (DnnaB) producing novel red colour compounds 
pheofungin A-D (1.09 -1.12).23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5 Current strategies in the search for new metabolites 
Although, the recent advances in genome analysis allowed the identification of silent gene clusters 
and expression of silent metabolism by generic manipulation, the unambiguous identification of 
individual metabolites in an fungal extract using generic methods remains challenging.24 Thus, in 
addition to refactoring biosynthetic gene clusters via genome editing, there are several other 
approaches that have been reported for the activation of cryptic BGCs. Moreover, adaptation of 
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advanced analytical approaches, particularly mass spectrometry (MS/MS) based dereplication 
significantly enhanced the microbial drug discovery paradigm.1 The following sections of this chapter 
will provide a brief overview of the strategies to explore the novel fungal secondary metabolites. 
 
(i) Chemical dereplication 
Historically, the UV and liquid chromatography (LC) based identification and isolation of microbial 
secondary metabolites led to the discovery of thousands of secondary metabolites.4 Later on, the 
introduction of LC-hyphenated techniques (LC-UV-DAD, LC-MS, LC-NMR) constrained the 
isolation and identification of novel natural products.25 However, novel approaches to enhance the 
dereplication has become a matter of great interest in recent years to avoid the re-isolation of known 
metabolites as well as the targeted isolation of new metabolites.  
 
A breakthrough in natural product analytics has been the introduction of ultra-high pressure liquid 
chromatography (UHPLC) in combination of time-of-flight (TOF) MS detector.26 Several approaches 
were further adopted to process large and complex three-dimensional UHPLC-HRMS data sets, such 
as principal component analysis (PCA) and cluster analysis, as a very efficient dereplication tool.27 
Although, LC-HRMS-PCA has been a successful tool, several recent approaches of MS/MS-based 
dereplication has been regarded as more accurate method for dereplication as similar metabolites 
possess similar MS/MS fragmentation pattern.28  
 
There are several databases specific for microbial secondary metabolites with their chromatographic 
and MS or MS/MS profiles. For example, Kildgaard et al. listed about 1300 compounds for the 
dereplication of marine-derived fungal secondary metabolites.29 A number of public and commercial 
databases for dereplication of natural products include DEREP-NP,30 Antibase, Marin-lit, 
(http://pubs.rsc.org/marinlit/introduction), Pubchem (https://pubchem.ncbi.nlm.nih.gov), ZINC,31 
NAPROC-13,32 NMRShiftDB (https://nmrshiftdb.nmr.uni-koeln.de). The recently introduced Global 
Natural Products Social Molecular Networking (GNPS; http://gnps. ucsd.edu),33 provides an open 
access data driven platform, that allowed the analysis of high-resolution tandem mass spectrometry 
(MS/MS) data.   
In recent years, GNPS based molecular networking received a great interest with its advanced 
application in natural-product-related research projects involving dereplication and quantification, 
discovery, biosynthesis and chemical ecology.34,35 For example, the first application of GNPS 
molecular networking analysis of HR-MS/MS spectra of 35 Salinospora strains isolated from ten 
global collection sites, facilitated the identification of known metabolites and their derivatives, along 
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with the  identification of new analogues of rare classes of metabolites produced by Salinospora sp. 
(e.g. salaniketal, staurosporin, and rifamycin analogues). Careful analysis of the clusters in the 
molecular network followed by large scale cultivation revealed the production of new sulfur 
containing peptide retimycin A (1.13) by Salinospora sp. Molecular networking coupled with genome 
sequence data for Salinospora sp. also provides a rapid method to access the relationships between 
the presence of a BGC and the detection of its secondary metabolic production.36 
 
 
 
 
 
Several studies also reported the application of molecular networking to a diverse array of marine 
and terrestrial microbial samples to replicates the known molecules, along with the identification of 
related analogues of rare molecules.37 
Naman et al. reported the untargeted metabolomic study of 10 organic extracts from Symploca sp., 
revealed the presence of several interesting chemical leads in the organic extracts. Subsequent target-
directed isolation revealed the identification of a relatively rare gem-dichlorovinylidene moiety, 
caracolamide A (1.14), an ion channel modulating dichlorovinylidene containing phenethylamide 
from Panamanian marine cyanobacterium Symploca sp.38 Other examples include the discovery of 
structurally intriguing anti-fungal and antitumor lipopeptides, malyngamide C (1.15) and 
malyngamide C acetate (1.16) from O. hirsuta ;39 a series of new anti-bacterial amino-polyketide, 
vitroprocines (1.17) from marine-derived Vibrio sp.;40 a new congeners of cyanotoxins, microcystin 
MthyR (1.18) from a cyanobabterium,41 using GNPS molecular networking analysis of HR-MS/MS 
data.   
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(ii) Investigating microbes from unusual source 
In the ongoing search for new drug leads, it has been postulated that, emphasis should be given to 
explore the under-explored micro-environments, that could lead to the discovery of new chemical 
species.42 Soil (including terrestrial soil), plants (endophytes) and marine sources (including the deep-
sea sediment, sponges, tunicates, corals, mangrove, mollusk) already been proved as the fertile 
sources of potential microbes with diverse secondary metabolic profiles.43 Among the recently 
introduced unique micro-environments, animal gastro-intestinal tract (GIT), such as from fish GIT, 
been proved as a rich harbor of microbes.44 For example, secondary metabolites isolated from fish 
GIT included an antibacterial lipid sebastenoic acid (1.19) from S. hygroscopius from Halichoeres 
bleekeri fish; perinadine (1.20) and scalusamides A-C (1.21-1.23) from Penicillium citrinum isolated 
from parrot fish.24  
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Eukaryote hosts including both invertebrates (e.g. nematodes) and arthropods (e.g. ants, wasps, 
beetles) also become a powerful source of microbes, that produce metabolites with significant 
anticancer and antimicrobial properties.45  
 
A 2010 study by Niu et al. reported the isolation of four nemadotoxic aurovertin-type metabolites, 
including a new metabolite aurovertin I (1.24) from a fungus Pochonia chlamydoporia, isolated from 
a root-knot tobacco nematode parasite Meloidogyne incognita.46 Another study by Oh et al. reported 
the isolation of a 20-carbon polyene peroxide, mycangimycin (1.25) with pronounced antifungal 
activity, from a southern pine beetle host derived actinomycete.47 
 
 
 
 
 
 
 
 
 
 
(iii) Bioassay-guided isolation 
Bioactivity guided fractionation has proven successful as well as established platform to isolate bio-
active metabolites from natural sources. This has been a prioritizing tool in microbial natural product 
research for decades, in particular search for new anti-cancer, antibiotic, anti-oxidant and anti-
inflammatory agents.48 The discovery of penicillin by tracking the antibiotic activity of P. notatum, 
is the historical example of bioactivity guided discovery of a fungal secondary metabolites.49 
Mevinolin (later described as lovastatin) also discovered as a bio-guided search for highly potent 
competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase.50 
 
Bioassay-guided isolation of active compounds can lead to false result as a “cocktail-effect”, because 
of the complexity of natural product extracts, where the activity of known compounds can mask the 
activity of interesting target compounds.51  However, the recent advances in the chromatographic 
separation have provided new possibilities to accelerate the bioassay-guided fractionation. The micro-
fractionation approach of HPLC separation with parallel QTOF-MS data acquisition has been 
extended to the high-throughput screening (HTS) of thousands of fractions to identify the compounds 
with targeted biological activity.52  
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Several approaches also include the screening of microbial libraries for a desired activity, has proven 
successful in the discovery of new bioactive compounds. A 2009 by Parish et al.53 reported the 
screening of a library of secondary metabolites from both actinomycetes and fungi, in search for 
molecules capable of inhibiting the SecA protein (involved in bacterial resistance to toxins). The 
study resulted in the isolation and characterization of a new cis-decalin secondary metabolite, 
pannomycin (1.26), isolated from an extract of a fungus Geomyces pannorum. Thaker et al.54 also 
reported the activity-guided isolation of an antibiotic factumycin (1.27), active against Gram-negative 
bacteria. The study also found the synergistic activity of factumycin with tetracycline, which offer a  
possible new application of factumycin as a lead in Gram-negative targeted antibiotic combination 
therapy.  
 
 
 
 
 
 
 
 
 
 
 
Crawford et al. reported the bioassay-guided isolation of cyclic depsipeptides, xenematides (1.28-
1.31) from a nematode (Steinernema carpocapsae) associated Gram-negative bacteria X. 
nematophila.55  
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A recent study by Naman et al. reported a LC-MS/MS molecular networking integrated with 
bioassay-guided isolation of a new and cyclic octapeptide, samoamide A (1.32) from an American 
Samoan marine cyanobacteria, possessed dipeptidyl peptidase enzyme inhibition activity against non-
small-cell-lung cancer cells.56 
 
 
 
 
 
 
 
 
 
 
(iv) Variation in the culture and media conditions 
Apart from the molecular techniques, cultivation-dependent approaches have been widely 
implemented to unveil the microbial chemical diversity.57 It was always a challenge to provide the 
optimal conditions for specific organisms in regard of their environmental ecology (Figure 1.2). 
However, the concept “One Strain Many Compounds OSMAC)” forwarded by Bode et al. in 2002, 
based on the assumptions that biosynthetic pathways of secondary metabolites are influenced and 
regulated at transcriptional, translational and enzymatic levels by different external factors (e.g., 
media composition, temperature, pH, salinity and aeration rate). These factors can be applied as 
triggers to turn on or up-regulate the expression of the silent biosynthetic gene clusters.57 Many 
successful cases have been reported the application of this very simple and effective OSMAC 
approach for diversifying microbial secondary metabolites, some examples are summarized below.  
 
 
Figure 1.2: Examples of differences between natural growth and standard laboratory conditions. 
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The standard cultivation of Sphaeropsidales sp. resulted in the production of antifungal 
spirobisnaphthalene compound cladosporin bisepoxide (A). However, Bode et al. (2002) reported 
that the addition of oat to the cultivation media of Sphaeropsidales sp. F-24707, resulted the 
production of eight new spirobisnaphthalene analogues cladospirones  B-I (1.33-1.40).57  
 
 
 
 
 
 
 
 
 
 
 
 
 
A 2007 study by Paranagama et al. reported that a simple changes in the culture medium, such as 
from tap water to distilled water resulted in the production of six new fungal metabolites, cytosporons 
F-I (1.41-1.44), quadriseptin A (1.45), and 5¢- hydroxymonocillin III (1.46).58 
 
 
 
 
 
 
 
 
 
 
 
 
 
A study by Kirstin et al. (2011) demonstrated the effect of environmental factors on the secondary 
metabolism of fungus. In this study they reported the production of two novel polyketides, 
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sanghaspirodins A and B (1.47-1.48) by A. nidulans, when cultivated in a media with a limited supply 
of nitrogen.23 Another 2012 study reported the differential expression of silent BGCs of A. nidulans 
under continuous growth with limited supply of nitrate, orthophosphate and glucose, resulted the 
expression of a novel prenylated benzophenone derivative, pre-shamixanthone (1.49).59 
 
 
 
 
 
 
 
 
 
 
A 2018 study published by Dewapriya et al., stated the optimum production of extensively N-
methylated linear peptides, talaropeptides A-D (1.50) from an Australian marine tunicate derived 
Talaromyces sp.; just upon changing the culture media from solid to liquid with maximum aeration 
and no shaking.60 
 
Another 2018 study by Mohamed et al. also mentioned the impacts of culture conditions in the 
production of bianthracenes lincolnenin A-B (1.51-1.52), by Streptomyces lincolnensis ACM-4234. 
According to the literature, the production of lincolnenin A-B was limited to only two media 
conditions among ´ 33 different media conditions.61 
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(v) Microbial co-cultivation 
Microbial co-cultivation have been considered as ecology-inspired approach for the activation of 
silent BGCs of microbes involved in co-cultivation.62 The hypothesis of co-cultivation based on the 
fact that in natural environments, micro-organisms interact with each other by producing 
communication tools, mostly secondary metabolites; where microbes often compete for limited 
nutrients and space, that creates a biotic stress in microbial communities. This biotic stress can 
activate complex regulation mechanisms, which leads to the biosynthesis of highly diverse natural 
products, such as pheromones, defensive molecules and metabolites that are involved in symbiotic 
associations.63 In contrast, during mono-culture of microbes in standard laboratory conditions, many 
secondary metabolite biosynthetic gene cluster remain silent due to the absence of particular 
interactions that microbe experienced in natural habitat. Research to date revealed that, microbes 
often been challenged with other co-existing microbes or microbes from different habitat revealed as 
a successful strategy to explore the silent, novel, bioactive secondary metabolites.64  
 
Research to dates indicates that both liquid and solid co-cultivation involving bacteria-fungi, fungi-
fungi or bacteria-bacteria in laboratory, to mimic the inter/intra-species cross-talk in microbial system 
in nature. The results lead to the induction of previously unexpressed pathways for bioactive 
compounds. Several examples reported the production of several new secondary metabolites from 
microbes induced by co-cultivation; including polyketide oosponol and oospoglycol (1993);65 
diterpenoids (2002);66 alkaloids marinamide and methyl-marinamide (2006);67 aminoglycosides 
rhodostreptomycins A and B (2008);68 diketopiperazine alkaloids, such as glionitrin (2009).69 Some 
more recent examples of co-cultivation based activation of secondary metabolites are discussed 
below.  
In 2009, a study by Schroeckh et al. reported the activation of silent polyketide synthase (PKS) gene 
cluster in the model fungus A. nidulus upon co-cultivation with soil dwelling Streptomyces 
rapamycinicus.64 The electron microscopy analysis revealed an intimate physical interaction between 
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the bacterial and fungal mycelia led to the biosynthesis of the archetypal polyketide orsellinic acid 
(1.53) along with lecanoric acid (1.54). Continuous investigation revealed that the Streptomyces 
activated the silent metabolism through histone modification via Saga/Ada mediated histone 
acetylation in the histone acetyltransferase complex.70  
 
 
 
 
 
 
A 2011 study reported the production of two new formyl xanthocillin analogues, fumiformamide 
(1.55) and N,N′-((1Z,3Z)-1,4-bis(4-methoxyphenyl)buta-1,3-diene-2,3-diyl)diformamide (1.56) by 
fungus Aspergillus fumigatus when co-cultured with bacteria Streptomyces peucetius. Analysis of the 
LC-MS traces of the extracts of the single control culture of A. fumigatus confirmed the presence of 
these metabolites in very low proportions.71  
 
 
 
 
Another 2011 study reported the co-cultivation of pathogenic fungus A. fumigatus with actinomycete 
Streptomyces rapamycinicus, resulted the activation of silent biosynthetic gene clusters as well as 
several accessory genes (e.g. fccA, fccR and fccB), confirmed by the whole array of genome and 
northern blotting analysis. Chemical profiling of co-cultured extract also revealed the activation of 
two new prenylated polyketides, fumicyclines A and B (1.57 and 1.58) by the fungus, which might 
contribute to the fungal defensive mechanism as both 1.57 and 1.58 moderately inhibited the growth 
of S. rapamycinicus. 72 
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Bertrand et al. (2013) 73 reported the co-cultivation of two fungi Trichophyton rubrum and Bionectria 
ochroleuca on agar, resulted the  de novo induction of the production of five metabolites, confirmed 
by UHPLC-TOF-MS analysis. However, only the structure of one metabolite (1.59) was identified 
by microflow NMR as a sulfate-containing compound. 1.59 was only found in the co-culture while 
the non-sulfated form PS-990 (1.60) was present in both of the single culture of Bionectria ochroleuca 
and co-culture.  
 
 
 
Another study by Whitt et al. (2014) reported co-culture between the fungus Fusarium pallidoroseum 
with bacterium S. erythraea, resulted the production of three decalin-type tetramic acids (1.61-1.63) 
by the fungus as a defensive chemical against the bacterium.74 
 
 
 
 
 
A 2017 study by Zhuo et al.62 reported that co-cultivation of Chaunopycnis sp. and Trichoderma 
hamatum , two fungal strains co-isolated from the inner tissue of an intertidal rock platform mollusk 
(Siphonaria sp.), resulted in transcriptional activation of a rare class of 2-alkenyl-tetrahydropyran, 
chaunopyran A (1.64).  
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1.6 Summary 
Notwithstanding the past historic success, microbial biodiscovery is facing challenges and there is an 
urgent need to shift to the best practice discovery methodology. To address the challenges, the 
scientific community has revitalized the discipline by (i) rationally exploiting the collections of 
microbes (ii) developing advanced analytical tools for rapid identification of known metabolites 
(dereplication). Fortunately, the recent discoveries of cryptic biosynthetic gene clusters (BGCs) 
revealed the hidden potentials of microbes. Even with the presence of complex regulatory 
mechanisms, microbes do not express their full biosynthetic capacities while growing in the standard 
laboratory conditions, where many BGCs remain silent. Apart from the genomic strategies, several 
cultivation mediated approaches were reported to exploit these hidden capacities of the biosynthetic 
machinery processes of microbial metabolism, such as varying culture conditions and microbial co-
cultivation. Additionally, the recent development in the sophisticated analytical techniques and 
powerful data mining software has started to provide partial/full structure information of a large 
number of microbial extracts, enhanced the dereplication of known metabolites and the rapid 
identification of new/novel metabolites.  
 
1.7 Focus of this thesis 
This thesis focused on exploring the chemical diversity of Australian microorganisms to address the 
following aims through the mentioned objectives. 
 
Aim and objectives  
Aim 1: Develop robust, reproducible, quantitative methodology to document secondary metabolic 
profile of bacterial and fungal cultures (called “MATRIX”). 
• High-throughput (HTP) cultivation and extraction of microbes using “MATRIX” 
• HTP profiling of the obtained extracts by UHPLC-DAD analysis and UHPLC-QTOF-
MS/MS method. 
• Rapid dereplication to enhance the identification of new/silent metabolites. 
• Global Natural Products Social Molecular Networking (GNPS) analysis to visualize the 
chemical similarity as well as to explore the new metabolites.  
 
Aim 2: Isolation of new microbial metabolites by applying chemical and bioactivity profiling to 
inspire drug discovery. 
• Chemical profiling of microbes using HPLC-MS and UHPLC-QTOF-MS/MS analysis for 
rapid dereplication and easy identification of new metabolites. 
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• Evaluation of bioactivity by applying a panel of in-house bioassays includes antimicrobial, 
anthelmintic and cytotoxic properties.  
• Scale-up cultivation, bioassay guided fractionation and purification, characterization of 
structurally diverse metabolites of prioritized microbes. 
 
Aim 3: Investigate the chemical cues that drive activation of silent BGCs in selected co-cultures and 
use this methodology to access new chemical diversity.  
• Finding the examples of bacterial-bacterial, fungal-fungal, bacterial-fungal co-cultures. 
• Identifying the chemical cues that drive co-culture mediated activation of silent BGCs. 
• Isolate and identify new “silent” metabolites to explore the chemical diversity of microbes. 
• Use of the natural chemical cues and the MATRIX to probe the activation of silent BGCs in 
other microbes. 
 
To achieve the targets, we started the isolation of microbes from sheep faeces (an unexplored source 
of microbes) supplied form different sheep farms in NSW, Australia. From the supplied samples, ´ 
102 morphologically diverse fungal (´ 86) and bacterial (´ 16) strains were isolated to assemble a 
library. Isolates were allowed to culture in two different culture media (ISP2 and M1) in both agar 
and liquid conditions. The obtained EtOAc crude extracts were assembled for chemical profiling 
using UHPLC-DAD and HPLC-DAD-MS analysis. Total ´ 15 fungi, bearing interesting chemical 
profile were chosen to cultivate according to the MATRIX approach. The ´ 33 extracts obtained from 
the MATRIX cultivation of each strain was allowed to UHPLC-QTOF-MS/MS analysis followed by 
the GNPS analysis for rapid identification and dereplication that is described in Chapter 2. Chapter 
3, 4 and 5 illustrates the isolation, structure elucidation and biological activities of new metabolites.   
In parallel, in order to explore the cryptic biosynthetic genes and stimulate the chemical potential, a 
set of microbes were allowed to co-culture in pairs. The obtained results from the co-cultivation 
studies is been described in chapter 6. Chapter 7 added some synthetic studies to rearrange the 
structure of anthranilic acid derived hydrazones. 
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2 Chapter 2: Chemical dereplication, media optimization and prioritization of 
microorganisms 
2.1 Introduction 
This chapter describes the preliminary work conducted at the start of my PhD studies. It starts with 
the assembly of a microbial isolate library from sheep faecal samples, followed by cultivation and 
EtOAc extraction to generate a crude extract library. All the extracts from the crude extract library 
were then analysed by UHPLC-DAD and UHPLC-QTOF-MS/MS method. The data generated by 
UHPC-QTOF was further processed using GNPS based molecular networking analysis for 
dereplication and prioritization of isolates. Selected isolates were then evaluated using MATRIX 
approach. All the MATRIX extracts were further analysed using UHPC-QTOF and HPLC-DAD ESI-
MS, followed by GNPS analysis to optimize the suitable media and conditions for the target 
metabolites. This chapter also discusses the prioritization of microbes based on the co-cultivation and 
a brief description on the bioassay-guided approach of microbial biodiscovery.  
 
2.2 Background 
Helminths, commonly known as parasite worms, are large multicellular organisms belonging to the 
phylum ‘Nematode’. Between the two major phyla of helminths, nematodes are the major intestinal 
worms. Among the classes, Haemonchus contortus1 is one of the predominant gastrointestinal 
parasite feeds on the blood and causes gastritis, anaemia and many other complications (like 
haemonchosis).2 This parasite causes an infection to millions of small ruminants (e.g. sheep, goat) 
leading to death and significant losses in production. Economic losses are estimated at billions of 
dollars per year. Moreover, increasing drug resistance in H. contortus has been reported in many 
Australian sheep farms and thus, there is a need for novel and effective drugs to control this emerging 
problem.3 
 
Life-cycle of H. contortus: During their life cycle, after hatching from their eggs, H. contortus larvae 
molts several times. At first, eggs pass out of the host in faeces and continue to develop into the larvae 
L1 and L2 by feeding on bacteria/fungi in the faeces and within one-week L2 larvae molts to infectious 
L3 which migrates from faeces onto pasture. Sheep, goats and other ruminants become infected when 
they graze and ingest the L3 infecting larvae (Figure 2.1).4 
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Figure 2.1: Life cycle of Haemonchus contortus. 
 
Role of microbial natural products as anthelmintics: Since the discovery of avermectins (IC50 =7.30 
µM) (metabolites isolated from Streptomyces avermitilis, in 1974, microbial secondary metabolites 
have revolutionized the animal health industry.5 Later in 1981, Yamazaki et al. reported a novel 
anthelmintic metabolite, paraherquamide (2.1) from fungus P. paraherqui, possessed potent 
anthelmintic activity against ivermectin resistant Haemonchus contortus (IC50 =9.0 µM).6 A recent 
study by Omura et al. reported the isolation of a novel anthelminthic metabolite nafuredin (2.2), 
isolated from Aspergillus niger, showed potent activity (IC50 = 0.17 µM), with a novel mode of action, 
inhibition of quinone binding site of complex I in helminth mitochondria and toxicity to helminth 
enzymes.7 
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2.3 Hypothesis 
Therefore, we hypothesised that, microbes co-existing with the nematode larvae, have the capacity to 
produce natural chemical defences against parasites/nematodes and these defensive chemicals 
produced by microbes might be a potential source of novel anthelmintics. In my PhD project, a 
microbial library was constructed, from sheep faecal sample infected with intestinal parasite 
Haemonchus contortus. Along with the exploration of chemical diversity of microbes from an 
unusual source (i.e., sheep faecal sample), we investigated the anti-parasitic secondary metabolites 
from microbes co-existed with parasites. We employed a modified Haemonchus contortus larval 
development assay (LDA) to detect metabolites with anti-parasitic activity. In addition to LDA, 
antimicrobial and cytotoxicity assay was employed to exclude any potent antimicrobial or cytotoxic 
metabolites.  
 
2.4 Assembly of microbial library 
Faecal samples (´ 21) were obtained from a sheep farm in NSW, Australia. The faecal samples were 
processed by two different methods, (a) stamping and (b) heat shock dilution method using two agar 
based isolation media (M1 and ISP2). A total of ´ 102 microbes (´ 68 bacteria and ´ 34 fungi) were 
isolated and preserved in cryovials using 15% of glycerol and preserved at - 80 °C freezer.  
 
 
 
 
 
 
 
 
 
 
 
 
2.5 Analytical cultivation and extraction  
 All isolated microbes (´ 102) were cultured in ISP2 and M1 media in both agar (in petridish plates) 
and liquid (in 24-well microbioreactor, containing 1.5 mL of liquid medium) conditions. After 
incubation at 29 °C for 7-10 days with necessary shaking at 190 rpm, cultures were extracted with 
EtOAc. EtOAc extracts (´ 408) were then transferred into 96-deep well plate (1 mg/mL in 20% 
DMSO) to generate a crude extract library.  
Figure 2.2: Morphology of selected fungal isolates cultivated on agar plate. 
Figure 2.3: Morphology of selected bacterial isolates cultivated on agar plate. 
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2.6 Chemical profiling  
The crude EtOAc extracts from extract library were redissolved in MeOH, filtered and an aliquot (1 
μL) was analysed by UHPLC-DAD employing an Agilent Zorbax C8 1.8 μm (2.1 ´ 50 mm) column, 
with a 2.5 min gradient elution at 0.417 mL/min from 90% H2O/ MeCN to 100% MeCN and inclusive 
of an isocratic 0.01% trifluoroacetic acid (TFA) modifier, with online detection at 210, 254, 280, 340 
and 400 nm. All data were analyzed using Agilent Open Lab CDS Rev.C.01.03 (37) ChemStation 
software. So far ´ 408 extracts were acquired and evaluated based on their UV-vis spectrum, to 
minimize the replicates as well as to identify the common metabolites.  
 
2.7  Global Natural Products Social (GNPS) Molecular Networking analysis  
GNPS is a tandem mass spectrometry (MS/MS) data organizational approach that has been recently 
introduced in the drug discovery.8 Currently, GNPS is one of the largest library of publicly shared 
MS/MS database, deposited by laboratories across the world. The greatest application of GNPS is the 
dereplication of known metabolites by comparing the MS/MS spectra and assessment of relationship 
between the measured and library data.9 Furthermore, molecular networking concept enables the  
visualization of large data sets as graphs of spectral similarity called spectral networks or molecular 
networks, where each node is a consensus MS/MS spectrum and edges between the nodes indicate 
the degree of similarity between consensus spectra (Figure 2.4).8 Data visualization of molecular 
networks can now be performed off-line using Cytoscape;10 where the attributes of the molecular 
network can be tuned to help data interpretation, such as node size can be correlated to the intensity 
of the precursor ion or node color can be used to map different samples; where edge thickness can be 
proportional to the cosine score.8, 11 Apart from the application for drug discovery leads, molecular 
networking is also been used to visualize medication and drug metabolism, in clinical diagnosis and 
precision medicine.  
 
Figure 2.4: An overview of the molecular network.  
Molecular Networking
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To take the advantages of GNPS based dereplication, microbial extracts from extract library were 
analysed by UHPLC-QTOF-MS/MS. Briefly, aliquot (1 µL) of each extract was analysed by 
UHPLC-QTOF to obtain the MS/MS data. The UHPLC conditions were as follows: column, Agilent 
SB-C8 1.8 μm, 2.1 × 50 mm; flow rate, 0.5 mL/min; gradient, 10 % MeCN/H2O to 100 MeCN with 
constant 0.1% formic acid; injection volume, 1μL. The source parameters were: electrospray positive 
ionisation; mass range of m/z 100-1700; scan rate 10 ´ per sec; MS/MS scan rate 3 ´ per sec; three 
fixed collision energy 10, 20 & 40 eV; source gas temperature 325° C; gas flow 10 L/min; and 
nebulizer 20 psig. The scan source parameters were: VCap 4000; fragmentor 100; skimmer 45; and 
octupole RFPeak 750. The QTOF-LC-MS/MS data was then converted to .mzXML format using MS 
converter. The molecular networks were generated using online workflow at GNPS 
(https://gnps.ucsd.edu). For the clustering of consensus MS/MS data, parameters were set with a 
precursor ion mass tolerance of 2.0 Da and a fragment ion mass tolerance of 0.5 Da. A minimum 
cluster size of 2, cosine score 0.65 and minimum number of fragments of 6, were selected for 
molecular networking. The precursor window was filtered in a 25 Da range. The spectral networks 
were imported into Cytoscape (3.5.1 and 3.7.1) and visualized using force directed layout where 
nodes represented parent masses and edge thickness corresponded to cosine score.  
Further analysis of the generated molecular network was performed according to the following 
workflow (Figure 2.5).  
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Figure 2.5: Flow chart of GNPS based dereplication, (A) cultivation of strains from microbial library and EtOAc 
extraction, (B) UHPLC-DAD analysis of the EtOAc extract, (C) GNPS based molecular network, (D) MS/MS analysis 
and identification of known metabolites. 
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Figure 9.01: Morphology of some bacterial and fungal strains cultured on agar-based media. 
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For the identification and distribution of secondary metabolites, extracts from the morphologically 
similar fungus were grouped together and created a molecular network (Figure 2.6). The molecular 
network generated a MS/MS similarity map that allowed the visualization of structurally related 
molecules (called cluster), where the unique molecules remain as a single loop. A careful analysis of 
the molecular network was performed in three different ways, (i) identification of known metabolites 
from the GNPS library data search, (ii) identification of the presence of new analogue of known 
metabolites and (iii) investigation of the unknown/new metabolites. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: (A) Molecular network obtained from the GNPS analysis of the 30 different fungus from microbial library, 
(B) Cluster of known metabolites with new analogues. 
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For example, the library search for the metabolites present in the molecular network of the fungal 
metabolites identified the presence of known fungal metabolite fungisporin (cyclic tetrapeptide 
isolated from P. chrysogenum)12 produced by three different fungal isolates (Figure 2.7). The detailed 
analysis of the cluster (Figure 2.6, cluster B) also indicated the presence of new analogues of 
fungisporin, sharing similar constituents that showed similar MS/MS fragmentation (Figure 2.5), 
therefore enhanced the dereplication based identification of new metabolites. 
 
 
 
 
 
 
 
 
 
 
 
Continued analysis for the higher molecular ions in the molecular network revealed the presence of 
a parent mass (m/z = 800) as a single loop, suggesting its unique presence. Further search also revealed 
that CMB-NF091 was the unique source of that parent mass (m/z = 800) (Figure 2.8). Analysis of 
the HPLC-MS profile of corresponding fungus CMB-NF091 also confirmed the production of the 
molecular ion, m/z = 800 (M+Na)+ (Figure 2.9).  Further isolation and identification of this metabolite 
from CMB-NF091 will be discussed in Chapter 3.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: Identification of metabolites resulted from library hits and their distribution into different groups.  
Figure 2.8: Identification of unique metabolites from the molecular network analysis. 
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Figure 2.9: HPLC-MS profile of the fungus CMB-NF091; peak highlighted in red is the corresponding metabolite with 
m/z = 800 (M+Na)+ and green is the internal standard.  
  
2.8 MATRIX cultivation of microbes  
Total ´ 15 fungi from the microbial library were selected based on their unique chemical profile and 
the GNPS molecular networking based analysis. To further optimize the production of secondary 
metabolites by the selected fungus, a practical, cost effective, quantitative and reproducible method 
has been developed using 24-well microbioreactor called “MATRIX”. According to this approach, ´ 
11 different media (Table 2.1) were prepared in both agar and liquid conditions. To control the 
number, the microbioreactor plate was designed according to the Figure 2.10. In the each well of 
microbioreactor, 1.5 mL of liquid media for liquid culture and 2.5 mL of agar media for agar culture 
was added. All the wells were then inoculated with 15 µL of freshly prepared inoculum of fungus. 
After inoculation, all the microbioreactors were then incubated at 29 °C for over 10 – 15 days with 
necessary shaking at 190 rpm. After cultivation, the cultures were extracted with EtOAc (2.0 mL/well) 
and each resultant extract was dried down under N2. A total of ´ 33 extracts were obtained from one 
fungus according to this MATRIX culture approach. 
 
Table 2.1: Different culture media and condition used for the MATRIX analysis 
Culture media 
Solid Liquid static Liquid shaking 
i M1 agar xii M1 broth xxiii M1 broth 
ii ISP2 agar xiii ISP2 broth xxiv ISP2 broth 
iii ISP4 agar xiv ISP4 broth xxv ISP4 broth 
iv Potato dextrose agar xv Potato dextrose broth xxvi Potato dextrose broth 
v YES agar xvi YES broth xxvii YES broth 
vi Sabouraud dextrose agar xvii Sabouraud dextrose broth xxviii Sabouraud dextrose broth 
vii Tryptic soy agar xviii Tryptic soy broth xxix Tryptic soy broth 
viii Basal agar xix Basal broth xxx Basal broth 
ix Czapeck agar xx Czapeck broth xxxi Czapeck broth 
x M2 agar xxi M2 broth xxxii M2 broth 
xi PYG agar xxii PYG broth xxxiii PYG broth 
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Table 2.2: List of 11 different media with their composition (per litre). 
Media Composition (per litre) 
M1 Peptone (2.0 g), Yeast extract (4.0 g), Starch (10.0 g) 
ISP2 Yeast extract (4.0 g), Malt extract (10.0 g), Glucose (4.0 g)  
ISP4 Soluble starch (10.0 g), CaCO3 (2.0 g), (NH4)2SO4 (2.0 g), K2HPO4 (1.0 g), MgSO4.7H2O (1.0 g), NaCl (1.0 
g), FeSO4.7H2O (1 mg), MnCl2.7H2O (1.0 mg), ZnSO4.7H2O (1.0 mg) 
PDB Potato extract (4.0 g), Dextrose (20.0 g) 
YES Sucrose (150 g), Yeast extract (20 g), MgSO4.7H2O (0.5 g), ZnSO4.7H2O (0.01 g), CuSO4.5H2O (0.005 g)  
SDB Peptic digest of animal tissue (5.0 g), Pancreatic digest of casein (5.0 g), Dextrose (40.0 g)  
TSB Pancreatic digest of casein (15.0 g), papain digest of soybean (5.0 g), NaCl (5.0 g), glucose (2.5 g)  
Basal K2HPO4 (1.5 g), MgSO4.7H2O (0.025 g), CaCl2 (0.025 g), FeSO4.7H2O (0.015 g), and ZnSO4.7H2O (0.005).  
Czapek K2HPO4 (1.0 g), NaNO3 (0.3 g), KCl (0.005 g), MgSO4.7H2O (0.005 g), FeSO4 (0.0001 g), Sucrose (30 g).  
M2 Mannitol (40.0 g), Maltose (40.0 g), Yeast extract (10.0 g), K2HPO4 (2.0 g), MgSO4.7H2O (0.5 g), 
FeSO4.7H2O (0.01 g) 
PYG Peptone (10 g), Yeast Extract (5 g) Dextrose (20 g)  
   (for solid-based media= agar 18 g/L) 
 
 
Figure 2.10: Microbioreactor plate layout for MATRIX cultivation of fungus. 
2.9 Chemical profiling of the MATRIX extracts 
The dried EtOAc extracts obtained from liquid shaking and liquid static culture were suspended in 
MeOH (60 µL), while the extracts from agar cultures were redissolved in MeOH to get the final 
concentration 1 mg/mL and filtered. An aliquot (1 µL) of all extract were analyzed by UHPLC-DAD, 
Agilent Zorbax C8 1.8 µm (2.1 ´ 50 mm) column, 0.417 mL/min from 90% H2O/MeCN to 100% 
MeCN, inclusive of an isocratic 0.01% trifluroacetic acid (TFA) modifier. The UHPLC-DAD 
analysis of the extracts obtained from all media blank/control was also performed and compared when 
necessary.  
For example, all ´ 33 UHPLC-DAD profile obtained from MATRIX cultivation of CMB-NB162 
were overlaid to the same scale. Analysis revealed that the chemical profiles of CMB-NB162 
obtained from different agar cultures were quite different, even the chemical profile differs for the 
extracts obtained from agar, liquid shaking and liquid static cultures (Figure 2.11 and 2.12).  Further 
analysis included HPLC-DAD-MS analysis, UV, retention time (tR) for all the metabolic profiles and 
control/media blank as well. The reproducibility of the microbioreactor cultivation has already been 
reported. However, this study confers significant advantages as it allows a wider comparison of 
metabolic profiles obtained from agar, liquid static and liquid shaking conditions. The strategies 
applied in MATRIX cultivation appeared very effective upon comparing the UHPLC-DAD profiles 
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of the microbial extracts and signified the (i) selection of suitable media for the expression of 
maximum number of metabolites, (ii) selection of best suitable media and condition for any unique 
metabolite. Further study on CMB-NB162 was described in Chapter 4 and 5. 
 
 
Figure 2.11: UHPLC-DAD profile of the extracts obtained from the liquid shaking cultivation of CMB-NB162 in (a) 
PYG, (b) M1, (c) ISP4, (d) M2 and the UV-vis profile of the respected peaks. Peaks highlighted with same colour shares 
the same UV-vis spectra, green = internal standard. 
 
Figure 2.12: UHPLC-DAD profile of the extracts obtained from the cultivation of CMB-NB162, (a) YES liquid shaking, 
(b) YES liquid static (c) YES agar (d) YES media blank. Peaks highlighted with same colour shares the same UV-vis 
spectra, green = internal standard. 
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2.10 GNPS analysis of the MATRIX extracts 
Total ´ 33 EtOAc extracts obtained from MATRIX cultivation of one fungus were analyzed by 
UHPLC-QTOF-MS/MS followed by GNPS molecular network generation and visualization 
according to same method described in section 2.7. The cluster analysis in the molecular network 
helped to calculate the distribution of metabolites across different media and conditions. 
Interpretation of node size according to the ion abundance was performed to scale-up the isolable 
metabolites (Figure 2.13). The cluster for metabolites of interest were further analyzed by correlating 
the UHPLC-DAD chromatographic peaks with their corresponding m/z values and retention time. 
Accompanying literature search of the generated molecular ion was achieved to identify the 
known/new metabolites present in a cluster.  
 
 
Figure 2.13: Flow chart of GNPS based dereplication and identification of new metabolites, (A) MATRIX cultivation of 
selected strains from microbial library and EtOAc extraction, (B) UHPLC-DAD analysis of the MATRIX extract, (C) 
UHPLC-QTOF-MS/MS analysis and GNPS based molecular network and identification of known/new metabolites. 
 
2.11 Co-cultivation based prioritization of microbes 
During the process of isolation of microbes from their complex culture, we noticed some clear zone 
of inhibition by one strain in the culture plate. Later, we isolated the strains from their mixed culture 
plate and allowed to grow them together again according to the co-cultivation approach. Two strains 
were allowed to grow in one agar plate. After that the individual and conflict zone was collected and 
extracted manually. Further analysis of the chemical profiles from different zones of the co-cultivated 
plate were analysed according to the flow chart in Figure 2.14. After chemical profiling, two fungus 
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and one bacterial strain were selected for fungal-bacterium co-cultivation, will be discussed in chapter 
6. 
 
Figure 2.14: Co-cultivation of microorganisms and the identification of secondary metabolites involved in co-cultivation. 
 
2.12 Bio-activity based selection of microbes 
Here we also performed a bioassay-guided isolation strategy to select the stains producing bioactive 
metabolites. Therefore, extracts from crude extract library were evaluated for antibacterial activity 
against Gram-positive bacteria (Staphylococcus aureus, ATCC 25923 and Bacillus subtilis, ATCC 
6051 or ATCC 6633); Gram-negative bacteria (Escherichia coli ATCC 11775 or ATCC 25922); 
antifungal activity against ( Candida albicans ATCC 90028 or ATCC 10231) 
anthelmintic/nematocidal activity (larval development assay, LDA); and cytotoxicity against multiple 
human cancer cell lines (lung cancer cell line NCI-H460 and colon cancer cell line SW620). The 
crude extracts with antibacterial activity against Gram-positive bacteria in the primary screening were 
evaluated against multi-drug resistant strains, methicillin-resistant Staphylococcus aureus (MRSA) 
and vancomycin resistant Enterococcus faecalis (VRE). Priority was given to strains showed 
antimicrobial and anthelmintic property but not cytotoxicity to mammalian cells. Following sections 
will describe the bioassay-guided isolation of anthelmintic metabolites from fungus CMB-NF100, as 
a case study. 
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2.13 Case study: Isolation of anthelmintic metabolites from Penicillium sp. CMB-NF100 
2.13.1 Isolation and identification of CMB-NF100 
The fungus CMB-NF100 was isolated from a faecal sample sourced from a sheep infected with 
Haemonchus contortus, cultured on ISP2 agar, incubated at 29 °C for 7 days. Genomic DNA from 
this isolate was extracted from the mycelia using DNeasy plant and tissue DNA kit (QIAGEN). The 
18s rRNA genes were amplified by PCR using both ITS1 and ITS4 primers. The BLAST data search 
for the closest match resulted the 99% homology to the reported Penicillium sp. suggested that CMB-
NF100 to be closely related to Penicillium janthinellum. 
 
2.13.2 Analytical cultivation and chemical analysis 
The pure fungus (CMB-NF100) was cultured on ISP2 agar and incubated for 10 days at 29° C.  After 
incubation, agar was sliced and extracted with EtOAc (20 mL). The decanted organic phase was 
evaporated in vacuo to yield a crude extract (2.5 mg). The crude extract was resuspended in MeOH 
(5 mg/mL) and subjected to HPLC-DAD-MS analysis. The chemical profile showed the production 
of six major metabolites (Figure 2.15 and Table 2.3). 
 
Figure 2.15: HPLC-DAD-ESIMS chromatogram (210 nm) of CMB-NF100 crude extract (inset the UV-vis spectra of the 
respected peaks). The extract was eluted with Zorbax SB-C8 column, 150 ´ 4.6 mm, 5 µm, 1mL/min gradient elution 
from 10% H2O/MeCN to 100% MeCN inclusive of isocratic 0.05% formic acid modifier, over 15 min.  
Table 2.3: LC-MS data of the corresponding of peaks. 
Peak 
No. 
HPLC-MS data 
tR (min)  (M+H)+  (M-H)- Molecular Mass 
a 5.873 309.2 307.2 308.0 
b 11.385 568.2 566.2 567.2 
c 11.838 570.2 568.2 569.0 
d 14.688 586.2 584.2 585.2 
e 14.878 602.2 600.2 601.0 
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2.13.3 Medium scale cultivation and fractionation 
A loop of spores from Penicillium sp. CMB-NF100 was streaked on ISP2 agar plates (´ 20) and 
incubated at 29° C for 10 days. After incubation, combined agar/mycelia were extracted with EtOAc 
(2 ´ 300 mL) and the decantated organic phases were evaporated to dryness in vacuo to yield the 
crude extract (59.0 mg). The resulted crude extract was then subjected to liquid-liquid partitioning 
between n-hexane and aqueous MeOH (100 mL of each). The MeOH soluble fraction (43.0 mg) was 
fractionated by preparative HPLC (Scheme 2.1 in the experimental section) (Figure 2.16). The 
obtained ´ 35 fractions were tested against Haeomoncus contortus larvae by LDA method and for 
cytotoxicity against human colon carcinoma cell lines (SW620). Fractions 4-5, 7-8 and 28-30 showed 
potent (> 90% inhibition) anthelmintic activity. Fractions 4-5 and 28-30 showed moderate cytotoxic 
activity, while fractions 7-8 did not exhibit any cytotoxic activity (Figure 2.17 and 2.18). UHPLC-
QTOF-MS/MS analysis of the LDA active fractions 4-5 and 7-8 revealed the presence of metabolites 
with molecular ion (m/z = 568 – 570). Generated molecular formula, supported by literature search, 
suggested that these metabolites belong to the janthitrem family of fungal mycotoxin, commonly 
produced by Penicillium sp.13 Further isolation and purification from fractions 4-5 and 7-8 resulted 
pure metabolites 2.3(1.5 mg) and 2.4 (1.8 mg). 
 
 
Figure 2.16: Preparative HPLC chromatogram (210 nm) of CMB-NF100. The extract was eluted with PhenomenexÒ C8 
column, 250 ´ 10 mm, 10 µm, 20 mL/min gradient elution from 10% H2O/MeCN to 100% MeCN inclusive of isocratic 
0.01% TFA as modifier, over 30 min. 
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Figure 2.17: Larval development assay (LDA) of the fractions of the crude extract of CMB-NF100 (10 µg/well). Red 
colour indicated the active fractions. (Ive = Ivermectin, served as standard, DMSO = positive control). 
 
 
Figure 2.18: Cytotoxicity profiling of the preparative fractions of the CMB-NF100 crude extracts against human colon 
carcinoma cell lines (SW620) at 10 µg/well concentration. Experiments were performed in triplicates. Fractions 4-5 and 
28-30 showed moderate to potent cytotoxicity.  
2.13.4 Structure elucidation 
2.13.4.1 JBIR-137 (2.3) 
 
 
 
 
 
Metabolite 2.3 was isolated as a light red colour compound. HRESI(±)MS analysis of 2.3 returned a 
molecular ion (M+H)+ attributed to a molecular formula (C37H45NO4, Dmmu - 0.6) requiring ´ 16 
double bond equivalents (DBEs). 1D and 2D NMR data (DMSO-d6) (Figure 2.19 and Table 2.4) for 
2.3 displayed 37 carbon signal including seven methyl, six methylene (one olefinic), nine methine 
(two aromatic, three olefinic and three oxygen-bearing) and 15 quaternary carbon. Online searching 
1 2 3 4 5 6 7 8 9 10 11 12
A
B Control DMSO 20%
Crude-ISP2-
agar
Crude-ISP2-
agar
Prep-Fr-4 Prep-Fr-5 Prep-Fr-6 Prep-Fr-7 Prep-Fr-8 Prep-Fr-9
C Control DMSO 20% Prep-Fr-10 Prep-Fr-11 Prep-Fr-12 Prep-Fr-13 Prep-Fr-14 Prep-Fr-15 Prep-Fr-16 Prep-Fr-17
D Control DMSO 20% Prep-Fr-18 Prep-Fr-19 Prep-Fr-20 Prep-Fr-21 Prep-Fr-22 Prep-Fr-23 Prep-Fr-24 Prep-Fr-25
E Control Ive, 10 µM Prep-Fr-26 Prep-Fr-26 Prep-Fr-27 Prep-Fr-28 Prep-Fr-29 Prep-Fr-30 Prep-Fr-31 Prep-Fr-32
F Control Ive, 10 µM Prep-Fr-33 Prep-Fr-34 Prep-Fr-35
Collection-1-
14 min
wash
G Control Ive, 10 µM
H
4 5 6 7 8 9 10 11 12 13 14 15 16 18 19 20 21 22 17 23 24 25 26 27 28 29 30 31 32 33 34 35
0
50
100
150
Fractions
C
el
l v
ia
bi
lit
y 
(%
 o
f c
on
tr
ol
)
NH
O O
OHOH
JBIR-137 (2.3)
H
H
Chapter 2: Chemical dereplication, media optimization and prioritization of microorganisms 
 
 
39 
with the molecular formula and structure fragments established through diagnostic 2D NMR 
correlations (Figure 2.20) resulted that 2.3 is a known fungal metabolite JBIR-137, an indole 
diterpenoids type compound, isolated from an Aspergillus sp, fA75.14 
The 1H NMR data (DMSO-d6) for 2.3 displayed the presence of an exchangeable proton (δH 10.69, 
s) that showed HMBC correlations to C-3a (δC 125.2), C-7a (δC 138.3), C-2 (δC 153.8), C-3 (δC 116.4).  
HMBC spectrum also revealed the correlation of aromatic protons, H-4 (δH 7.05, s) to the C-6 (δC 
127.0), C-7a (δC 138.3), C-3 (116.4) and H-7 (δH 7.45, s) to the C-3a (δC 125.2), C-7a (δC 138.3), C-5 
(135.2), allowed the assignment of a benzene ring structure (ring A),  thus confirmed the presence of 
an indole moiety in the structure of 2.3. 
Analysis of 1D and 2D data (DMSO-d6) for 2.3 also confirmed the presence of diterpenoid moiety. 
In the HMBC spectrum, the correlation from a singlet methyl proton H-14¢-CH3 (δH 1.72) to the 
oxymethine carbon C-13¢ (δC 79.6), olefinic quaternary carbon C-14¢(δC 143.5) and exomethylene 
carbon C-15¢ (δC 110.4) proved the presence of an isopropenyl group. The COSY spectrum further 
showed the sequence from H-13¢ (δH 3.71) to the olefinic methine H-11¢ (δH 5.54) through the 
oxymethine H- 12 ¢ (δH 3.84). In addition, HMBC correlation from H-13¢ (δH 3.71) and H-11¢ (δH 
5.54) to the oxymethine carbon C-8¢ (δC 73.4), from H- 12¢ (δH 3.84) to the olefinic quaternary carbon 
C-9¢ (δC 147.4) confirmed the presence of a six membered ether ring (C).  
The COSY correlation from methylene H-7¢ (δH 2.05, δH 1.79) to both methylene H-6¢ (δH 2.46, δH 
1.70) and oxymethine H-8¢ (δH 4.51) along with the HMBC correlation from H-7¢ (δH 2.05, δH 1.79) 
to the quaternary C-5¢ (δC 42.6) and from H-8¢ (δH 4.51) to the oxygenated quaternary C-10¢ (δC 76.3), 
confirmed the presence of another cyclohexane ring (D).  
The sequence from methylene H-1¢ (δH 1.85, δH 1.63) to both methylene H-3¢-CH2 (δH 2.58, δH 2.30) 
was observed in the COSY spectrum. In addition, HMBC correlations from H-1¢ (δH 1.85, δH 1.63) to 
C-3¢ (δC 49.8) and C-5¢ (δC 42.6); from H-2¢ (δH 1.93, δH 1.58) to C- 4¢ (δC 49.5) and C-10¢ (δC 76.3) 
confirmed the ring E. The further HMBC correlations from H-3¢ (δH 2.73) to C-2 (δC 153.8), C-3 (δC 
116.4) and from H-3¢-CH2 (δH 2.58, δH 2.30) to C-4¢ (δC 49.5), C-2 (δC 153.8) also confirmed the 
presence of F ring connected to the B ring of indole moiety. 
The substructure of remaining isoprene units of 2.3 was established as follows. Methyl singlets H-
4¢¢/ H-3¢¢-CH3 (δH 1.45) showed HMBC correlations to quaternary C-2¢¢ (δC 141.2) and oxygenated 
C-3¢¢ (δC 72.7). The methine H-1¢¢ (δH 6.42) showed HMBC correlations to C-2¢¢ (δC 141.2), C-1¢¢¢ (δC 
134.0), C-5 (δC 135.2), C-6 (δC 127.0) showed the formation of one isoprene unit as well as formation 
of five membered ring G connected to ring C. Another set of methyl singlet H-4¢¢¢/ H-3¢¢¢-CH3 (δH 
1.39) showed HMBC correlations to methine C-2¢¢¢ (δC 129.1) and oxygenated C-3¢¢¢ (δC 72.5) 
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confirmed the formation of another isoprene unit. HMBC correlation of methine H-2¢¢¢ (δH 6.69) to 
C-3¢¢¢ (δC 72.5) and C-2¢¢ (δC 141.2) supported the formation of ring H.  
The structure elucidation was further supported by comparing the 1D and 2D NMR data including 
HSQC, HMBC and COSY, outlined in Table 6.5, Figure 6.6 and by comparing the [a]D - 42.7 (c 
0.05, MeOH) with the reported for JBIR-137 [a]D - 66 (c 0.13, MeOH).14 The relative 
stereochemistry of the stereogenic centers C-3¢, C-4¢, C-5¢, C-8¢, C-10¢, C-12¢, C- 13¢ of JBIR-137 
were reported based on spin-spin coupling constant values and compared with the reported data for 
janthitrems and penitrems, bearing the same diterpenoid moiety.15  
 
 
 
 
 
 
 
 
Figure 2.19: 1H NMR (600 MHz, DMSO-d6) spectrum of JBIR-137 (2.3). 
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Table 2.4: 1D and 2D NMR (600 MHz, DMSO-d6) data for JBIR-137 (2.3) 
Position δC δH, mult, (J in Hz) COSY HMBC 
Indole (C1-C7) 
1-NH  10.69, s  2, 3, 3a, 7a 
2 153.8    
3 116.4    
3a 125.2    
4 110.0 7.05, s  3, 6, 7a, 1¢¢ 
5 135.2    
6 127.0    
7 105.5 7.45, s  3a, 5, 7a, 1¢¢¢ 
7a 138.3    
Diterpene (C1¢- C15¢) 
1¢ 33.6 a, 1.85, m 
b, 1.63, m 
2¢ 2¢, 5¢ 
2¢ 21.5 a, 1.93, m 
b, 1.58, m 
1¢, 3¢ 4¢, 10¢ 
3¢ 49.8 2.73, m 2¢, 3¢-CH2 2, 3 
4¢ 49.5    
5¢ 42.6    
6¢ 26.7 a, 2.46e 
b, 1.70f 
7¢ 5¢, 8¢ 
7¢ 28.6 a, 2.05, m 
b, 1.79, m 
6¢, 8¢ 6¢, 8¢ 
8¢ 73.4 4.51, dd (8.5, 1.5) 7¢ 11¢, 13¢ 
9¢ 147.4    
10¢ 76.3    
11¢ 118.3 5.54, dd (5.5, 1.5) 12¢ 8¢, 9¢, 10¢, 13¢ 
12¢ 63.2 3.84, d (5.5) 11¢, 13¢ 9¢ 
13¢ 79.6 3.71, br s 12¢, 15¢ 8¢, 14¢, 15¢, 14¢- CH3 
14¢ 143.5    
15¢ 110.4 a, 5.00, br s 
b, 4.84, br s 
13¢ 13¢, 14¢, 14¢- CH3 
3¢-CH2 27.4 a, 2.58g 
b, 2.30, dd (11.0, 6.0) 
3¢ 2, 4¢ 
4¢-CH3 16.7 1.24, s  4¢, 5¢ 
5¢-CH3 19.7 0.95, s  4¢, 5¢, 6¢ 
14¢-CH3 20.1 1.72, s  13¢, 14¢, 15¢ 
10¢-OH  4.30, s  10¢ 
Isoprene (C1¢¢ - C4¢¢) 
1¢¢ 121.7 6.42, br, s 2¢¢¢ 5, 6, 2¢¢, 1¢¢¢ 
2¢¢ 141.2    
3¢¢ 72.7    
4¢¢ 31.8a 1.45c  2¢¢, 3¢¢ 
3¢¢-Me 31.8a 1.45c  2¢¢, 3¢¢, 4¢¢ 
Isoprene (C1¢¢¢ - C4¢¢¢) 
1¢¢¢ 134.0    
2¢¢¢ 129.1 6.69, br, s 1¢¢ 6, 2¢¢, 3¢¢¢ 
3¢¢¢ 72.5    
4¢¢¢ 31.0b 1.39d  2¢¢¢, 3¢¢¢ 
3¢¢¢-Me 31.0b 1.39d  2¢¢¢, 3¢¢¢ 
   a-b = assignments for resonances (same superscript within a column) are interchangeable,  
    e -g = assignments for overlapping resonances. 
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Table 2.5: 1H and 13C NMR (methanol-d4) data comparison of JBIR-137 (2.3) with published data. 
Position δH, mult, (J in Hz)a δC a δH, mult, (J in Hz)b14 δCb 14 
Indole (C1-C7) 
2  153.8  153.8 
3  116.4  117.6 
3a  125.2  126.0 
4 7.08, s 110.0 7.11, s 110.6 
5  135.2  136.9 
6  127.0  128.6 
7 7.47, s 105.5 7.48, s 105.4 
7a  138.3  139.2 
Diterpene (C1¢- C15¢) 
1¢ a 1.99 c; b 1.66d 33.6 a 1.95, m; b 1.66, m 34.7 
2¢ a 2.09, m; b 1.68d 21.5 a, 2.05, m; b 1.66, m 22.1 
3¢ 2.80, m 49.8f 2.80, m 50.7 
4¢  49.5f  51.8 
5¢  42.6  43.5 
6¢ a 2.63e; b 1.69b 26.7 a 2.61, m; b 1.65, m 27.9 
7¢ a 2.16, m; b 1.97c 28.6 a 2.18, m; b 1.93, m 29.0 
8¢ 4.59, dd (9.0, 1.5) 73.4 4.62, 66 (9.0, 1.5) 73.8 
9¢  147.4  149.0 
10¢  76.3  77.6 
11¢ 5.71, dd (6.0, 1.5) 118.3 5.71, dd (6.0, 1.5) 118.3 
12¢ 3.97, br d (5.8) 63.2 3.96, br d (6.0) 64.0 
13¢ 3.85, br s 79.6 3.86, br s 80.3 
14¢  143.5  143.0 
15¢ a 5.10, br s; b 4.93, br 
s 
110.4 a 5.14, br s; b 4.96, br s 110.5 
3¢-CH2 a 2.64e 
b 2.37, dd (13.0, 9.0) 
27.4 a 2.64, dd (10.0, 8.0) 
b 2.36, dd (13.0, 10.0) 
28.0 
4¢-CH3 1.33, s 16.7 1.30, s 16.6 
5¢-CH3 1.06, s 19.7 1.03, s 20.1m 
14¢-CH3 1.79, s 20.1 1.78, s 20.1m 
Isoprene (C1¢¢ - C4¢¢) 
1¢¢ 6.38, br s 121.7 6.36, d (2.0) 122.8 
2¢¢  141.2  141.6 
3¢¢  72.7  74.6 
4¢¢ 1.51f 31.8h 1.51j 31.8 n 
3¢¢-Me 1.51f 31.8h 1.51 j 31.8 n 
Isoprene (C1¢¢¢ - C4¢¢¢) 
1¢¢¢  134.0  135.2 
2¢¢¢ 6.51, br s 129.1 6.47, d (2.0) 128.6 
3¢¢¢  72.5  74.0 
4¢¢¢ 1.45g 31.0i 1.44k 31.2 0 
3¢¢¢-Me 1.45g 31.0i 1.44 k 31.2 0 
      NMR measured at a = 600 MHz, b = 400 MHz. c-k = assignments for overlapping resonances. 
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2.13.4.2 Janthitrem E (2.4) 
 
 
 
 
 
 
 
Metabolite 2.4 was isolated as a red colour compound. HRESI(±)MS analysis of 2.4 returned a 
molecular ion (M+H)+ attributed to a molecular formula (C37H47NO4, Dmmu +1.2) requiring ´ 15 
double bond equivalents (DBEs). The molecular formula of 2.4 was consistent with the molecular 
formula of 2.3, revealed that 2.4 have the same structure skeleton, with the presence of two more 
protons. The 1D NMR data (DMSO-d6) for 2.4 (Figure 2.21 and Figure 2.22) displayed 37 carbon 
signal including seven methyl, eight methylene, seven methine (two aromatic, one olefinic and three 
oxygen-bearing) and 15 quaternary carbon. The major difference was the replacement of two methine 
by two methylene (H-1¢¢, δH 3.26; and H-2¢¢¢, δH 3.16) at C-1¢¢ (δC 36.0) and C-2¢¢¢ (δC 34.3) 
respectively at the isoprene units, that resulted the positioning of double bond between C-2¢¢ and C-
1¢¢¢. Detailed analysis of 1D and 2D NMR data (DMSO-d6) supported the structure of 2.4 (Figure 
2.23 and Table 2.6). Consequently, 2.4 was elucidated as the new metabolite, janthitrem E, belongs 
to the janthitrem class. The relative stereochemistry of the stereogenic centres of 2.4 was confirmed 
by comparing spin-spin coupling constant values with the reported for JBIR-137 and by comparing 
the [a]D - 24.6 (c 0.05, MeOH) with the reported for JBIR-137 [a]D - 66 (c 0.13, MeOH).14 
 
 
 
 
 
 
Figure 2.20: Key 2D NMR (DMSO-d6) correlations of JBIR-137 (2.3). 
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Figure 2.21: 1H NMR (600 MHz, DMSO-d6) spectrum of janthitrem E (2.4) 
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Figure 2.22: 13C NMR (150 MHz, DMSO-d6) spectrum of janthitrem E (2.4). 
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Figure 2.23: Key 2D NMR (DMSO-d6) correlation for janthitrem E (2.4). 
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Table 2.6: 1D and 2D NMR (600 MHz, DMSO-d6) data for janthitrem E (2.4). 
Position δC δH, mult, (J in Hz) COSY HMBC 
Indole (C1-C7) 
1-NH  10.52, s  2, 3, 3a, 7a 
2 152.8    
3 115.0    
3a 122.9    
4 113.2 7.03, s  3, 6, 7a, 1¢¢ 
5 138.2    
6 131.9    
7 101.8 7.27, s  3a, 5, 7a, 1¢¢¢ 
7a 139.5    
Diterpene (C1¢- C15¢) 
1¢ 33.7 a, 1.84, m 
b, 1.62, m 
2¢ 2¢, 5¢ 
2¢ 21.5 a, 1.93, m 
b, 1.68d 
1¢, 3¢ 4¢, 10¢ 
3¢ 49.7 2.72, m 2¢, 3¢-CH2 2, 3 
4¢ 50.7    
5¢ 42.6    
6¢ 26.9 a, 2.46e 
b, 1.57, m 
7¢ 5¢, 8¢ 
7¢ 28.4 a, 2.05, m 
b, 1.79, m 
6¢, 8¢ 6¢, 8¢ 
8¢ 73.3a 4.49, dd (10.5, 8.5) 7¢ 11¢, 13¢ 
9¢ 147.4    
10¢ 76.1    
11¢ 118.2 5.57, d (5.5) 12¢ 8¢, 9¢, 10¢, 13¢ 
12¢ 63.0 3.83, d (5.5) 11¢, 13¢ 9¢ 
13¢ 79.5 3.70, br s 12¢, 15¢ 8¢, 14¢, 15¢, 14¢- CH3 
14¢ 143.3    
15¢ 110.4 a, 5.00, br s 
b, 4.84, br s 
13¢ 13¢, 14¢, 14¢- CH3 
3¢-CH2 27.5 a, 2.58 dd (8.0, 4.7) 
b, 2.28, dd (12.0, 8.0) 
3¢ 2, 4¢ 
4¢-CH3 16.7 1.21, s  4¢, 5¢ 
5¢-CH3 19.7 0.93, s  4¢, 5¢, 6¢ 
14¢-CH3 20.1 1.71, s  13¢, 14¢, 15¢ 
10¢-OH  4.28, s  10¢ 
Isoprene (C1¢¢ - C4¢¢) 
1¢¢ 36.0 3.26, br, s  5, 6, 2¢¢, 1¢¢¢ 
2¢¢ 142.0    
3¢¢ 73.3a    
4¢¢ 30.8 1.33b  2¢¢, 3¢¢ 
3¢¢-Me 30.9 1.33b  2¢¢, 3¢¢, 4¢¢ 
Isoprene (C1¢¢¢ - C4¢¢¢) 
1¢¢¢ 133.8    
2¢¢¢ 34.3 3.16, s  6, 2¢¢, 3¢¢¢ 
3¢¢¢ 72.1    
4¢¢¢ 29.8  1.23c  2¢¢¢, 3¢¢¢ 
3¢¢¢-Me 29.9 1.23c  2¢¢¢, 3¢¢¢ 
    a-e = assignments for overlapping resonances. 
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The dose dependent anthelmintic activity of JRIR-127 (2.3) and janthitrem E (2.4) against drug 
resistance H. contortus was evaluated using our in-house LDA (Figure 2.24), showed anthelmintic 
potential with IC50 of 10.2 and 1.99 µM respectively. The antimicrobial and cytotoxic properties of 
JRIR-127 (2.3) and janthitrem E (2.4) was also been evaluated and compared. Comparative analysis 
revealed that janthitrem E (2.4) is a potent anthelmintic compound. 
 
 
Figure 2.24: Dose response LDA activity of JBIR-137 (2.3) and janthitrem E (2.4). 
 
Figure 2.25: Antimicrobial profile of JBIR-137 (2.3) and janthitrem E (2.4). 
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Figure 2.26: Cytotoxicity profile of JBIR-137 (2.3) and janthitrem E (2.4). 
 
Fungal metabolite janthitrems, bearing indole-diterpenoid moiety, are known as tremorgenic 
mycotoxin. Janthitrem A was first isolated from ryegrass pastures derived fungus P. janthinellum in 
1980.16 Later in 1992, Wilkins et al. isolated two other analogues of janthitrems, B and C.15 Several 
studies reported the production of tremorgenic mycotoxin janthitrems (2.5), by ryegrass pasture fungi, 
including other mycotoxins, shearinines (2.6), paxillines (2.7), penitrems (2.8), lolitrems (2.9); 
sharing the same indole-diterpenoid skeleton.18,19 Literature reported that the indole-diterpenes share 
common architectural features, the signature elements being an indole core, biosynthetically derived 
from tryptophan and a diterpene framework derived from mevalonate. Other studies also reported the 
total synthesis of most complex tremorgenic indole alkaloid penitrems.20 
 
Interest in these compounds was continued in search of their association with sheep suffering from a 
tremorgenic disorder called ryegrass disorder. A study by Babu et al. reported that, though janthitrems 
bear the same core structure as lolitrems, the most tremorgenic compounds responsible for ryegrass 
staggers; isolated new analogues of janthitrems are less tremorgenic. The structure activity 
relationship study on different analogues of janthitrems revealed the significant differences in the 
induction of tremors in mouse. In result, janthitrems analogues possessed anti-insecticidal activity 
against porina larvae.21 Another study also reported the anti-insecticidal activity of shearinines A - C 
against H. zea, the corn earworm. Hence, further investigations might help to establish the structure 
activity relationship of indole-diterpenoid containing metabolites with their insecticidal properties.  
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2.14 Conclusion 
This chapter summarizes the assembly of microbial isolates obtained from sheep faecal sample, 
followed by cultivation and EtOAc extraction to generate a crude extract library, with the application 
of strategies to prioritize microbes for further studies. Prioritization strategies includes the MATRIX 
cultivation, chemical profiling, biological profiling and co-cultivation of microbes. This chapter also 
describes method development for the GNPS molecular networking based chemical dereplication and 
identification of unknown/new metabolites present in the crude extracts of microbes. The findings 
from this chapter will be followed in the following chapters of this thesis.  
 
2.15 Experimental 
2.15.1 General experimental 
See Appendix I: General Experimental, page 260. 
 
2.15.2 Media preparation 
Two agar-based isolation media (M1 and ISP2) was used for initial processing of sheep faecal 
samples. After weighing, all the media composition was dissolved in distilled water and autoclaved 
at 121 °C for 20 min. After sterilization, the media solution was allowed to cool down (~50 °C) and 
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then supplemented with the antifungal cyclohexamide (100 μg/mL) and the antibacterial rifampicin 
(5 μg/mL) to stop the growth of any fast-growing bacteria or fungi. Then the media (10 mL) were 
poured into the petridishes, kept for solidification and preserved them in the cold room at 4°C for 
further use. 
 
2.15.3 Isolation and purification of microbes 
Twenty-one faecal samples infected with Haemonchus contortus were provided in sterile 50 mL 
falcon tube and stored at 4 °C until processed. All the samples were processed by two different 
methods and were inoculated into two agar-based isolation media (M1 and ISP2). 
 
a) Stamping method 
In this method, the sheep faecal sample (1 g) was aseptically inoculated onto the pre-prepared agar 
plate by stamping eight to nine times in a circular fashion, giving a serial dilution effect. The agar 
plates were sealed with parafilm, labelled and kept in an incubator set at 29 °C with continuous 
monitoring. 
 
b) Heat shock dilution method 
About 1 g of faecal sample was added to 8 mL of sterile water, heated for 25-30 min at 55°C in water 
bath. After vigorous shaking, the supernatant was diluted serially (10-1, 10-2, 10-3) by transferring 1 
mL into 9 mL of sterile water by means of sterile pipette. 50 μL from each dilution was then 
inoculated onto the agar plates and spread the inocula with sterile rod to make a uniform distribution 
of samples. Then the agar plates were incubated at 29 °C with continuous monitoring. 
 
After incubation, the spores or mycelia of each microbial strain were individually transferred into the 
agar plates of respective medium from their mixed culture plates. The plates of each pure strain were 
sealed with parafilm and kept in an incubator set at 29 °C. After purification each strain was assigned 
by a unique code. The code format was CMB-NB001, where “NB” stands for “Nematode Bacteria” 
and the “001” represents a sequential code number per sample or CMB-NF001, where “NF” stands 
for “Nematode Fungi” and the “001” represents a sequential code number per sample. 
 
2.15.4 Purification of microbes 
Solid culture: All the pure strains were inoculated onto the agar-based medium and then cultivated in 
incubator at 29 °C for 7-10 days with periodic inspection of the plates. The incubation time varied 
(up to 21 days) based on the growth of the slowly growing microbes.
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Liquid culture: The spores or mycelia of microbial strains were individually transferred to sterile 24-
well microbioreactor (already loaded with 1.5 mL of respective liquid media) by using sterile 
inoculation loop in sterile condition. The microbioreactor plates were incubated in an orbital platform 
shaker at 190 rpm under 29°C for 7-10 days. The incubation time varied (up to 21 days) based on the 
growth of the slowly growing microbes. 
 
2.15.5 Cryopreservation of microbes  
Pure strains cultured in both solid and liquid medium were preserved in 2 ml screw-cap cryovial in 
glycerol. At first, 500 μL of sterile 30% glycerol and 500 μL of respective broth medium were 
transferred into each vial under sterile condition. After that 100 μL of inocula from the broth culture 
or few spores/mycelia from solid agar plates were transferred into the pre-labelled respective vial. 
The contents of the vials were then mixed thoroughly by inverting several times after capping the 
vial. Per viable isolates, cryovial (´ 4) were prepared, two from liquid medium and two from solid 
medium. The vials were kept in - 20°C freezer for one hour’s snap freezing and then stored in - 80°C 
freezer for long term cryopreservation. 
 
2.15.6 Generation of crude extract library 
Solid cultures (agar plate) containing microbial strain were cut into small pieces inside the fume hood 
and transferred to 50 mL falcon tubes containing EtOAc (20.0 mL). The chopped agar was soaked in 
EtOAc followed by shaking for 30 min on the platform shaker at 150 rpm. The decantated organic 
phase was evaporated to dryness in vacuo and the organic layer was re-dissolved in 100% MeOH and 
transferred into pre-weighed vial by filtering through 0.45 μm Millipore sterile filter. For the liquid 
cultures in microbioreactor were extracted in situ with EtOAc (2 mL) after shaking at 150 rpm for 30 
min and the organic layer was transferred into clean vial by filtering through 0.45 μm Millipore sterile 
filter and dried down under N2 gas at 40 °C. The dried crude extract was then preserved in  - 20 °C 
freezer for further chemical analysis. 
 
2.15.7 Chemical analysis 
a) Sample preparation 
Crude extracts from agar cultures were redissolved in HPLC grade MeOH to make the concentration 
1 mg/mL and crude extracts from liquid culture in microbioreactor were redissolved in 60 μL of 
MeOH (HPLC grade). 
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b) UHPLC-DAD analysis of microbial crude extracts 
Aliquots (1 μL) were analyzed by UHPLC-DAD employing an Agilent Zorbax C8, 1.8 μm (2.1 × 50 
mm) column, 0.417 mL/min from 90% H2O/ MeCN to 100% MeCN and inclusive of an isocratic 
0.01% trifluoroacetic acid (TFA) modifier, with online UV-vis detection at 210, 254, 340, 400 and 
460 nm. The resulting chromatographic data were analyzed by comparing with the negative control 
in the same scale.  
c) HPLC-DAD-MS analysis of microbial crude extracts  
Aliquots (10 μL) were subjected to HPLC-DAD-ESI(±)MS analysis employing an Agilent Zorbax 
SB-C8 5 μm (150 × 4.6 mm) column, with a 15 min gradient elution at 1 mL/min from 90% 
H2O/MeCN to 100% MeCN, followed by a 5 min hold, and inclusive of an isocratic 0.05% formic 
acid (HCO2H) modifier with online UV-vis detection at 210, 254, 360 and 400 nm.  
 
9.7 High-throughput (HTP) microbioreactor cultivation of microbes using “MATRIX” 
Selected organisms were allowed to grow in eleven different media with different compositions (both 
agar and liquid) and allowed to incubate them in three different conditions (agar-static, liquid-shaking 
and liquid-static). For agar-static condition, ´ 11 wells of a 24-well microbioreactor were loaded with 
eleven different media (agar) (2.5 mL) and the microbioreactor was tilted at 45° angle to maximise 
the surface of the agar medium and kept tilted until solidification of the media. Another ´ 11 wells 
of the same microbioreactor were leaded with eleven different media (liquid) (1.5 mL) for liquid-
static culture, while remaining two wells were retained blank as control. 
For liquid-shaking conditions, ´ 11wells of a 24-well microbioreactor were loaded with eleven 
different media (liquid) (1.5 mL). All the wells were inoculated (15 μL) with the microbes and then 
incubated them at 29 °C for 7-10 days with necessary shaking at 190 rpm. The incubation time varied 
(up to 21 days) based on the growth of the slowly growing microbes.  
 
9.7.1 Microbioreactor culture extraction and chemical analysis  
The solid culture in microbioreactor was sliced inside the wells. Both the solid and liquid 
microbioreactor cultures were extracted in situ with EtOAc (2 mL) after shaking at 150 rpm for 30 
min and the organic layer was transferred into clean vial by filtering through 0.45 μm Millipore sterile 
filter and dried down under N2 gas at 40 °C. The dried crude extracts obtained from liquid culture 
were then redissolved in MeOH (60 μL) and crude extract from solid culture were redissolved in 
MeOH (1 mg/mL) containing an internal standard. An aliquot (1 μL) were analyzed by UHPLC-DAD 
employing an Agilent Zorbax C8 1.8 μm (2.1 × 50 mm) column, 0.417 mL/min from 90% H2O/MeCN 
to 100% MeCN and inclusive of an isocratic 0.01% TFA modifier, with online UV-Vis detection at 
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210, 254, 340, 400 and 460 nm. All data were analyzed using Agilent Open Lab CDS Rev.C.01.03 
(37) ChemStation software. 
2.15.8 GNPS molecular networking analysis 
UHPLC-QTOF analysis was performed employing Agilent Zorbax C8 1.8 μm (2.1 × 50 mm) column, 
with a 4.50 min gradient elution at 0.417 mL/min from 90% H2O/MeCN to 100% MeCN and 
inclusive of an isocratic 0.1% formic acid as modifier, coupled with Agilent 6545 Q-TOF, mass range 
100 – 1700 m/z. MS/MS analysis was performed to detect the ions at an intensity above 1000 counts 
with 10 scans/s, a isolation width of ~ 4 m/z using three different collision energies and a maximum 
of 3 selected precursors per cycle. The MS/MS Mass Hunter data files (.d) data were converted to 
.mzXML file format using MS convert software and loaded to the GNPS (https:// 
gnps.ucsd.edu/ProteoSAFe/static/gnpssplash. jsp), platform through FileZilla software, with default 
parameters.  
 
2.15.9 Bioassays 
2.15.9.1 Larval development assay (LDA) 
Recovery of eggs: 
For this assay, nematode eggs from sheep faecal samples (infected with Haemonchus contortus) were 
recovered by adapting our in-house protocol.  According to the method, faecal samples with positive 
egg counts were combined and weighted. Slurry was made using approx. 5 mL/gm of tap water. The 
slurry was allowed to successively filter through a 1 mm kitchen strainer, 180 μm and 100 μm 
Endecotts sieves. The collected filtrate was then transferred into 50 mL falcon tubes and then 
centrifuged at 3000 rpm for 10 min. The supernatant was discarded into a beaker containing 10% 
sodium hypochlorite. Pellets were re-suspended in saturated sodium chloride solution (specific 
gravity: 1.18-1.20) until the 50 mL mark of the falcon tube. All the falcon tubes were then shaken 
vigorously for 1 min prior to centrifuge at 2000 rpm for 10 min. The obtained supernatant was then 
filtered through 100 μm and 20 μm Endecotts sieves. After that, the 20 μm Endecotts sieve was 
flipped over into a clean beaker and rinsed with sterile water in order to retrieve the eggs.  Sugar 
gradients were prepared into 50 mL falcon tubes using a Pasteur pipette to make a gentle layer as 
follows: first 10 mL 40%, then 10 mL of 25% and 15 mL of 10% cold saturated sucrose solutions 
(specific gravity: 1.27-1.30). 10-15 mL of egg mixtures were added to the top of the sugar gradient 
with Pasteur pipette. Tubes were then centrifuged at 3500 rpm from 7 min using soft acceleration and 
deceleration. The ‘fuzzy’ layers (between the 10% and 25% interface) were collected using glass 
pipette and transferred into 50 mL Falcon tubes. Fuzzy layers were filtered through a 20 μm Endecotts 
sieve and rinse with sterile water to remove all excess sugar. The 20 μm Endecotts sieve was flipped 
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over and rinsed approximately 100 mL of sterile water. The collected filtrate was centrifuged at 2000 
rpm for 10 min to concentrate the eggs. The number of eggs was counted under the microscope using 
10 μL aliquots. The egg mixture was diluted to obtain 50 eggs per 10 μL. Amphotericin B (25 μg/ 
mL) solution was added to minimize to growth of any unwanted organisms.  
Screening for activity: 
10 μL of the crude extracts (10 μg) or pure compounds (dissolved in DMSO and diluted with H2O to 
give a 480 µM stock solution in 10% DMSO) were first added to the bottom of the 96-well plate. 10 
μL of food containing Nutritive medium (27 m of 1 g yeast solution, 90 mL 0.85% NaCl and 3 mL 
of 10x concentrated Earle’s solution) and live E.coli (4:1) was added to the each test well followed 
by the addition of 130 mL of sterile water. 10 μL of eggs (50-60 eggs) mixture was transferred into 
the plate and allowed to incubate at 27°C for 10 days. The mortality of the larvae was monitored 
everyday under light microscope equipped with a CCD video camera. The number of L3 larvae was 
counted on the 10th day of incubation.  Inhibition was measured as the % development compared to 
negative control (0.1% DMSO) while Ivermectin (1μM) was used as a positive control.     
 
2.15.9.2 Antimicrobial assay 
See Appendix I: General Experimental, page 261. 
 
2.15.9.3 Cytotoxicity assay 
See Appendix I: General Experimental, page 262. 
 
2.15.10 Taxonomy of CMB-NF100 
ITS gene sequence  
CTGGGTCACCTCCCACCCGTGTTTATCATACCTAGTTGCTTCGGCGGGCCCGCCGTCATGGCCGCC
GGGGGGCACCCGCCCCCGGGCCCGCGCCCGCCGAAGCCCCCCCTGAACGCTGTCTGAAGATTGCAG
TCTGAGCGATTAGCTAAATCAGTTAAAACTTTCAACAACGGATCTCTTGGTTCCGGCATCGATGAA
GAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAGTCTTTGAACG
CACATTGCGCCCCCTGGTATTCCGGGGGGCATGCCTGTCCGAGCGTCATTGCTGCCCTCAAGCACG
GCTTGTGTGTTGGGCCCCCGCCCCCCGGCTCCCGGGGGGCGGGCCCGAAAGGCAGCGGCGGCACCG
CGTCCGGTCCTCGAGCGTATGGGGCTTCGTCACCCGCTCTGTAGGCCCGGCCGGCGCCCGCCGGCG
ACCCCCCTCAATCTTTCTCAGGTTGACCTCGGATCAGGTAGGGATACCCGCTGAACTTAAGCATAT
CATAAACGGAGGA 
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Blast search (closest match) 
 
 
2.15.11 Medium scale cultivation of CMB-NF100 and isolation of metabolites 
CMB-NF100 was streaked on ISP2 agar plates (´ 20) and incubated at 29° C for 10 days. After 
incubation, combined agar/mycelia were extracted with EtOAc (2 ´ 300 mL) and the decantated 
organic phases were evaporated to dryness in vacuo to yield the crude extract (59.0 mg). The resulted 
crude extract was then subjected to liquid-liquid partitioning between n-hexane and aqueous MeOH 
(100 mL of each). The MeOH soluble fraction (43.0 mg) was fractionated by preparative HPLC to 
yield JBIR-137 (2.3) and janthitrem E (2.4). 
Chapter 2: Chemical dereplication, media optimization and prioritization of microorganisms 
 
 
56 
 
 
 
 
 
 
 
 
 
 
 
JBIR-137 (2.3): Light red powder, UV (MeOH) lmax (log e) 255 (4.50), 335 (4.12) nm; [α]D - 42.7, 
c 0.05, MeOH); 1D and 2D NMR (600 MHz, DMSO-d6) see Table 2.4 and Figures 2.19 – 2.20; 
HRESI(+)MS m/z 568.3415 [M+H]+  (calcd for C37H46NO4 568.3421). 
 
Janthitrem E (2.4): Red powder, UV (MeOH) lmax (log e) 255 (4.50), 335 (4.12) nm; [α]D - 24.7, c 
0.05, MeOH); 1D and 2D NMR (600 MHz, DMSO-d6) see Table 2.6 and Figures 2.21 – 2.23; 
HRESI(+)MS m/z 570.3590 [M+H]+  (calcd for C37H48NO4 570.3578). 
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3 Chapter 3: Talaropyrolide A: A New cyclic hexapeptide from sheep faeces 
derived fungus Talaromyces sp. (CMB-NF091) 
3.1 Introduction 
The fungus Talaromyces sp. CMB-NF091 was isolated from sheep faecal sample supplied from a 
sheep farm in NSW, Australia. The Global Natural Product Social (GNPS) molecular networking 
analysis followed by analytical chemical profiling of CMB-NF091 on ISP2 agar revealed a single 
dominant metabolite (MW 777). A miniaturized 24-well microbioreactor plate cultivation 
(MATRIX) was employed to investigate the wider secondary metabolism capabilities of CMB-
NF091 under multiple culture conditions. All the generated extracts were then analysed by HPLC-
DAD-ESIMS and UPLC-QTOF-MS/MS. The secondary metabolite production across ´ 33 different 
media conditions were visualized using the GNPS molecular networking analysis approach, to 
determine the optimum condition for the production of the desired metabolites. This was followed by 
scale-up cultivation of CMB-NF091 under suitable media condition, leading to the isolation and 
identification of a new cyclic hexa-peptide talaropyrolide A (3.01). This chapter focuses on the 
application of MATRIX approach along with molecular networking analysis and the isolation and 
structure elucidation of talaropyrolide A (3.01). 
 
3.2 Chemical profiling of Talaromyces sp. CMB-NF091 
3.2.1 Isolation and taxonomic identification of CMB-NF091 
CMB-NF091 showed light yellowish filamentous morphology when cultivated on ISP2 agar medium 
plate (Figure 3.1). Genomic DNA from this isolate was extracted from the mycelia using a DNeasy 
plant and tissue DNA kit (QIAGEN). The 18s rRNA genes were amplified by PCR using both the 
ITS1 and ITS4 primers. The BLAST data searching of the gene sequences and generation of the 
phylogenetic tree (Figure 3.2) by PhyML Maximum Likelihood analysis1 confirmed the CMB-
NF091 as a Talaromyces sp.  
 
 
 
 
 
 
 
Figure 3.1: Photograph of the fungus CMB-NF091cultured on ISP2 agar plate. 
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Figure 3.2: Phylogenetic tree by PhyML Maximum Likelihood analysis of 18s rRNA sequences showing the relationship 
of CMB-NF091 among selected reference strains (RefSeq GenBank) with their accession numbers.  
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KT803055.1 Talaromyces aculeatus
MF686805.1 Talaromyces pinophilus
KF572452.1 Talaromyces pinophilus
JN624892.1 Acremonium cellulolyticus
KF193985.1 Acremonium cellulolyticus
HQ871990.1 Fungal endophyte
KM396386.1 Talaromyces flavus
MF683088.1 Talaromyces verruculosus
MF683087.1 Talaromyces pinophilus
MF686804.1 Talaromyces verruculosus
JF327821.1 Talaromyces flavus
LT899791.1 Talaromyces angelicus
MH137680.1 Talaromyces flavus 
GU973629.1 Penicillium sp. A
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3.2.2 Analytical cultivation and chemical profile analysis 
A single colony of CMB-NF091 applied to an ISP2 agar plate was incubated at 29 °C for 7 day, after 
which the agar was diced and extracted with EtOAc (20 mL) and concentrated in vacuo to yield 
extract (1.5 mg). An aliquot (5 µL from 5 mg/mL in MeOH) was analysed by HPLC-DAD-ESI(±)MS 
(Zorbax SB-C8 5 µm, 150 × 4.6 mm column, with 1 mL/min gradient elution over 15 min from 90% 
H2O/MeCN to 100% MeCN, with a constant 0.5% formic acid in MeCN modifier). The HPLC-DAD-
ESI(±)MS analysis of the EtOAc extracts revealed the presence of a dominant metabolite 3.01 (MW 
777 amu) at tR = 9.12 min (Figure 3.3). 
 
Figure 3.3: HPLC-DAD (210 nm) chromatograms of (a) ISP2 agar media, (b) crude extract of CMB-NF091 cultured on 
ISP2 agar media. Inset is UV-vis (DAD) spectra of highlighted red peak. Green highlighted peak is the internal standard. 
 
3.2.3 MATRIX cultivation and GNPS analysis of CMB-NF091 
To fully explore the accessible secondary metabolite potential, a systemic investigation on the effect 
of culture conditions was conducted according to the MATRIX approach (discussed in chapter 2). 
After cultivation in ´ 11 different media under ´ 3 different culture conditions, the obtained ´ 33 
crude extracts were analysed by HPLC-DAD-MS for chemical profiling. All the crude extracts were 
also analysed by UHPLC-QTOF-MS/MS analysis for GNPS studies and generation of molecular 
network using GNPS platform.2 
 
The molecular network (MN) obtained for the ´ 33 different extracts of CMB-NF091 showed the 
presence of different classes of compounds that share MS/MS spectral similarities (Figure 3.4). In 
the generated MN, the obtained total nodes were filtered from the media and solvent peaks. A peak 
list was then built by correlating the HPLC chromatographic peaks with their corresponding m/z 
values and retention time. The targeted search showed the presence of 3.01 (m/z = 778, red in the 
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cluster) in a six membered cluster in a quantitative level along with three isomers. The further 
chromatographic analysis of the HPLC-MS profile showed the maximum level of production of 3.01 
on ISP2 agar media along with ´ 33 different media conditions (Figure 3.5).   
 
Figure 3.4: Molecular network of the crude extracts obtained from the MATRIX cultivation of CMB-NF091. Related 
parent ions were clustered based on their MS/MS fragmentation similarities. 
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Figure 3.5: HPLC-DAD (210 nm) profiles of crude extracts of CMB-NF091 cultured in different culture conditions and 
the UV-vis spectrum with m/z values of the highlighted red peak (3.01). (green = internal standard).   
 
3.2.4 Scale-up cultivation and fractionation of CMB-NF091 metabolites 
Following the MATRIX cultivation, GNPS analysis and chemical profiling, a scale-up cultivation on 
ISP2 agar (´ 40) plates yielded a crude EtOAc extract (80 mg) that was sequentially subjected to 
solvent trituration (n-hexane, DCM and MeOH). Reversed-phase fractionation of the combined DCM 
and MeOH soluble extracts yielded talaropyrolide A (3.01) (Scheme 3.7, in the experimental section). 
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3.2.5 Structure elucidation 
3.2.5.1 Talaropyrolide A (3.01) 
 
 
 
 
 
 
 
 
 
 
 
HRESI(+)MS analysis of 3.01 revealed as a sodiated molecular ion [(M+Na)+] attributed to a 
molecular formula C40H55N7O9 (Δmmu + 0.2) requiring ´ 17 double bond equivalents (DBEs). The 
preliminary examination of 1H NMR (DMSO-d6) data for 3.01 (Figure 3.6) suggested a peptide like 
structure, as evidenced by a series of amino acid a-protons (dH 4.06 – 5.26) and amide N-H 
resonances.  The 13C NMR (DMSO-d6) data for 3.01 (Figure 3.7) also exhibited characteristic 
resonances for aromatic carbons (dC 115.0 – 155.9) and amide carbonyls (dC 169.8 – 171.6), 
suggestive of a peptide like natural product. Further analysis of 1H- 13C HSQC and COSY data of 
3.01 also confirmed the presence of ´ 7 amino acid a-protons (Figure 3.8 and 3.9), while a C3 
Marfey’s analysis identified the presence of the five amino acid residues L-Tyr, D-allo-Ile, L-Pro, L-
Thr and L-Ala (Figure 3.10).  
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Figure 3.6: 1H NMR (600 MHz, DMSO-d6) spectrum of talaropyrolide A (3.01). 
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Figure 3.7: 13C NMR (150 MHz, DMSO-d6) spectrum of talaropyrolide A (3.01). 
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Figure 3.8: 1H - 13C HSQC (DMSO-d6) data for talaropyrolide A (3.01). Expansion shows resonances for the amino 
acid a-protons.   
 
Figure 3.9: COSY (DMSO-d6) data for talaropyrolide A (3.01). Expansion shows resonances for the amino acid a-
protons and N-Hs.   
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Table 3.1: 1D and 2D NMR (DMSO-d6) data for talaropyrolide (3.01) 
 
a – f assignments for overlapping resonances 
Position δH, mult, (J in HZ) δC COSY 1H-13C HMBC  ROESY 
L-Ala1 
1  171.4    
2 4.30, dd (6.2, 6.3) 48.7 3, N-H 1, 3, C-1 (D-allo-Ile 2) N-H, N-H (D-allo-Ile 2) 
3 1.30, d (6.3) 20.3 2 1, 2 2, N-H 
N-H 7.41, d (6.2)  2 1, C-1 (D-allo-Ile 2) 3 
D-allo-Ile2 
1  170.2d    
2 5.26, dd (9.5, 1.9) 51.8 3, N-H 1, 3, 4, 6 3, 5, N-H (L-Tyr3) 
3 1.85, m 36.7 2, 4, 6 4, 6 2, 4, 6 
4 1.18, m 26.3 3, 5 2, 5 6 
5 1.03a, m 11.7 4 3, 4  
6 0.82, d (6.8) 14.6 3 2, 3, 4 N-H 
N-H 8.19, d (9.5)  2 2, C-1 (L-Tyr3) 2, 6, H-2 (L-Ala1),   
H-2 (L-Tyr3) 
L -Tyr3 
1  171.6    
2 4.59, dd (9.4, 1.9)                                                                                                                                                                                                                                                   56.5 3, N-H 1, 3, C-1 (L-Pro4) 3, 5/9, N-H (D-allo-Ile 2) 
3 a. 2.95, m; b. 2.91, m 36.1 2 1, 4, 5, 9 2, 5/9 
4  127.6    
5/9 7.06, d (8.4) 129.8 6/8 3, 7, 9/5 2, 3, 6/8 
6/8 6.66, d (8.4) 115.0 5/9 4, 7, 8/6 5/9 
7  155.9    
N-H 8.30, d (9.4)  2  2, H-2 (D-allo-Ile 2) 
L-Pro4 
1  170.2d    
2 4.38, dd (8.6, 1.6) 61.7 3a, 3b 1, 3, 4, 5 3a, 4a 
3 a. 2.14, m; b. 1.99, m 29.4 2, 4a, 4b 5 2 
4 a. 1.96, m; b. 1.76, mb 23.8 3a, 3b, 5a, 5b 2, 3 2 
5 a. 3.75, m ; b. 3.66, m 46.0 4a, 4b 3, 4  
D-allo-Ile5  
1  170.1    
2 4.88, dd (8.8, 3.3) 54.8 3, N-H 1, 3, 4, 6 3, 4, 5, H-2 (L-Thr6) 
3 1.76b, m 38.3 2, 4, 6 1, 4, 6 2 
4 a. 1.45, m 
b. 1.03a, m 
26.5 3, 5 2, 3 2 
5 1.04 12.0 4 3, 4 2 
6 0.42, d (6.7) 13.8 3 2, 4, 5 N-H 
N-H 7.99, d (8.8)  2 1 2, 6, H-4'(Pya-enol) 
L-Thr6  
1  169.8    
2 4.06, dd (9.6, 2.5) 58.6 3, N-H 3, (C-1)-L-Ala1 4, H-2 (D-allo-Ile 5) 
3 4.12, dd (6.2, 2.5) 66.3 2, 4 2, 4  
4 1.03a 20.7 3 2, 3 2 
N-H 8.53c  2   
Pya [acetal tautomer (95%)]  
1'  168.0    
2' 8.53 c 118.2    
3'  139.0    
4' 7.80, d (8.0) 128.7 5' 1', 3', 6' 5', N-H (D-allo-Ile 5) 
5' 7.12, dd (7.6, 7.6) 122.5 4', 6' 3', 7' 4', 6' 
6' 7.48, dd (8.0, 5.6) 132.4 5', 7' 3', 4' 5' 
7' 8.49 118.8 6¢ 2', 5'  
1'-OH 12.03, s, br   2'  
Pya [ester tautomer (5%)] 
4' 7.37, d (7.5)     
5' 7.13e     
6' 7.43f     
7' 8.08, d (8.1)     
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Figure 3.10: C3 Marfey’s HPLC-DAD-ESI(+)MS analysis (Agilent Zorbax SB-C3 column, 5 µm, 4.6 × 150 mm, 50 °C, 
with a 1 mL/min, 55 min linear gradient elution from 15% to 60% MeOH/H2O with a 5% isocratic modifier of 1% formic 
acid in MeCN). (a) DAD (340 nm) chromatogram of hydrolysate of talaropyrolide A (3.01) derivatized with D-FDAA. 
(b-f) Single ion extraction chromatograms at m/z [M+H]+ for derivatized hydrolysate of 3.01 (solid red coloured) 
compared to an authentic standard(s) (dotted) for (b) m/z = 372, D-Thr + D-FDAA (tR = 15.8 min), L-Thr + D-FDAA (tR 
= 22.2 min), D-allo-Thr + D-FDAA (tR = 17.3 min), L-allo-Thr + D-FDAA (tR = 20.4 min), (c) m/z = 434, D-Tyr + D-
FDAA (tR = 15.9 min), L-Tyr + D-FDAA (tR = 33.3 min), (d) m/z = 384, D-allo-Ile + D-FDAA (tR = 36.0 min), L-allo-Ile 
+ D-FDAA (tR = 45.5 min), D-Ile + D-FDAA (tR = 35.5 min), L-Ile + D-FDAA (tR = 45.0 min), (e) m/z = 368, L-Pro + L-
FDAA (tR = 21.6 min), D-Pro + L-FDAA (tR = 23.9 min), (f) m/z =  342, D-Ala + D-FDAA (tR = 21.3 min), L-Ala + D-
FDAA (tR = 27.9 min) * residual of Marfey’s reagent (D-FDAA). 
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Following C3 Marfey’s analysis, the regiochemistry of the six amino acid residues was made from 
detailed 1D and 2D NMR analysis as described below. 
Fragment L-Ala1 and D-allo-Ile2-NH 
The sequence of amino acid L-Ala1 and D-allo-Ile2 was established by interpretation of HMBC and 
ROSEY correlations. A strong correlation between was visible the H-2 (dH 4.30) of L-Ala1 and the N-
H (dH 8.19) of D-allo-Ile2 in the ROESY spectra (Figure 3.11). Though the C-1 carbonyl resonances 
for D-allo-Ile2 and L-Pro4 overlapped (dC 170.2), an HMBC correlation was observed from both H-2 
(dH 4.30) and N-H (dH 7.41) of L-Ala1 to the C-1 carbonyl (dC 170.2) of D-allo-Ile2, consistent with 
the ROESY correlation, suggestive the assignment of D-allo-Ile2 next to L-Ala1 residues (Figure 3.12 
and 3.13).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Expanded 1H – 13C HMBC (DMSO-d6) data for fragment L-Ala1-D-allo-Ile2-NH. Expansion shows 
resonances for the amino acid a-protons. 
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Figure 3.13: 1H – 13C HMBC (DMSO-d6) data for talaropyrolide A (3.01). Expansion shows resonances for N-Hs.  
 
Fragment D-allo-Ile2 and L-Tyr3-NH 
The fragment D-allo-Ile2 to L-Tyr3 was also evident an interpretation of key correlations observed in 
the HMBC and ROSEY spectra (Figure 3.14). Specifically, HMBC correlations observed both from 
the N-H (dH 8.19) of D-allo-Ile2 and H-2 (dH 4.59) of L-Tyr3 to the C-1 (dC 171.6) of L-Tyr3, established 
the connection between these two amino acids (Figure 3.15). Additional ROESY correlations 
between H-2 (dH 5.26) of D-allo-Ile2 and N-H (dH 8.30) of L-Tyr3 and between H-2 (dH 4.59) of L-Tyr3 
and the N-H (dH 8.19) of D-allo-Ile2, supplied the linkage of amino acids D-allo-Ile2 and L-Tyr3 
residues (Figure 3.14). 
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Figure 3.14: Key 2D NMR (DMSO-d6) correlations for fragment D-allo-Ile2-L-Tyr3-NH. 
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Figure 3.15: 1H – 13C HMBC (DMSO-d6) data for talaropyrolide A (3.01). Expansion shows resonances for N-Hs. 
Fragment L-Tyr3-L-Pro4-NH 
The next sequence of L-Tyr3 and L-Pro4 was established based on HMBC correlations. Though the 
C-1 carbonyls of D-allo-Ile2 and L-Pro4 was overlapped (dC 170.2), HMBC correlations from H-2 (dH 
4.59) of L-Tyr3 to the C-1 carbonyl (dC 170.2) of L-Pro4 suggested the presence of L-Pro4 next to L-
Tyr3 (Figure 3.16 and Figure 3.17).  
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Figure 3.16: Key 2D NMR (DMSO-d6) correlations for fragment L-Tyr3-L-Pro4-NH. 
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Figure 3.17: 1H-13C HMBC (DMSO-d6) data for talaropyrolide A (3.01). Expansion shows resonances for the amino acid 
a-protons.   
Fragment D-allo-Ile5-L-Thr6-O-Pya or D-allo-Ile5-L-Thr6-NH-Pya 
The other sequences of D-allo-Ile5 to L-Thr6 and the pyridyl moiety (Pya) was established based on 
ROESY correlations.  The ROESY correlation between H-2 (dH 4.06) of L-Thr6 and H-2 (dH 4.88) of 
D-allo-Ile5 and between the N-H (dH 7.99) of D-allo-Ile5 and H-4¢ (dH 7.80) of -Pya, was supportive 
the D-allo-Ile5-L-Thr6-Pya moiety (Figure 3.18).  
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Fragment L-Thr6 and L-Ala1-NH 
Another sequence fragment of L-Thr6-L-Ala1 was determined based on the HMBC correlations. In 
the HMBC spectra, a correlation from H-2 (dH 4.06) of L-Thr6 to the C-1 (dC 171.4) of L-Ala1, 
confirmed a of L-Thr6 to L-Ala1 linkage (Figure 3.19 and Figure 3.20).  
 
Figure 3.19: 1H – 13C HMBC (DMSO-d6) data for talaropyrolide A (3.01). Expansion shows resonances for the amino 
acid a-protons. 
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Figure 3.21: Key 2D NMR (DMSO-d6) correlations of talaropyrolide A (3.01). 
 
UHPLC-QTOF-MS/MS fragmentation of Talaropyrolide A (3.01) 
Further analysis UHPLC-QTOF-MS/MS fragmentation of 3.01 identified a fragment ion (m/z 431) 
corresponds to the structure fragment -L-Tyr3-D-allo-Ile2-L-Ala1, confirmed the presence of this 
moiety. Talaropyrolide A (3.01) also showed a fragment ion (m/z 665.3301) corresponds to the loss 
of D-allo-Ile5 followed by a subsequent generation of fragment (m/z 568) suggesting the presence of 
-L-Pro4 in the same sequence. The further generation of fragment ion (m/z 405) advising the loss of -
L-Tyr3 residue. The subsequent generation of fragment (m/z 286.1766) suggestive to the loss of -pya  
residue (Figure 3.22). 
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Figure 3.22: UHPLC-QTOF-MS/MS fragmentation of talaropyrolide A (3.01). 
3.2.5.2 Cyclic peptide vs depsipeptide 
Although the HMBC correlation from H-2 (dH 4.06) of L-Thr6 to the C-1 (dC 171.4) of L-Ala1 residues 
was supportive of a “cyclic peptide” rather than “cyclic depsipeptide” structure for 3.01, however, 
further evidence of this assignment was required. 
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Literature reports have demonstrated that alkaline hydrolysis of cyclic depsipeptides can result in 
selective hydrolysis or reduction of the lactone moiety to yield linear peptides.3-5. According to the 
literature data, ring opening of 3.01 could performed as described below. 
 
 
 
Scheme 3.1: Proposed hydrolysis and reduction scheme for 3.01 
 
3.2.5.3 Attempted LiOH hydrolysis of 3.01 
A study by Tariq et al.6 reported the LiOH based hydrolysis of the lactone moiety of some model 
depsipeptides. following the reported method, 3.01 (0.5 mg) was dissolved in 1 mL of 1 mM LiOH 
(in methanol) and stirred for 12 h at 40 °C. Aliquots taken at different time point (1 h, 2 h and 12 h) 
were analyzed by HPLC-MS and UHPLC-QTOF-MS/MS. Single ion extraction for the desired 
hydrolyzed molecular ion in the HPLC-MS-chromatogram analyses failed to detect the presence of 
any linear peptide, and 3.01 recovered after 12 h of treatment (Figure 3.23).  
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Figure 3.23: (a) HPLC-DAD-MS chromatogram of talaropyrolide A (3.01) (b) single ion extraction chromatogram at 
m/z = 778 (M+H)+, (c) single ion extraction chromatogram at m/z = 796 (M+H)+. 
 
3.2.5.4 Attempted KOH hydrolysis of 3.01 
Another study by Anokha et al.7 reported that KOH based hydrolysis of a sponge derived cyclic 
depsipeptide theopapuamide, resulted in cleavage of lactone linkage to yield the linear peptide.  
Following this literature method, 3.01 (0.5 mg) was dissolved in 1 mL of 1N KOH (in methanol) and 
stirred for 12 h at 40 °C. Aliquots taken at different time point (1 h, 2 h and 12 h) were analyzed by 
HPLC-MS and UHPLC-QTOF-MS/MS, but failed to detect the production of any linear peptide, with 
3.01 recovered after 12 h of treatment (Figure 3.24).  
 
 
Figure 3.24: (a) HPLC-DAD-MS chromatogram of talaropyrolide A (3.01) (b) single ion extraction chromatogram at 
m/z = 778 (M+H)+, (c) single ion extraction chromatogram at m/z = 796 (M+H)+. 
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3.2.5.5 Attempted NaBH4 reduction of 3.01 
Other studies reported the NaBH4 based hydrolysis and reduction of lactone linkages in cyclic 
depsipeptides. For example, NaBH4 based reduction of a tricyclic depsipeptide microviridin revealed 
the linear analogue, which helped to prove the amino acid sequence.4 Following this literature method, 
3.01 (0.5 mg) was dissolved in 1 mL of 1 mM NaBH4 (in methanol) and stirred for 12 h at 40 °C.  
Aliquots taken at different time point (1 h, 2 h and 12 h) were analyzed by HPLC-MS and UHPLC-
QTOF-MS/MS. A careful search failed to detect the reduced molecular ion mass in the HPLC-MS 
chromatogram, with 3.01 recovered after 12 h of treatment (Figure 3.25).  
 
 
Figure 3.25: (a) HPLC-DAD-MS chromatogram of talaropyrolide A (3.01) (b) single ion extraction chromatogram at 
m/z = 778 (M+H)+, (c) single ion extraction chromatogram at m/z = 782 (M+H)+. 
 
All the above studies supported the cyclic peptide structure of 3.01, also suggested the presence of an 
ester linkage between 2-pyridyl acetyl (Pya) and L-Thr6 residue of peptide, that supposed to cleave 
during the attempted LiOH/KOH hydrolysis of 3.01 (Scheme 3.2). However, search for the 
corresponding of molecular ion (M+H)+ 659 (3.01 without -Pya moiety) in the chromatogram, failed 
to detect , with 3.01 recovered after 12 h of treatment (Figure  3.26 and Figure 3.27). The possible 
reason could be the acetal-ester tautomerism about the 2-pyridyl acetyl moiety of 3.01, which was 
differentially expressed in different solvents, and discussed in the following part of this chapter. 
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Scheme 3.2: Proposed cleavage of lactone linkage to release the 2-pyridyl moiety from 3.01. 
 
Figure 3.26: (a) HPLC-DAD-MS chromatogram of talaropyrolide A (3.01) (b) single ion extraction chromatogram at 
m/z = 778 (M+H)+, (c) single ion extraction chromatogram at m/z = 659 (M+H)+. 
 
 
Figure 3.27: (a) HPLC-DAD-MS chromatogram of talaropyrolide A (3.01) (b) single ion extraction chromatogram at 
m/z = 778 (M+H)+, (c) single ion extraction chromatogram at m/z = 659 (M+H)+. 
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3.2.6 Confirmation of a binary equilibrium for 3.01 
The 1D NMR (both in DMSO-d6 and methanol-d4) data for 3.01 revealed a doubling resonance. 
Further analysis of the 1H NMR (DMSO-d6) data for 3.01 revealed the resonance of the 2-pyridyl 
(Pya) moiety as a 95:5 mixture of acetal-ester tautomers, where the dominant acetal tautomer 
evidenced by doubled methine resonances for C-2¢ (dC 118.2) and H-2¢ (dH 8.53). In contrast, the 1H 
NMR (methanol-d4) data for 3.01 showed a 1:1.5 mixture of acetal-ester tautomers (Figure 3.28).  
The methanol-d4 data also featured the quantitative deuterium exchange about C-2¢ of the 2-pyridyl 
moiety (Figure 3.28). The latter was validated by HRESIMS analysis of 3.01, which confirmed the 
predicted deuterium incorporation (C40H53D2N7O9, Δmmu - 0.4) consistent with a facile acetal-ester 
tautomerism (Figure 3.30).  
 
Figure 3.28: Plausible acetal-ester tautomeric structure of 2-pyridyl moiety of talaropyrolide A (3.01). Expanded 1H 
NMR of the aromatic proton zone, top = methanol-d4, bottom = DMSO-d6. 
 
  
 
Figure 3.29: HRESI (+)MS spectrum of talaropyrolide A (3.01). 
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Figure 3.30: HRESI (+)MS spectrum of talaropyrolide A (3.01) with D2O. 
 
3.2.7 Elucidating the tautomerism  
Significantly, to the best of our knowledge neither the 2-
pyridyl acetate nor 2-pyridyl acetamide have been reported in 
the natural product literature with the only presence of this 
moiety being for semi-synthetic anti-tubercular agent 
spectinamide (3.02), synthesized by the derivatization of the 
antibacterial Streptomyces spectabilis metabolite 
spectinomycin.8  To better understand the acetal-ester tautomerism, we synthesized a series of 
derivatives of 2-pyridyl acetic acid i.e., 2-pyridyl acetyl benzoate (3.03), 2-pyridyl acetyl benzamide 
(3.04), O-(2-pyridyl acetyl)-N-Boc-L-Thr-OH (3.08), O-(2-pyridyl acetyl)-N-Boc- L-Thr-NH2 (3.09), 
N-(2-pyridyl acetyl)-O-t-butyl- L-Thr-OH (3.14) and N-(2-pyridyl acetyl)-O-t-butyl- L-Thr-NH2 
(3.15).  
3.2.7.1 Synthesis of 2-pyridyl acetyl benzoate (3.03) and 2-pyridyl acetyl benzamide (3.04) 
 
2-pyridyl acetyl benzoate (3.03) 
 
A single step synthesis of benzoate derivatives of 2-pyridyl acetic acid was conducted according to 
Scheme 3.3 (detail in the experimental section).  
 
 
 
 
 
 
 
 
 
 
 
N
OH
O N
O
O
(3.03)
Br
 DMF, 0℃ to rt, 
over night
NaHCO3
Scheme 3.3: Synthesis of 2-pyridyl acetyl benzoate (3.03) 
(C40H53D2N7O9, Dmmu - 0.4) 
HO
H
N
O
O O
HN
O N
OH
H
NH
H
H
OH
spectinamide (3.02)
Chapter 3: Talaropyrolide A: A new cyclic hexapeptide from sheep faeces derived fungus Talaromyces sp. (CMB-NF091) 
 
 
83 
 
 
 
Figure 3.31: 1H NMR (600 MHz, DMSO-d6) spectrum of 2-pyridyl acetyl benzoate (3.03) 
 
Table 3.2: 1D and 2D NMR (600 MHz, DMSO-d6) data for 2-pyridyl acetyl benzoate (3.03) 
Position δC δH, mult, (J in Hz) COSY HMBC 
1 66.4 5.13, s  1¢, 2, 3/7 
2 136.4    
3/7 128.5 7.36a  1, 2 
4/6 128.3 b 7.34a   
5 128.3 b 7.32a   
1¢ 170.4    
2¢ 42.7 3.98, s  1¢, 3¢, 4¢ 
3¢ 154.3    
4¢ 125.3 7.49, d (7.6) 5¢ 2¢, 3¢, 6¢ 
5¢ 138.8 7.90, dd (7.6, 7.6) 4¢, 6¢ 3¢, 7¢ 
6¢ 123.2 7.41, dd (7.6, 5.0) 5¢, 7¢ 4¢, 7¢ 
7¢ 148.4 8.57, d (5.0) 6¢ 3¢, 5¢, 6¢ 
     a – b assignments for overlapping resonances. 
 
 
 
 
Comparative analysis of NMR data of 3.03 from both methanol-d4 and DMSO-d6 revealed the 
resonances for H-2¢ (δH 3.98), consistent with a single ester tautomer. Significantly methanol-d4 data 
featured the quantitative deuterium exchange about H-2¢ (Figure 3.33), consistent with a facile ester-
acetal equilibrium. 
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Figure 3.32: Key 2D NMR (DMSO-d6) correlations for 2-pyridyl acetyl benzoate (3.03) 
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Figure 3.33: 1H NMR (600 MHz) spectrum of 2-pyridyl acetyl benzoate (3.03), red (methanol-d4), blue (DMSO-d6).  
 
2-pyridyl acetyl benzamide (3.04) 
A single step synthesis of benzyl amide derivatives of 2-pyridyl acetic acid was carried out according 
to Scheme 3.4 (detail in the experimental section).  
 
 
 
 
Figure 3.34: 1H NMR (600 MHz, DMSO-d6) spectrum of 2-pyridyl acetyl benzamide (3.04). 
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Table 3.3: 1D and 2D NMR (600 MHz, DMSO-d6) data for 2-pyridyl acetyl benzamide (3.04) 
Position δC δH, mult, (J in Hz) COSY HMBC 
1 42.7 4.03, s  2, 3/7 
2 134.4    
3/7 129.2 7.45a   
4/6 129.0 7.39a   
5 128.9 7.41a   
1¢ b    
2¢ 128.2 7.43a   
3¢ 143.3    
4¢ 110.0 7.72, d (8.0) 5¢ 2¢, 6¢, 7¢ 
5¢ 127.7 7.54, dd (8.0, 7.2) 4¢,  4¢, 6¢, 7¢ 
6¢ 124.9 7.43a 5¢, 7¢ 3¢, 4¢, 7¢ 
7¢ 119.5 7.98, d (8.3)  4¢, 5¢, 6¢ 
1¢-OH  13.7, br s  2¢ 
NH  8.18, br s  1, 1¢ 
    a = assignments for overlapping resonances, b = signal not observed. 
 
 
 
 
The detailed analysis of NMR (DMSO-d6) data for 3.04 revealed resonances for an aminol tautomer 
(H-2¢, dH 7.43; C-2¢,dC 128.2; 1¢-OH, dH 13.7), while the methanol-d4 data revealed resonances for an 
amide tautomer, with deuterium exchange about H-2¢ (Figure 3.36).  
 
 
 
 
 
 
 
 
Figure 3.35: Key 2D NMR (DMSO-d6) correlations for 2-pyridyl acetyl benzamide (3.04) 
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Figure 3.36: 1H NMR (600 MHz) spectrum of 2-pyridyl acetyl benzamide (3.04), red (methanol-d4), blue (DMSO-d6). 
 
3.2.8 Synthesis of O-(2-pyridyl acetyl)-N-Boc-L-Thr-OH (3.08) and O-(2-pyridyl acetyl)-N-
Boc-L-Thr-NH2 (3.09) 
To incorporate the threonine with the 2-pyridyl acetyl moiety through an ester linkage, O-(2-pyridyl 
acetyl)-N-Boc-L-Thr-OH (3.08) and O-(2-pyridyl acetyl)-N-Boc-L-Thr-NH2 (3.09) were synthesized 
according to Scheme 3.5 (detail in the experimental section). 
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Scheme 3.5: Synthesis of O-(2-pyridyl acetyl)-N-Boc-L-Thr-OH (3.08) and O-(2-pyridyl acetyl)-N-Boc-L-Thr-NH2 
(3.09). (i) benzyl bromide, NaHCO3, DMF, 0 °C 2 h, rt 12 h, under N2 (ii) 2-pyridyl acetic acid HCl, DMAP, EDC, DCM, 
0 °C 2h, rt 12 h, under N2 (iii) 10% Pd/C, EtOAc, rt, 14 h, H2 gas, (iv) NH4Cl, EDC HCl salt, HOBt, DMF, 0° C 30 min, 
rt, 3 h, under N2. 
 
 O-(2-pyridyl acetyl)-N-Boc-L-Thr-OH (3.08) 
 
 
 
 
 
 
 
 
 
Figure 3.37: 1H NMR (600 MHz, DMSO-d6) spectrum of O-(2-pyridyl acetyl)-N-Boc-L-Thr-OH (3.08). 
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Table 3.4: 1D and 2D NMR (600 MHz, DMSO-d6) data for O-(2-pyridyl acetyl)-N-Boc-L-Thr-OH (3.08). 
Position dC dH, mult (J in Hz) COSY HMBC 
1 171.2    
2 56.8 4.19, dd (3.5, 3.5) 3, NH 1, 3, 4, N-CO2C(CH3)3 
3 70.4 5.20, m 2, 4 1, 2, 4 
4 16.7 1.18, d (6.3) 3 2, 3 
NH  6.99, d (9.1) 2  
N-CO2C(CH3)3 155.8    
N-CO2C(CH3)3 78.5    
N-CO2C(CH3)3 28.1 1.40, s  N-CO2C(CH3)3 
1¢ 168.9    
2¢ 41.9 3.89, br s  1', 3' 
3¢ 153.1    
4¢ 124.9 7.49, d (7.8) 5¢ 2¢, 3¢, 5¢, 6¢ 
5¢ 138.8 7.93, dd (7.8, 7.6) 4¢, 6¢ 3¢, 4¢, 6¢ 
6¢ 122.9 7.44, dd (7.6, 5.2) 5¢, 7¢ 5¢, 7¢ 
7¢ 147.4 8.58, d (5.2) 6¢ 3¢, 5¢, 6¢ 
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Figure 3.38: Key 2D NMR (DMSO-d6) correlations for O-(2-pyridyl acetyl)-N-Boc-L-Thr-OH (3.08). 
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O-(2-pyridyl acetyl)-N-Boc-L-Thr-NH2 (3.09) 
 
 
 
 
 
Figure 3.39: 1H NMR (600 MHz, DMSO-d6) spectrum of O-(2-pyridyl acetyl)-N-Boc-L-Thr-NH2 (3.09). 
 
Table 3.5: 1D and 2D NMR (600 MHz, DMSO-d6) data for O-(2-pyridyl acetyl)-N-Boc-L-Thr-NH2 (3.09). 
Position dC dH, mult (J in Hz) COSY HMBC 
1 171.3    
2 57.7 4.07, dd (4.3, 4.3) 3, NH 1, 3, 4, N-CO2C(CH3)3 
3 71.0 5.11, m 2, 4 1, 2, 4 
4 17.0 1.15, d (6.3) 3 2, 3 
NH  6.65, d (8.8) 2 2 
NH2 
  
7.43, s 
7.19, s  
1, 2 
1, 2 
N-CO2C(CH3)3 155.8    
N-CO2C(CH3)3 78.5    
N-CO2C(CH3)3 28.0 1.47, s  N-CO2C(CH3)3 
1¢ 169.2    
2¢ 42.1 3.92, br s  1', 3' 
3¢ 153.2    
4¢ 125.6 7.54, d (7.6) 5¢ 2¢, 3¢, 5¢, 6¢ 
5¢ 139.8 7.99, dd (7.6, 6.8) 4¢, 6¢ 3¢, 4¢, 6¢ 
6¢ 123.5 7.50, dd (6.8, 6.1) 5¢, 7¢ 5¢, 7' 
7¢ 147.4 8.61, d (6.1) 6¢ 3¢, 5¢, 6¢ 
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Comparative analysis of NMR (DMSO-d6 and methanol-d4) data for both O-(2-pyridyl acetyl)-N-
Boc-L-Thr-OH (3.08) and O-(2-pyridyl acetyl)-N-Boc-L-Thr-NH2 (3.09) revealed the resonances for 
a single ester tautomer, while the methanol-d4 data featured quantitative deuterium exchange about 
H-2¢, indicating a facile ester-acetal equilibrium (Figure 3.41 - 3.42). 
 
 
 
 
 
 
 
Figure 3.41: 1H NMR (600 MHz) spectrum of O-(2-pyridyl acetyl)-N-Boc-L-Thr-OH (3.08), red (methanol-d4), blue 
(DMSO-d6), (x = impurities). 
 
 
[ppm] 8  6  4  2 
7' 6'
4'5'
3 2
2'
D
M
SO
-d
6
4
NH
7' 6'
4'5'
3
2
N
-C
O
2-C
(C
H
3) 3
4
H
2O
H
2O
m
et
ha
no
l-d
4
X
N
-C
O
2-C
(C
H
3) 3
NH2
O
N
H
O
O
O
O
N
1
3
1′ 2′
4′
7′
COSY
HMBC
Figure 3.40: Key 2D NMR (DMSO-d6) correlations for O-(2-pyridyl acetyl)-N-Boc-L-Thr-NH2 (3.09). 
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Figure 3.42: 1H NMR (600 MHz) spectrum of O-(2-pyridyl acetyl)-N-Boc-L-Thr-NH2 (3.09), red (methanol-d4), blue 
(DMSO-d6). 
 
 
3.2.9 Synthesis of N-(2-pyridyl acetyl)-O-t-butyl-L-Thr-OH (3.14) and N-(2-pyridyl acetyl)-
O-t-butyl-L-Thr-NH2 (3.15) 
Synthesis of the N-substituted derivatives of L-Threonine, N-(2-pyridyl acetyl)-O-t-butyl-L-Thr-OH 
(3.14) and N-(2-pyridyl acetyl)-O-t-butyl-L-Thr-NH2 (3.15), was carried out according to Scheme 3.6 
(detailed in the experimental section). 
 
 
 
Scheme 3.6: Synthesis of N-(2-pyridyl acetyl)-O-t-butyl-L-Thr-OH (3.14) and N-(2-pyridyl acetyl)-O-t-butyl-L-Thr-NH2 
(3.15) (i) benzyl bromide, NaHCO3, 0 °C 2 h, rt 12 h, under N2, DMF (ii) 20% piperidine, DCM, 20 min, 0 °C - rt, (iii) 
2-pyridyl acetic acid HCl, DMAP, DCC, 0 °C 2 h, rt 12 h, under N2, DCM, (iii) 10% Pd/C, EtOAc, rt, 14 h, H2 gas, (iv) 
NH4Cl, EDC HCl salt, HOBt, 0 °C, 30 min, rt, 3 h, under N2, DMF.   
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N-(2-pyridyl acetyl)-O-t-butyl-L-Thr-OH (3.14) 
 
 
 
Figure 3.43: 1H NMR (600 MHz, DMSO-d6) spectrum of N-(2-pyridyl acetyl)-O-t-butyl-L-Thr-OH (3.14). (x = 
impurities). 
 
Table 3.6: 1D and 2D NMR (600 MHz, DMSO-d6) data for N-(2-pyridyl acetyl)-O-t-butyl-L-Thr-OH (3.14). 
Position dC dH, mult (J in Hz) COSY HMBC 
1 172.0    
2 57.6 4.23, m  3, NH 1, 3, 4 
3 67.1 4.10, m 2, 4 2, 4 
4 20.5 1.03, d (6.2) 3 2, 3 
NH  8.00, d (8.8) 2 2 
O-C(CH3)3 73.1    
O-C(CH3)3 28.2 1.09, s  O-C(CH3)3 
1¢ 169.3    
2¢ 44.3 3.77, m  1', 3', 4' 
3¢ 156.3    
4¢ 123.7 7.34, d (7.7) 5¢ 2¢, 5¢, 6¢ 
5¢ 136.5 7.72, dd (7.7, 7.5) 4¢, 6¢ 3¢, 4', 6¢, 7' 
6¢ 121.7 7.24, dd (7.5, 4.8) 5¢, 7¢ 4', 5¢ 
7¢ 148.8 8.47, d (4.8) 6¢ 3¢, 5¢ 
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N-(2-pyridyl acetyl)-O-t-butyl-L-Thr-NH2 (3.15) 
 
 
 
 
Figure 3.45: 1H NMR (600 MHz, DMSO-d6) spectrum of N-(2-pyridyl acetyl)-O-t-butyl-L-Thr-NH2 (3.15) 
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Figure 3.44: Key 2D NMR (DMSO-d6) correlations for N-(2-pyridyl acetyl)-O-t-butyl-L-Thr-OH (3.14).  
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Table 3.7: 1D and 2D NMR (600 MHz, DMSO-d6) data for N-(2-pyridyl acetyl)-O-t-butyl-L-Thr-NH2 (3.15) 
Position dC dH, mult (J in Hz) COSY HMBC 
1 172.1    
2 58.2 4.13, dd (6.3, 3.2)  3, NH 1', 1, 3, 4 
3 67.1 3.97, m 2, 4 1, 2, 4 
4 19.9 0.97, d (6.3) 3 2, 3 
NH  7.89, d (8.4) 2 2 
NH2 
  
7.18, s 
7.22, s  
1, 2 
1, 2 
O-C(CH3)3 73.8    
O-C(CH3)3 28.5 1.12, s  O-C(CH3)3 
1¢ 169.5    
2¢ 44.9 3.77, dd (8.0,4.0)  1', 3' 
3¢ 156.7    
4¢ 124.3 7.36, d (7.5) 5¢ 2¢, 5¢, 6¢ 
5¢ 137.1 7.76, dd (7.5, 7.5) 4¢, 6¢ 3¢, 6¢ 
6¢ 122.2 7.28, dd (7.5, 4.8) 5¢, 7¢ 4', 5¢, 7' 
7¢ 149.1 8.48, br s 6¢ 3¢, 5¢ 
 
 
 
 
 
Comparative analysis of NMR (DMSO-d6 and methanol-d4) data for both N-(2-pyridyl acetyl)-O-t-
butyl-L-Thr-OH (3.14) and N-(2-pyridyl acetyl)-O-t-butyl-L-Thr-NH2 (3.15) revealed resonances for 
a single amide tautomer, while the methanol-d4 data featured the quantitative deuterium exchange 
about H-2¢, suggestive of a facile amide-ester equilibrium (Figure 3.47 - 3.48).  
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Figure 3.46: Key 2D NMR (DMSO-d6) correlations for N-(2-pyridyl acetyl)-O-t-butyl-L-Thr-NH2 (3.15) 
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Figure 3.47:  1H NMR (600 MHz) spectrum of N-(2-pyridyl acetyl)-O-t-butyl-L-Thr-OH (3.14), red (methanol-d4), blue 
(DMSO-d6). (x = impurities) 
 
 
 
Figure 3.48: 1H NMR (600 MHz) spectrum of N-(2-pyridyl acetyl)-O-t-butyl-L-Thr-NH2 (3.15), red (methanol-d4), 
blue (DMSO-d6). (x = impurities) 
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3.2.10 Discussion 
Analysis of the NMR (DMSO-d6) data for all synthetic compounds revealed the resonances for a 
single ester/amide tautomerism, except for 2-pyridyl acetyl benzamide (3.04) which showed the 
existences of both aminol-amide tautomers. Significantly, all experienced quantitative deuterium 
exchange at H-2¢ of the 2-pyridyl moiety in methanol-d4, confirmed a facile equilibrium.  
 
However, the NMR (DMSO-d6) data for the natural product 3.01 revealed the resonances for both 
acetal-ester tautomerism, with significant 1H NMR chemical shift differences about the 2-pyridyl 
acetyl (Pya) tautomer. The effects of acetal-ester tautomerism also caused the differences in the 1H 
NMR chemical shift observed for other remote amino acid residues, in particular the far reached 
tyrosine residue (Figure 3.49).   
 
Figure 3.49: 2D HSQC NMR (600 MHz, DMSO-d6) spectrum of talaropyrolide A (3.01), circles highlighted the 
differences in the chemical shifts due to the acetal (black colour) and ester (red colour) tautomerism. 
Literature reports reveal that Talaromyces sp. produce a variety of interesting bioactive compounds, 
ranging from antibiotics to cytotoxins, examples includes tetraene lactones, diphenyl ethers, 
episaustdiol and enthaquinones.9 By contrast, reports of peptides from Talaromyces sp. are limited to 
the cyclic pentapeptide cyclochlorotine (3.16)10 from a foodborne mold Talaromyces islandicus; 
cyclic heptapeptides talaromin A  (3.17) and B (3.18)11 from a endophytic fungus Talaromyces 
wortmannin; talarolide A (3.19) and talaropeptides A-D (3.20) from an Australian marine tunicate 
derived Talaromyces sp.12,13 
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Exploration of the secondary metabolic capacity of Talaromyces sp. CMB-NF091 (a sheep faeces 
derived fungus) led to the isolation and identification of a new cyclic peptide talaropyrolide A (3.01), 
bearing a 2-pyridyl acetyl moiety, unprecedented in the natural products literature.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.11 Biological assays 
Talaropyrolide A (3.01) was tested against the Gram-negative bacteria Escherichia coli (ATCC 
11775) and the Gram-positive bacteria and Bacillus subtilis (ATCC 6633) and fungus Candida 
albicans (ATCC 90028) where 3.01 exhibited no growth inhibition (up to 30 µM) (Figure 3.50). 
However, the bacteriostatic activity of 3.01 against susceptible Staphylococcus aureus (ATCC 25923) 
attracted our attention to explore the activity. Therefore, talaropyrolide A (3.01) was found 
bacteriostatic against both methicillin resistant S. aureus (MRSA) and vancomycin resistant E. 
faecalis (VRE) (Figure 3.51). 
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Talaropyrolide A (3.01) was also been evaluated as non-cytotoxic (up to 30 µM) when tested against 
cell lines SW620 (adherent epithelial like, human colorectal carcinoma) and NCI-H460 (adherent 
epithelial like, human lung carcinoma) (Figure 3.52).  Pure compound (3.01) also been tested in the 
LDA assay but revealed as inactive. 
 
 
 
Figure 3.50: Antimicrobial assay screening graphs of talaropyrolide A (3.01); rifampicin and amphotericin B served as 
standard for both bacteria and fungi respectively, while DMSO served as positive control. 
 
 
 
 
 
Figure 3.51: Bacteriostatic assay of talaropyrolide A (3.01) against VRE (vancomycin resistant Enterococcus faecalis) 
and MRSA (methicillin resistant Staphylococcus aureus); methicillin, vancomycin and daptomycin served as standard, 
while DMSO served as positive control. 
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Figure 3.52: Screening of talaropyrolide A (3.01) cytotoxicity against human cancer cells. 
 
3.2.12 Conclusion 
In this study we reported the isolation, characterization and structural conformation of rare fungal 
cyclic hexapeptide talaropyrolide A (3.01) bearing a rare 2-pyridyl acetyl moiety. MATRIX 
cultivation under ´ 33 different media conditions revealed that the production of talaropyrolides was 
culture media and condition dependant. The study also demonstrated the acetal-ester tautomerism of 
the 2-pyridyl acetyl moiety and suggested that this equilibrium may be mediated by 
hydrophobic/hydrophilic conditions and evokes conformational changes in the 3D structure of the 
cyclic peptide. This raises the possibility that the 2-pyridyl acetyl moiety acts as an environmental 
sensor, influencing 3D structure, and potentially the biological properties of 3.01. 
 
3.2.13 Future directions 
The GNPS study of the ´  33 MATRIX extracts revealed that Talaromyces sp. CMB-NF091 produces 
one more cyclic peptide analogue along with other high molecular weight metabolites. Therefore, 
further studies including the whole genome sequencing could be performed to exploit the biosynthetic 
capacity of CMB-NF091. Moreover, total synthesis of talaropyrolide A and other possible analogues 
could provide detailed understanding of the acetal-ester tautomerisms and ecological role of 2-pyridyl 
acetal moiety of talaropyrolides.  
 
3.3 Experimental  
3.3.1 Isolation and identification of fungus Talaromyces sp., CMB-NF091 
The fungus CMB-NF091 was isolated in 2015 form sheep faecal sample, collected and supplied from 
sheep farm in NSW, Australia. The samples were processed in two different methods: (1) stamping 
and (2) dilution and heat-shock; and then inoculated into two different isolation media (M1 & ISP2) 
containing cyclohexamide and rifampicin (100 μgml-1 and 10 μgml-1 respectively). After inoculation, 
all plates were incubated for 10-14 days at 29 °C with periodic examination. A pure culture of fungus 
CMB-NF091 was obtained by single-colony serial transfer on ISP2 agar plates and then 
cryopreserved at – 80 °C in 15% aqueous glycerol.  
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Genomic DNA from this isolate was extracted from the mycelia using a DNeasy plant and tissue 
DNA kit (QIAGEN) as per the manufacturer protocol. The rRNA genes were amplified by PCR using 
the universal primers ITS1 (5′-TCCGTAGGTGAACCTGCGG-3′) and ITS4 (5′ 
TCCTCCGCTTATTGATATGC-3′) purchased from Sigma-Aldrich. The PCR mixture (50 µL) 
contained genomic DNA (1 µL, 20–40 ng), four deoxynucleoside triphosphates (dNTP, 200 µM each), 
MgCl2 (1.5 mM), primer (0.3 µM each), 1 U of Taq DNA polymerase (Fisher Biotec) and PCR buffer 
(5 µL). The PCR products were purified with PCR purification kit (QIAGEN) and sequenced. 
BLAST analysis (NCBI database) showed that the amplified ITS sequence has 98% homology with 
other members of the genus Talaromyces. 
 
Phylogenetic tree obtained by PhyML Maximum Likelihood analysis was constructed using the top 
similar 18S rRNA sequences displayed after BLAST on Refseq RNA NCBI database using CMB-
NF091 18S rRNA as queries. The JC69 model was used to infer phylogeny sequences. Sequences 
alignments were produced with the MUSCLE program. Phylogenetic tree was constructed using the 
UGENE program using the aforementioned models and visualized using Ugene’s tree view. 
Taxonomic analysis identified CMB-NF091 as a Talaromyces sp 
 
Gene sequence of CMB-NF091 
CGCGGCCACCTCCCACCCTTGTCTCTCTACACCTGTTGCTTTGGCGGGCCCACCGGGGCCACCTGG
TCGCCGGGGGACGCACGTCCCCGGGCCCGCGCCCGCCGAAGCGCTCTGTGAACCCTGATGAAGATG
GGCTGTCTGAGTACGATGAAAATTGTCAAAACTTTCAACAATGGATCTCTTGGTTCCGGCATCGAT
GAAGAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCCGTGAATCATCGAATCTTTGA
ACGCACATTGCGCCCCCTGGCATTCCGGGGGGCATGCCTGTCCGAGCGTCATTTCTGCCCTCAAGC
ACGGCTTGTGTGTTGGGTGTGGTCCCCCCGGGGACCTGCCCGAGGGGCGGGCTCCGTCTGGTCCTC 
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Blast search (Closest match) 
 
 
3.3.2 Analytical cultivation and chemical analysis 
A single colony of CMB-NF091 applied to an ISP2 agar plate and incubated at 29 °C for 7 d, after 
which the agar was diced and extracted with EtOAc (20 mL) and concentrated in vacuo to yield crude 
extract (1.25 mg). The crude extract was redissolved in MeOH (5 mg/mL) and an aliquot (5 µL) was 
analysed by HPLC-DAD-ESI(±)MS (Zorbax SB-C8 5 µm 150 × 4.6 mm column, 5 µm, 15 min, flow 
rate 1 mL/min gradient elution from 90% H2O:MeCN to 100% MeCN with a constant 0.5% HCO2H 
in MeCN modifier). 
 
3.3.3 MATRIX cultivation and chemical profiling of CMB-NF091 
CMB-NF091 was cultivated under × 33 different culture conditions according to MATRIX approach 
(Figure 3.54). The resulting × 33 cultures were extracted with EtOAc (2 mL), after which the 
decanted organic layer was dried under N2 and re-suspended in MeOH (60 μL) containing the internal 
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standard. Aliquot (1 μL) were subjected to UPLC-DAD analysis (Agilent Zorbax C8 1.8 μm, 2.1 × 
50 mm column, with a 2.50 min gradient elution at 0.417 mL/min from 90% H2O/MeCN to 100% 
MeCN and inclusive of an isocratic 0.01% trifluoroacetic acid modifier).  
 
 
3.3.4 Acquisition of UHPLC-QTOF data for GNPS molecular networking of MATRIX 
extracts 
UHPLC-QTOF-MS/MS analyses were performed as described in Chapter 2. The MS/MS data were 
acquired with auto MS/MS analysis using fixed collision energy at 30.0 eV. The same method 
described in Chapter 2 was used for GNPS molecular networking analysis, with default parameters. 
 
3.3.5 Scaled-up cultivation, fractionation and purification of CMB-NF091 metabolites 
A scaled-up fermentation of CMB-NF091 was carried out on ´ 40 ISP2 agar plates, at 29 °C for 10 
days. After which the combined agar extracted with EtOAc (300 mL) and concentrated in vacuo to 
yield a crude extract (80 mg), that was sequentially triturated to yield n-hexane (20 mg), DCM (25.3 
mg) and MeOH (11.2 mg) soluble material. The combined DCM and MeOH solubles (36.5 mg) were 
subjected to solid phase extraction (SPE C8, 10% stepwise gradient elution, 95% H2O/MeCN to 100 
% MeCN) to yield Fractions A (8 mg), B (2 mg), C (10 mg) and D (5.3 mg). Fraction C was subjected 
to reversed phase semi-preparative HPLC (Zorbax C8, 5 µm, 4.6 × 150 mm column, with a 3 mL/min 
gradient elution over 20 mins from 30% MeCN/H2O to 60% MeCN/H2O, followed by a hold at 100% 
MeCN for 5 min, all with isocratic 0.01% TFA in MeCN as a modifier), to obtain talaropyrolide A 
(3.01) (4.8 mg, 2.25 %). (Scheme 3.7). The % yield is calculated as the estimated weight/weight % 
in the crude EtOAc extract. 
 
 
 
 
 
 
 
(a)
(b)
(c)
Figure 3.53: MATRIX cultivation of CMB-NF091 (a) agar, (b) liquid static (c) liquid shaking 
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(a) Trituration using n-hexane, DCM and MeOH 
(b) SPE C8 fractionation, 10%-100% MeOH/H2O, sub-fraction of similar profile was combined together 
(c) Semi-preparative HPLC: C8 30% - 60% MeCN/H2O, 3mL/min for over 30 min (modified by TFA 0.01% in 
MeCN) 
 
Scheme 3.7: Isolation scheme for CMB-NF091. 
Talaropyrolide A (3.01): yellowish white powder, [α]D – 50.0 (c 0.025, MeOH); UV (MeOH) λmax 
(log ε) 202 (4.08), 278 (1.99) nm; 1D and 2D NMR (600 MHz, DMSO-d6) see Tables 3.2 and Figures 
3.6 – 3.9; HRESI(+)MS m/z 800.3955 [M+Na]+ (calcd for C40H55N7NaO9 800.3953). 
 
3.3.6 Marfey’s analysis  
A sample of 3.01 (50 µg) in 6 M HCl (100 µL) was heated to 100 °C in a sealed vial for 12 h, after 
which the hydrolysate was concentrated to dryness at 40 °C under a stream of dry N2. The hydrolysate 
was then treated with 1 M NaHCO3 (20 µL) and D-FDAA (1-fluoro-2,4-dinitrophenyl- 5-D-alanine 
amide) as a 1% solution in acetone (40 µL) at 40 °C for 1 h, after which the reaction was neutralised 
with 1 M HCl (20 µL) and filtered (0.45 µm PTFE) prior to analysis.  
 
C3 Marfey’s analysis - An aliquot (10 µL) of analyte was subjected to HPLC-DAD-MS analysis 
(Agilent Zorbax SB-C3 column, 5 µm, 4.6 × 150 mm, 50 °C, with a 1 mL/min, 55 min linear gradient 
elution from 15% to 60% MeOH/H2O with a 5% isocratic modifier of 1% formic acid in MeCN) with 
amino acid content assessed by UV (340 nm) and ESI(±)MS monitoring, supported by SIE (single 
ion extraction) methodology, with comparison to authentic standards. 
 
CMB-NF091
ISP2-agar ( ✕ 40)
Crude extract 
(80 mg)
n-hexane DCM
(20 mg)
(4.8 mg)
(a)
(b)
(c)
(10 mg)(2 mg)(8 mg) (5.3 mg)
3.01
MeOH
Fr-A Fr-B Fr-C Fr-D
(25.3 mg) (11.2 mg)
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3.3.7 Biological assays  
See Appendix A: General Experimental, page 261-262. 
 
3.3.8 Synthesis of 2-pyridyl acetic acid derivatives 3.03, 3.04, 3.08 - 3.15 
3.3.8.1 Synthesis of 2-pyridyl acetyl benzoate (3.03) 
A stirred solution of 2-pyridyl acetic acid HCl (0.3 g, 1.73 mmol, 1.7 eq.) 
and NaHCO3 (0.16 g, 1.89 mmol, 1.85 eq.) in DMF (10 mL) at 0 °C under 
N2 was treated with benzyl bromide (0.4 mL, 0.3 g, 0.7 mmol, 0.6 eq.), 
and the reaction mixture was stirred for 2 h at 0 °C, then a further 14 h at 
r.t. After drying in vacuo the residue was taken up in H2O (50 mL), extracted with EtOAc (3 × 50 
mL), and the combined organic layers washed with brine (50 mL), dried over anhydrous MgSO4, 
filtered and concentrated in vacuo to yield a crude product. This product was purified by semi-
preparative HPLC (Zorbax C8, 5 µm, 4.6 × 150 mm column, with a 3 mL/min gradient elution over 
20 mins from 10% MeCN/H2O to 90% MeCN/H2O, followed by a hold at 100% MeCN for 5 min, 
all with isocratic 0.01% TFA), to yield 2-pyridyl acetyl benzoate (3.03) as a yellow oil (0.1 g, 
quantitative yield); HRESI(+)MS m/z  228.1017 [M+H]+ (calcd for C14H14NO2, 228.1019). 
 
3.3.8.2 Synthesis of 2-pyridyl acetyl benzamide (3.04) 
A stirred solution of 2-pyridyl acetic acid. HCl (0.17 g, 0.98 mmol, 0.96 
eq.) in DMF (10 mL) at 0 °C under N2 was treated with N, N¢-
Disiopropoylethylamine (DIPEA) (1.0 mL, 0.64 g, 5 mmol, 4.89 eq.), 
N,N,N¢,N¢-tetramethyl-O-(1H-benzotriazole-1-yl)uranium 
hexafluorophosphate (HBTU) (0.15 g, 0.4 mmol, 0.39 eq.) and benzyl amine (1 mL, 0.5 g, 0.5 mmol, 
0.48 eq.). The reaction mixture stirred for 2 h at r.t. After drying in vacuo the residue was taken up in 
H2O (100 mL), extracted with EtOAc (3 × 100 mL), and the combined organic layers washed with 
brine (100 mL), dried over anhydrous MgSO4, filtered and concentrated in vacuo to yield a crude 
product. This product was purified by semi-preparative HPLC (Zorbax C8, 5 µm, 4.6 × 150 mm 
column, with a 3 mL/min gradient elution over 20 mins from 10% MeCN/H2O to 90% MeCN/H2O, 
followed by a hold at 100% MeCN for 5 min, all with isocratic 0.01% TFA), to yield 2-pyridyl acetyl 
benzamide (3.04) as a yellow oil (30.0 mg); HRESI(+)MS m/z  227.1178 [M+H]+ (calcd for 
C14H15N2O, 227.1179). 
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3.3.8.3 Synthesis of N-Boc-L-Thr-OBn (3.06)  
A stirred solution of N-Boc-L-Thr-OH (3.05) (0.5 g, 2.28 mmol, 1.0 
eq.) and NaHCO3 (0.6 g, 7.09 mmol, 3.10 eq.) in DMF (90 mL) at 0 
°C under N2 was treated with benzyl bromide (3.94 mL, 0.5 g, 2.92 
mmol, 1.2 eq.), and the reaction mixture stirred for 2 h at 0 °C, then 
a further 14 h at r.t. After drying in vacuo the residue was taken up in H2O (100 mL), extracted with 
EtOAc (3 × 100 mL), and the combined organic layers washed with brine (100 mL), dried over 
anhydrous MgSO4, filtered and concentrated in vacuo to yield a crude product. This product was 
purified by silica (LC60A 40-60 micron) flash column chromatography 20-30% EtOAc/n-hexane to 
yield N-Boc-L-Thr-OBn (3.06) as a yellow oil (0.3 g): [a]D +25.7 (c 0.05, MeOH); UV-vis (MeOH) 
λmax (log ε): 258 (4.60); 1H NMR (600 MHz, methanol-d4), dH 7.31-7.37 (m, 5H), 5.18 (dd, J = 12.1, 
8.4 Hz, 1H), 4.81 (s, 2H), 4.30 (m, 1H), 1.45 (s, 9H), 1.21 (d, J =6.3 Hz, 3H);  13C NMR (600 MHz, 
methanol-d4), dC 171.2, 156.8, 135.8, 128.1, 127.8, 127.7, 79.4, 67.1, 66.5, 59.4, 27.3, 19.1; 
HRESI(+)MS m/z  332.1478 [M+Na]+ (calcd for C16H23NO5Na, 332.1468). 
3.3.8.4 Synthesis of O-(2-pyridinyl acetyl)-N-Boc-L-Thr-OBn (3.07) 
 A stirred solution of N-Boc-L-Thr-OBn (3.06) (0.3 g, 1 mmol, 1.0 eq.), 2-pyridyl acetic acid HCl salt 
(0.3 g, 1.73 mmol, 1.7 eq.) and DMAP (0.24 g, 1.96 mmol, 1.9 eq.), 
in DCM (250 mL) at 0 °C under N2 was treated with N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) 
(0.3 g, 1.57 mmol, 1.5 eq.), and stirred for 2 h at 0 °C, followed by 
14 h at r.t., after which the reaction mixture was concentrated in 
vacuo and the residue taken up with EtOAc (300 mL). The organic 
layer was washed with a saturated solution of NaHCO3, filtered and 
concentrated in vacuo to yield a crude product that was purified by silica (LC60A 40-60 micron) 
filtration (20-25% EtOAc/n-hexane) to yield O-(2-pyridinyl acetyl)-N-Boc-L-Thr-OBn (3.07) (0.21g, 
70%) as a colourless viscous oil that foams under low vacuum: [a]D + 24.5 (c 0.05, MeOH); UV-vis 
(MeOH) λmax (log ε): 260 (3.98); 1H NMR (600 MHz, methanol-d4), dH 8.47 (d, J = 4.7 Hz, 1H), 
4.78 - 4.80 (m, 2H), 7.31-7.34 (m, 6H), 5.41 (m, 1H), 5.01 (dd, J = 12.3, 8.2 Hz, 1H), 4.39 (d, J = 2.6 
Hz, 2H), 3.70 (m, 1H), 1.46 (s, 9H), 1.25 (d, J = 6.30 Hz, 3H); 13C NMR (600 MHz, methanol-d4), 
dC  171.5, 170.8, 158.6, 155.5, 150.1, 139.1, 139.0, 137.2, 129.7, 129.5, 126.0, 124.0, 81.1, 72.5, 68.4, 
58.9, 44.2, 28.9, 17.2; HRESI(+)MS m/z 429.2034 [M+H]+ (calcd for C23H29N2O6, 429.2020). 
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3.3.8.5 Synthesis of O-(2-pyridinyl acetyl)-N-Boc-L-Thr-OH (3.08) 
 A mixture of O-(2-pyridinyl acetyl)-N-Boc-L-Thr-OBn (3.07) (0.1 g) and 10% Pd/C (0.03 g) in 
EtOAc (50 mL) was stirred under a hydrogen atmosphere for 14 h at r.t., after which the reaction 
mixture was filtered, and the filtrate concentrated in vacuo to deliver a crude product. The crude 
product was purified by preparative HPLC (Zorbax C8, 5 µm, 21.2 × 150 mm column, with a 20 
mL/min gradient elution over 20 mins from 10% MeCN/H2O to 90% MeCN/H2O, followed by a hold 
at 100% MeCN for 5 min, all with isocratic 0.01% TFA), to yield O-(2-pyridinyl acetyl)-N-Boc-L-
Thr-OH (3.08) (50 mg, 50%) as a yellowish white powder: [a]D21.5 +14.8 (c 0.05, MeOH); UV-vis 
(MeOH) λmax (log ε): 258 (7.20); 1D and 2D NMR (600 MHz, DMSO-d6) see Tables 3.4 and Figures 
3.37 – 3.38; HRESI(+)MS m/z 339.1561 [M+H]+ (calcd for C16H23N2O6, 339.1551). 
3.3.8.6 Synthesis of O-(2-pyridinyl acetyl)-N-Boc-L-Thr-NH2 (3.09) 
 A solution of O-(2-pyridinyl acetyl)-N-Boc-L-Thr-OH (3.08) (0.05 g, 
0.147 mmol,  1.0 eq.) in DMF (5.0 mL) at 0 °C was treated with EDC HCl 
salt (0.12 g, 0.62 mmol, 4.27 eq.), NH4Cl (0.14 g, 2.64 mmol,  17.9 eq.) and 
HOBt (0.11 g, 0.814 mmol, 5.54 eq.) and the reaction mixture stirred at r.t. 
for 3 h, after which ice-cold H2O was added and the mixture extracted with 
EtOAc (20 mL). The organic layer was dried with anhydrous Na2SO4, and 
concentrated in vacuo to yield O-(2-pyridinyl acetyl)-N-Boc-L-Thr-NH2 
(3.09) (0.03 g, 60%) as yellowish white powder: [a]D +17 (c 0.05, MeOH); UV-vis (MeOH) λmax 
(log ε): 258 (7.20); 1D and 2D NMR (600 MHz, DMSO-d6) see Tables 3.5 and Figures 3.39 – 3.40; 
HRESI(+)MS m/z 360.1544 [M+Na]+ (calcd for C16H23N3O5Na, 360.1530). 
3.3.8.7 Synthesis of N-Fmoc-O-t-butyl-L-Thr-OBn (3.11) 
A stirred solution of N-Fmoc-O-t-Butyl-L-Thr (3.10) (0.3 
g, 1 mmol, 1.0 equiv.)  and NaHCO3 (0.6 g, 7.09 mmol, 7.0 
eq.) in DMF (90 mL) at 0 °C under N2 was treated with 
benzyl bromide (1.33 mL, 0.17g, 1 mmol, 1 eq.), and the 
reaction mixture stirred for 2 h at 0 °C, then a further 14 h 
at r.t. After drying in vacuo the residue was taken up in H2O (100 mL), extracted with EtOAc (3 × 
100 mL), and the combined organic layers washed with brine (100 mL), dried over anhydrous 
MgSO4, filtered and concentrated in vacuo to yield a crude product (0.25 g). The formation of N-
Fmoc-O-t-butyl-L-Thr-OBn (3.11) was confirmed by HPLC-MS analysis and HRESI(+)MS analysis. 
HRESI(+)MS m/z 510.2241 [M+Na]+ (calcd for C30H33NO5Na, 510.2251). The product was used 
without further purification or characterisation. 
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3.3.8.8 Synthesis of O-t-Butyl-L-Thr-OBn (3.12) 
A 0 °C solution of N-Fmoc-O-t-Butyl-L-Thr-OBn (3.11) (0.2 g, 0.5 mmol. 
1.0 eq.) in 20% piperidine in  DCM (3 mL) was stirred for 20 min and allow 
to warm to r.t., after which it was concentrated in vacuo to yield O-t-Butyl-
L-Thr-OBn (3.12) (0.1 g,  50%) as a yellowish oil: [a]D -14.4 (c 0.3, MeOH); 
UV-vis (MeOH) λmax (log ε): 266 (4.38); 1H NMR (600 MHz, DMSO-d6), 
dH 8.65 (s, br, 2H), 7.36 - 7.49 (m, 5H), 4.25 (s, 1H), 4.20 (m, 1H), 4.08 (d, J = 2.5 Hz, 2H), 1.20 (d, 
J = 6.6 Hz, 3H), 1.07 (s, 9H); HRESI(+)MS m/z 266.1756 [M+H]+ (calcd for C15H24NO3, 266.1751). 
3.3.8.9 Synthesis of N-(2-pyridinyl acetyl)-O-t-butyl-L-Thr-OBn (3.13) 
A stirred solution of O-t-butyl-L-Thr-OBn (3.12) (0.1 g, 0.384 
mmol, 1.0 eq.), 2-pyridyl acetic acid HCl salt (0.1 g, 0.57 mmol, 
1.4 eq.) and DMAP (0.1 mg, 0.81 mmol, 2.1 eq.), in DCM (250 
mL) at 0 °C under N2 was treated with dicyclohexylcarbodiimide 
(DCC) (0.1 g, 0.5 mmol, 1.3 eq.), and stirred for 2 h at 0 °C, 
followed by 14 h at r.t., after which the reaction mixture was concentrated in vacuo and the residue 
taken up with EtOAc (100 mL). The organic layer was washed with a saturated solution of NaHCO3 
(3 × 50 mL), followed by H2O (2 × 50 mL), before being dried over anhydrous MgSO4, filtered and 
concentrated in vacuo to provide a crude product. The crude product was purified by preparative 
HPLC (Zorbax C8, 5 µm, 21.2 × 150 mm column, with a 20 mL/min gradient elution over 20 mins 
from 10% MeCN/H2O to 90% MeCN/H2O, followed by a hold at 100% MeCN for 5 min, all with 
isocratic 0.01% TFA), to yield N-(2-pyridinyl acetyl)-O-t-butyl-L-Thr-OBn (3.13) (0.06 g, 60 %) as 
a colourless viscous oil: [a]D -12.3 (c 0.08, MeOH); UV-vis (MeOH) λmax (log ε): 262 (3.96); 1H 
NMR (600 MHz, DMSO-d6), dH 8.47 (d, J = 4.8 Hz, 1H), 8.31 (d, J = 8.8 Hz, 1H), 7.71 (t, J = 7.6 
Hz, 1H), 7.33-7.36 (m, 6H), 7.25 (dd, J = 4.8, 4.7 Hz, 1H), 4.42 (dd, J = 2.9, 5.7 Hz, 2H) (4.13 (m, 
1H), 3.80 (s, br, 2H), 1.07 (d, overlapped, 3H), 1.06 (s, 9H); 13C NMR (600 MHz, DMSO-d6), dC 
170.2, 169.6, 156.1, 148.7, 136.5, 135.6, 128.3, 127.9, 123.7, 121.7, 73.4, 66.9, 66.0, 57.6, 44.1, 28.0, 
21.1; HRESI(+)MS m/z 407.1951 [M+H]+ (calcd for C22H28N2O4Na, 407.1941). 
3.3.8.10 Synthesis of N-(2-pyridinyl acetyl)-O-t-butyl-L-Thr-OH (3.14) 
A mixture of N-(2-pyridinyl acetyl)-O-t-butyl-L-Thr-OBn (3.13) (0.06 g) 
and 10% Pd/C (0.06 gm) in EtOAc (10 mL) was stirred under a hydrogen 
atmosphere for 14 h at r.t., after which the reaction mixture was filtered, 
and the filtrate concentrated in vacuo to deliver a crude product. The crude 
product was purified by preparative HPLC (Zorbax C8, 5 µm, 21.2 × 150 
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mm column, with a 20 mL/min gradient elution over 20 mins from 10% MeCN/H2O to 90% 
MeCN/H2O, followed by a hold at 100% MeCN for 5 min, all with isocratic 0.01% TFA), to yield N-
(2-pyridinyl acetyl)-O-t-butyl-L-Thr-OH (3.14) (0.03 g, 50%) as a white powder: [a]D -16.8 (c 0.06, 
MeOH); UV-vis (MeOH) λmax (log ε): 264 8.00); 1D and 2D NMR (600 MHz, DMSO-d6) see Tables 
3.6 and Figures 3.43 – 3.44; HRESI(+)MS m/z 293.1507 [MH]- (calcd for C15H21N2O4, 293.1501). 
3.3.8.11 Synthesis of N-(2-pyridinyl acetyl)-O-t-butyl-L-Thr-NH2 (3.15) 
A solution of N-(2-pyridinyl acetyl)-O-t-butyl-L-Thr-OH (3.14) (0.03 g, 
0.1 mmol, 1.0 eq.) in DMF (3.0 mL) at 0 °C was treated with EDC HCl 
salt (0.04 g, 0.2 mmol, 2.0 eq.), NH4Cl (0.04 g, 0.75 mmol, 7.5 eq.) and 
HOBt (0.1 g,  0.08mmol, 0.8 eq.) and the reaction mixture stirred at r.t. 
for 3 h, after which ice-cold H2O was added and the mixture extracted 
with EtOAc (20 mL). The organic layer was dried with anhydrous Na2SO4, and concentrated in vacuo 
to yield N-(2-pyridinyl acetyl)-O-t-butyl-L-Thr-NH2 (3.15) (10 mg, 33.3%) as a yellow powder; [α]D 
-15.3 (c 0.25, MeOH); UV (MeOH) λmax (log ε): 264 (8.00); 1D and 2D NMR (600 MHz, DMSO-
d6) see Tables 3.7 and Figures 3.45 – 3.46;  HRESI(+)MS 316.1642 [M+Na]+ (calcd for 
C15H23N3O3Na, 316.1632). 
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4 Chapter 4: Chemical investigation of fungal isolate Spiromastix sp. (CMB-
NB162) 
4.1 Introduction 
This chapter extends on the chemical diversity of the fungus Spiromastix sp. CMB-NB162 isolated 
from sheep faecal sample supplied from sheep farm NSW, Australia. Analytical scale cultivation on 
ISP2 agar, extraction and chemical profiling confirmed the presence of distinct chlorinated 
metabolites having similar UV-vis spectrum. To investigate the wider secondary metabolite 
production capabilities, CMB-NB162 was allowed to culture according to MATRIX approach under 
´ 33 different media conditions.  All the obtained extracts were then subjected to UHPLC-DAD and 
HPLC-DAD-ESIMS analysis for detailed chemical profiling. Following QTOF-MS/MS analysis of 
the MATRIX extracts, molecular formula was generated using Agilent MassHunter software 
confirmed the presence of chlorinated metabolites in the extracts. Online database searching for the 
generated molecular formula with their corresponding molecular weight resulted in the identification 
of chlorinated depsidone molecules. Further GNPS analysis of the crude extract also confirmed the 
presence of some new depsidone metabolites clustering together with the known depsidone 
metabolites. Literature data search revealed that depsidones are typical fungal metabolites (mainly 
from Aspergillus sp., Penicillium sp., Spiromastix sp.), that exhibit various biological activities 
including potent herbicidal activity, HIV integrase inhibitor, anti-bacterial activity against multi-drug 
resistance bacteria.1, 2 Recent study revealed two more remarkable biological potentials of depsidones 
as exosite-targeting inhibitor of anthrax lethal factor and as inhibitors of the enzyme Rab 
geranylgeranyl transferase (potential therapeutics for the treatment of cancer and osteoporosis).1 
These results encouraged us to isolate and identify the new depsidones from the extract of CMB-
NB162.  
 
Scale-up cultivation of CMB-NB162 on the most preferred ISP2 agar media led to the isolation and 
identification of eight new metabolites (4.03 to 4.12), together with four known fungal metabolites, 
spiromastixone A (4.01), spiromastixone F (4.02), spiromastixone G (4.03) and spiromastol (4.04), 
depsidone based analogues isolated from an unidentified deep sea fungus Spiromastix sp.2 The 
structures were confirmed by 1D and 2D NMR spectroscopic studies. After purification, all the pure 
metabolites were tested for their antimicrobial and cytotoxic properties. All of them exhibited 
antimicrobial activity (MIC 0.3 – 1.0 µM) but they also exhibited cytotoxic potential (IC50 0.3 – 3.0 
µM) against human lung (NCI-H460) and colon (SW-620) carcinoma cell lines. 
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Figure 4.1: Spiromastix sp. metabolites (4.01 – 4.12). 
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4.2 Result and discussion 
4.2.1 Isolation and identification of CMB-NB162 
The fungus CMB-NB162 was isolated from sheep faecal sample supplied from sheep farm, NSW, 
Australia. The supplied sample was processed by both heat shock and serial dilution method and 
inoculated on ISP2 and M1 agar culture media. The plates were wrapped in parafilm and incubated 
at 29 °C for 2-3 weeks. A pure culture of fungus CMB-NB162 was obtained by single-colony serial 
transfer on ISP2 agar plate and then cryopreserved at –80 °C in 15% aqueous glycerol. When 
cultivated on ISP2 agar plate, CMB-NB162 showed white filamentous hyphae (Figure 4.2).  
 
 
 
 
 
 
 
 
 
 
Genomic DNA was isolated using a plant and tissue DNA kit (QIAGEN). The resulted genome data 
sequence was then analysed with National Center for Biotechnology Information (NCBI) nucleotide 
collection (nr/nt) database using BLAST (Basic Local Alignment Search Tool) to identify closely 
related strains for CMB-NB162. Phylogenetic tree obtained by PhyML Maximum Likelihood 
analysis was constructed using the top similar 18S rRNA sequences displayed after BLAST on Refseq 
RNA NCBI database using CMB-NB162 18S rRNA as queries. The JC69 model was used to infer 
phylogeny sequences. Sequences alignments were produced with the MUSCLE program.3 
Phylogenetic tree was constructed using the UGENE program using the aforementioned models and 
visualized using Ugene’s tree view.4 Taxonomic analysis confirmed that CMB-NB162 to be closely 
related to the reference strain Spiromastix sp. (accession number KP119636.1) with 96% homology 
(Figure 4.3). 
 
 
 
Figure 4.2: Morphology of the fungus CMB-NB162. Colony photo of the fungus cultured on ISP2 agar plate (left), 
light microscopic image (right). 
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Figure 4.3: Phylogenetic analysis of CMB-NB162 using analysis of ITS DNA sequences using the optimal nucleotide 
substitution model determined by jModeltest298 using UGENE99 software. Phylogenetic relationship of CMB-NB162 
with selected reference strains (RefSeq GenBank) shown with their accession numbers highlighted in blue. 
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4.2.2 Analytical cultivation and chemical analysis 
A single colony of CMB-NB162 was transferred to an ISP2 agar plate and was incubated at 29 °C 
for 7 d, after which the agar was diced and extracted with EtOAc (20 mL) and concentrated in vacuo 
to yield the extract (2.3 mg). An aliquot (5 µL from 5 mg/mL in MeOH) was analysed by HPLC-
DAD-ESI(±)MS (Zorbax SB-C8 5 µm, 150 × 4.6 mm column, with 1 mL/min gradient elution over 
15 min from 90% H2O/MeCN to 100% MeCN, with a constant 0.5% TFA in MeCN modifier). The 
HPLC-DAD-ESI(±)MS analysis of the EtOAc extracts revealed the presence of two major set of 
metabolites (highlighted in blue and purple in the Figure 4.4). The UHPLC-QTOF-MS/MS analysis 
of the crude extract followed by the generation of molecular formula and online database searching 
confirmed the of presence of chlorinated molecules (Table 4.1). The molecular formula of three 
metabolites were closely related to the known metabolites spiromastixones2 (belongs to the depsidone 
class), though there were no hit for the other metabolites. Therefore, we were encouraged to do the 
MATRIX study (as described in the Chapter 2) to fully explore the metabolic profile of CMB-NB162.  
 
Figure 4.4: HPLC-DAD (210 nm) profiles of (a) crude extracts of CMB-NB162 ISP2 agar, (b) ISP2 agar media only. 
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Table 4.1: LC-MS profile of the metabolites of CMB-NB162 and molecular formula of corresponding metabolites. 
Peak 
no. 
Retention 
time 
(tR) (min) 
(M+H)+/ 
(M+Na) + (M-H)
 - MW Molecular formula Literature data search 
i 8.071 545.2 543.2 544 --- --- 
ii 8.509 545.2 --- --- --- --- 
iii 8.678 545.2 --- --- --- --- 
iv 10.163 527.0 525.0 526 --- --- 
v 11.620 329.0 327.0 328 C19H21O5 spiromastixone A 
vi 12.404 --- 361.2 --- C19H20Cl1O5 --- 
vii 13.105 --- 395.1 --- C19H18 Cl2O5 --- 
viii 13.413 344.0 342.0 343 C20H22O5 --- 
ix 13.805 --- 428.2 429 C19H17 Cl3O5 spiromastixone F 
x 14.870 --- 409.2 --- C19H15 Cl3O4 --- 
xi 15.570 --- 442.8 444 C20H19 Cl3O5 spiromastixone G 
xii 15.963 --- 441.8 --- C20H18 Cl3O5 --- 
 
4.2.3 MATRIX cultivation and chemical profiling of CMB-NB162 
To fully explore the accessible secondary metabolite potential, a systemic investigation on the effect 
of culture conditions was conducted according to the MATRIX approach. CMB-NB162 was allowed 
to culture in different culture conditions included different culture media (agar/broth) and conditions 
(agar static, liquid static, liquid shaking) using 24-well microbioreactor plate according to the method 
described in Chapter 2.  Resultant cultures were extracted in situ with EtOAc (2 mL) individually, 
after which the decanted organic layer was dried down under N2 and re-suspended in MeOH (60 μL). 
Obtained crude extracts were subjected to UHPLC-DAD and chemical profile analysis to reveal the 
presence of the target metabolites on ISP2 agar (Figure 4.5). 
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Figure 4.5: UPLC-DAD (210 nm) profiles of crude extracts of CMB-NB162 cultured in different culture conditions.  
 
4.2.4 Molecular network analysis (GNPS) 
All ´ 33 MATRIX extracts were analysed by UHPLC-QTOF(-)MS/MS to reveal the possible 
molecular formula of the metabolites along with a GNPS molecular network analysis (detailed in 
experimental section). The molecular network showed the presence of different classes of compounds 
with similar MS/MS profiles. A peak list was then built by analysing the HPLC chromatographic 
peaks in the GNPS with corresponding m/z values at a specific retention time. A cluster analysis 
revealed the presence of depsidones clustering with known spiromastixones (purple nodes). Scaled 
up cultivation and purification resulted in the identification of eight new metabolites (seven 
highlighted in the network in red colour, one is missing in this network due to poor ionization in the 
negative mode) along with the known metabolites. Two related metabolites (4.05 and 4.07) existed 
as single node (Figure 4.6).  
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Figure 4.6: Molecular network of the crude extracts obtained from the MATRIX cultivation of CMB-NB162. Selected 
clusters belong to the depsidone molecules (purple nodes: known metabolites; red nodes: isolated new metabolites). The 
GNPS excluded nodes associated with media and solvents. 
 
4.2.5 Large scale cultivation of CMB-NB198 and isolation of 4.01- 4.12 
MATRIX studies and chemical profiling showed that CMB-NB162 produced a large number of 
metabolites on ISP2 agar compared to other media. Based on these studies, a scale-up fermentation 
of CMB-NB162 on ISP2 agar (´ 100) was performed. The fungal mycelia with agar matrix were 
extracted with EtOAc (2 mL). The EtOAc layer was then concentrated to dryness in vacuo to yield a 
crude extract (510.0 mg). This crude extract was then sequentially triturated to yield n-hexane (156.8 
mg) and MeOH (354.0 mg) solubles. A portion of the MeOH soluble portion (100 mg) was 
fractionated by C18-SPE followed by reverse phase semi-preparative HPLC fractionation to obtain 
compounds 4.01- 4.12. (Scheme 4.1) 
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Scheme 4.1: Fractionation of the extract obtained from CMB-NB162 ISP2 agar cultivation (a) Liquid-liquid partitioning 
between [n-hexane (-1-1) and MeOH (-1-2), (b) C18-SPE fractionation 20 - 100 % MeCN, [20%- 40%  MeOH/H2O sub-
fractions combined (-1-2-1)], (c) Semi-preparative HPLC: C18 50%-to 60% MeCN/ H2O (modified by TFA 0.1%) over 
20 min, (d) Semi-preparative HPLC: C18 50%-to 70% MeCN/ H2O (modified by TFA 0.1%) over 20 min, (e) Semi-
preparative HPLC: C18 60%-to 80% MeCN/ H2O (modified by TFA 0.1%) over 20 min, (f) Semi-preparative HPLC: C18 
70%-to 90% MeCN/ H2O (modified by TFA 0.1%) over 20 min. 
 
 
Figure 4.7: HPLC-DAD (210 nm) profiles of crude extracts of CMB-NB198 showing compounds 4.01 – 4.12. 
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4.2.6 Structure elucidation 
4.2.6.1 Spiromastixone A (4.01) 
HRESI(+)MS analysis of 4.01 returned a sodiated pseudo-molecular 
ion ([M+Na]+) indicative of a molecular formula C19H20O5, (Dmmu + 
1.4). The 1H NMR (methanol-d4) data (Figure 4.8) for 4.01 exhibited 
the presence of four aromatic protons (dH 6.53, d, J =2.3, H-3; dH 6.58, 
d, J =2.3, H-5; dH 6.48, d, J= 2.8, H-1¢ and dH 6.47, d, J= 2.8 H-3¢), 
while their coupling constants were indicative of meta-substitution. 
The 13C NMR (methanol-d4) data for 4.01 (Figure 4.9) showed the presence of 12 aromatic carbons, 
a carbonyl carbon (dC 164.2) and six alkyl carbons. The COSY and HMBC correlation from H-8 to 
C-6 (dC 149.5), C-5 (dC 114.6) and C-1 (dC 111.7) and H-8¢ to C-6¢ (dC 135.7), C-5¢ (dC 141.7) and C-
1¢ (dC 112.5) confirmed the presence of two n-propyl units connected to two separate aromatic rings. 
The HMBC interactions from H-3 to C-1 (dC 111.7), C-2 (dC 163.7), C-5 (dC 114.6) and from H-5 to 
C-1 (dC 111.7), C-3 (dC 104.3), C-4 (dC 162.0), C-8 (dC 24.4) helped to establish a 1, 2- disubstituted 
6-propyl ring (A) with the presence of a phenol group at C- 4. Similar pattern of HMBC interaction 
also observed for proton H-1¢ and H-3¢ and helped to establish another aromatic ring to be 4¢, 5¢-
disubstituted 6¢-propyl ring (B) with a presence of a phenol group at C-2¢. The detailed analysis of 
2D NMR (methanol-d4) data also confirmed that the two aromatic rings are fused by one ether and 
one ester linkage forming another ring (C). All the 2D NMR data, including HSQC, HMBC and 
COSY, are outlined in the Table 4.2.  
Online searching determined that 4.01 was consistent with the fungal depsidone spiromastixone A.2 
Niu et al.2 first isolated spiromastixones in 2014, the fungal depsidones, from a deep sea derived 
Spiromastix sp. fungus, where most of the analogues are substituted by various numbers of chlorine 
atoms. The structure of depsidones was elucidated on the basis of extensive NMR and mass 
spectroscopic data analysis and chemical conversion. Literature also reported the presence of two 
subtypes of depsidone structure based on the orientation of ring C relative to the ring A by alkaline 
methanolysis to convert the methyl ester derivatives of depsidones.2 Though a wide range of 
metabolites with depsidone core structure was isolated form fungal strains, but the n-propyl 
substitution on ring A and B are rarely seen in the natural products.1 
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Figure 4.8: 1H NMR (600 MHz, methanol-d4) spectrum of spiromastixone A (4.01). (x = impurities) 
 
 
Figure 4.9: 13C NMR (150 MHz, methanol-d4) spectrum of spiromastixone A (4.01). 
 
 
 
 
 
 
 
 
 
1.01.52.02.53.03.54.04.55.05.56.06.57.0 ppm
3.
36
3.
46
2.
78
2.
81
4.
64
0.
86
0.
89
0.
93
1.
00
ppm
2.75 ppm 1.61.7 ppm
5 3 1' 3'
7, 7' 8' 8
9 9'H
2O
x
6.506.55
m
et
ha
no
l-d
4
2030405060708090100110120130140150160170 ppm
12
3, 3'
4
5
6
7
8 9,9'8'
7'
1'
6’
5'4'10
2'
m
et
ha
no
l-d
4
Figure 4.10: Key 2D NMR (methanol-d4) correlations for spiromastixone A (4.01). 
O
O
O
HO
OH1
2
4
6
7
9
10
1'
3'
5'
7'
9'
A BC
O
O
O
HO
OH1
2
34
5
6
78
9
10
1'
2'
3'4'
5'
6'
7' 8'
9'
COSY
HMBC
Chapter 4: Chemical investigation of fungal isolate Spiromastix sp. (CMB-NB162) 
 
 
122 
 
Table 4.2: 1D and 2D NMR data for spiromastixone A (4.01) and comparison with literature data. 
Position dC dH, mult (J in Hz)a COSY HMBC 
dH, mult 
(J in Hz)b 
δH, mult, 
(J in Hz)c 
1 111.7      
2 163.7      
3 104.3 6.53, d (2.3)  1, 2, 4, 5 6.55, d (2.3) 6.57, d (1.8) 
4 162.0      
5 114.6 6.58, d (2.3)  1, 3, 4, 8 6.58, d (2.3) 6.60, d (1.8) 
6 149.5      
7 35.4 2.75d 8 1, 5, 6, 9 2.66e 2.67, t (7.3) 
8 24.4 1.56, tq (7.5, 7.3) 7, 9 6, 7, 9 1.47, tq (7.5, 7.3) 1.48, tq (7.3, 7.0) 
9 12.8 1.03, t (7.3) 8 7, 8 0.84, t (7.3) 0.86, t (7.0) 
10 164.2      
1¢ 112.5 6.48, d (2.8)  2¢, 3¢, 5¢ 6.47, d (2.8) 6.47, d (1.8) 
2¢ 154.4      
3¢ 104.4 6.47, d (2.8)  1¢, 2¢, 4¢, 5¢ 6.48, d (2.8) 6.49, d (1.8) 
4¢ 144.6      
5¢ 141.7      
6¢ 135.7      
7¢ 31.3 2.73d 8¢ 1¢, 5¢, 6¢ 2.66 e 2.69, t (7.3) 
8¢ 23.4 1.67, tq (7.5, 7.3) 7¢, 9¢ 6¢, 7¢, 9¢ 1.57, tq (7.5, 7.3) 1.60, tq (7.3, 7.0) 
9¢ 12.8 0.91, t (7.3) 8¢ 7¢, 8¢ 0.96, t (7.3) 0.97, t (7.0) 
  a = 600 MHz, methanol-d4; b = 600 MHz, DMSO-d6; c = 400 MHz, DMSO-d6, literature2; d-e = assignments for 
overlapping resonances.  
 
 
4.2.6.2 Spiromastixone F (4.02) 
 
 
 
 
 
 
 
HRESI(-)MS analysis of 4.02 revealed a de-protonated molecular ion ([M-H]-) indicative of 
molecular formula (C19H17Cl3O5, Dmmu - 4.0), consisted with the chlorinated analogue of 4.01. 
Analysis of the 1D and 2D NMR (DMSO-d6) data (Figure 4.11, Figure 4.12 and Table 4.3) for 4.02 
supported the substitution of three aromatic protons by three chlorine atoms, while showed the 
presence of only one aromatic proton (dH 6.79, s, H-3¢). The HMBC correlation from H-3¢ to C-1¢ (dC 
117.5), C-2¢ (dC 152.0), C-5¢ (dC 141.7) also confirmed the position of the aromatic proton at ring B. 
Thus, the structure of 4.02 was proposed as a 3, 5, 1¢-trichlorinated analogue of 4.01. Online searching 
determined that 4.02 was consistent with spiromastixone F,2 a trichlorinated depsidone molecule 
isolated from a deep sea derived Spiromastix sp.  
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Figure 4.11: 1H NMR (600 MHz, DMSO-d6) spectrum of spiromastixone F (4.02). (x = impurities) 
 
Figure 4.12: 13C NMR (150 MHz, DMSO-d6) spectrum of spiromastixone F (4.02). 
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  Table 4.3: 1D and 2D NMR (DMSO-d6) data for spiromastixone F (4.02) and comparison with literature data. 
Position δC δH, multi, (J in Hz)a COSY HMBC δH, mult, (J in Hz)b 
1 114.5     
2 157.0     
3 111.1     
4 154.4     
5 120.9     
6 143.8     
7 33.8  2.76, m 8, 9 1, 5, 6, 8,9 2.73, t (7.6) 
8 22.7c 1.57, tq (7.5, 7.2) 7, 9 6, 7, 9 1.56, tq (7.0, 7.6) 
9 14.4d 0.88, t (7.2) 8 7, 8 0.88, t (7.0) 
10 161.8     
1¢ 117.5     
2¢ 152.0     
3¢ 105.9 6.79, s  1¢, 2¢, 5¢ 6.79, s 
4¢ 142.6     
5¢ 141.7     
6¢ 134.3     
7¢ 30.1 3.02, m 8¢, 9¢ 1¢, 5, ¢6¢ 3.02, t (7.6) 
8¢ 22.7 c 1.49, tq (7.5, 7.1) 7¢, 9¢ 6¢, 7¢, 9¢ 1.48, tq (7.0, 7.6) 
9¢ 14.4 d 0.98, t (7.1) 8¢ 7¢, 8¢ 0.98, t (7.0) 
2¢-OH, 4-OH  10.60, br s   11.5, br s 
   a = 600 MHz; b = 400 MHz, literature2; c, d = assignments for resonances (same superscript within a column) are 
interchangeable. 
 
4.2.6.3 Spiromastixone G (4.03) 
 
 
 
 
 
 
 
HRESI(-)MS analysis of 4.03 revealed a de-protonated molecular ion ([M-H]-) indicative of 
molecular formula C20H19Cl3O5 (Dmmu + 4.9), requiring three chlorine atoms in the structure. 
Analysis of 1D NMR (600 MHz, methanol-d4) data of 4.03 (Figure 4.14) showed the presence of 
one aromatic proton (dH 6.92, s, H-3¢) and a methoxy moiety (dH 3.85, s) in the structure of 4.03. The 
HMBC correlation from H-3¢ to C-1¢ (dC 120.3), C-2¢ (dC 155.0), C-5¢  (dC 144.4) confirmed the 
position of the proton at ring B. The position of the methoxy moiety was also confirmed while it 
showed HMBC correlation to C-2¢ (dC 155.0). Online searching resulted that 4.03 was consistent with 
spiromastixone G,2 a chlorinated depsidone analogue, previously reported as a co-metabolite with 
spiromastixone A (4.01).  The structure elucidation of 4.03 was further supported by the 2D NMR 
data, including HSQC, HMBC and COSY, as outlined in the Figure 4.16 and Table 4.4. 
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Figure 4.14: 1H NMR (600 MHz, methanol-d4) spectrum of spiromastixone G (4.03). (x = impurities) 
 
Figure 4.15: 13 C NMR (150 MHz, methanol-d4) spectrum of spiromastixone G (4.03). 
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 Table 4.4: 1D and 2D NMR data for spiromastixone G (4.03) and comparison with literature data. 
Position δC δH, multi,  (J in Hz)a COSY HMBC 
δH, mult,  
(J in Hz)b 
δH, mult,  
(J in Hz)c 
1 114.2      
2 158.9      
3 112.0      
4 157.4      
5 122.2      
6 144.6      
7 34.9 2.84, m 8 1, 5, 6, 8, 9 2.73, m 2.72, t (7.1) 
8 23.9 1.67, tq (7.5, 7.5) 7, 9 6, 7, 9 1.58, tq (7.5, 7.3) 1.58, tq (7.0, 7.1) 
9 14.5d 0.94, t (7.4) 8 7, 8 0.90, t (7.3) 0.90, t (7.0) 
10 163.7      
1¢ 120.3      
2¢ 155.0      
3¢ 103.3 6.92, s  1¢, 2¢, 4¢, 5¢ 7.10, s 7.11, s 
4¢ 145.0      
5¢ 144.4      
6¢ 136.3      
7¢ 31.2 3.18, m 8¢ 1¢, 5¢, 6¢, 8¢, 9¢ 3.05, m 3.04, t (7.1) 
8¢ 24.0 1.60, tq (7.5, 7.5) 7¢, 9¢ 6¢, 7¢, 9¢ 1.49, tq (7.5, 7.3) 1.48, tq (7.0, 7.6) 
9¢ 14.5d 1.03, t (7.5) 8¢ 7¢, 8¢ 0.98, t (7.5) 0.98, t (7.0) 
2¢-OMe 57.3 3.85, s  2¢ 3.84, s 3.83, s 
4-OH     3.85, s 3.85, s 
     a = 600 MHz, methanol-d4, b = 600 MHz, DMSO-d6, c = 400 MHz, DMSO-d6, literature2; d = assignments for resonances 
(same superscript within a column) are interchangeable. 
 
 
4.2.6.4 Spiromastol D (4.04) 
 
 
 
 
 
 
 
HRESI(-)MS analysis of 4.04 revealed a de-protonated molecular ion ([M-H]-) indicative of 
molecular formula C19H22O6, (Dmmu + 4.3). The analysis of 1D NMR (DMSO-d6) data of 4.04 
(Figure 4.17 and 4.18) indicated the presence of both aromatic ring A and B, with the presence of 
four oxygenated protons (dH 9.10, s, 2¢-OH; dH 9.20, s, 4¢-OH; dH 9.44, s, 4-OH and dH 12.61, br s, 1-
COOH).  The position of all oxygenated protons was also confirmed by their HMBC correlations. 
Since C-4¢ was positioned by a hydroxy group and C-1 by a carboxylic group, confirmed that the 
connection of ring A with B through an ether bond across C-5¢ to C-2. That helped to confirm the 
formation of ether and ester linkage between ring A and ring B for all other isolated metabolites from 
CMB-NB162. Online searching determined that 4.04 was consistent with spiromastol D,5 a 
polyphenol isolated from the deep sea Spiromastix sp. fungus.  The structure elucidation was further 
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supported by 2D NMR data (Figure 4.19), including HSQC, HMBC and COSY, as outlined in the 
Table 4.5. 
 
 
 
 
 
 
Figure 4.17: 1H NMR (600 MHz, DMSO-d6) spectrum of spiromastol D (4.04). (x = impurities) 
 
     
    
Figure 4.18: 13C NMR (150 MHz, DMSO-d6) spectrum of spiromastol D (4.04). 
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  Table 4.5: 1D and 2D NMR (DMSO-d6) data for spiromastol D (4.04) and comparison with literature data. 
Position δC δH, multi, (J in Hz)a COSY HMBC δH, multi, (J in Hz)b 
1 115.6     
2 157.0     
3 98.6 5.77, d (1.8)   1, 2, 4, 5 5.77, d (2.3) 
4 158.7     
5 109.0 6.19, d (1.8)  1, 3, 4, 7 6.21, d (2.3) 
6 141.8     
7 35.4 2.50c 8 1, 5, 6, 8, 9 2.51, t (6.5) 
8 24.2 1.55, tq (7.5, 7.2) 7, 9 6, 7, 9 1.56, m 
9 14.1d 0.89, t (7.2) 8 7, 8 0.90 t (7.3) 
1¢ 107.3 6.10, d (2.6)  2¢, 3¢, 5¢, 7¢ 6.11, d (2.8) 
2¢ 155.1     
3¢ 101.9 6.25, d (2.6)  1¢, 2¢, 4¢, 5¢ 6.27, d (2.8) 
4¢ 150.7     
5¢ 132.5     
6¢ 136.9     
7¢ 31.9 2.27, m 8¢ 1¢, 5¢, 6¢ 8¢, 9¢ 2.28, t (7.4) 
8¢ 23.4 1.39, tq (7.5, 7.2) 7¢, 9¢ 6¢, 7¢, 9¢ 1.40, m 
9¢ 14.1d 0.77 t (7.2) 8¢ 7¢, 8¢ 0.79 t (7.3) 
4-OH  9.44, s  3, 4, 5 9.45, s 
2¢-OH  9.10, s  1¢, 2¢, 3¢ 9.11, s 
4¢-OH  9.20, s  3¢, 4¢, 5¢ 9.21, s 
1-COOH 169.5     
1-COOH  12.61, br s  1 12.58, s, br 
   a = 600 MHz; b = 400 MHz, literature data5; c = signal obscured by solvent signal, d = assignments for resonances 
(same superscript within a column) are interchangeable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19: Selected 2D (DMSO-d6) correlations for spiromastol D (4.04). 
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4.2.6.5 Spiromastixone P (4.05) 
 
 
 
 
 
 
 
 
HRESI(+)MS analysis of 4.05 revealed a sodiated pseudo-molecular ion ([M+Na]+) indicative of 
molecular formula C20H22O5 (Dmmu + 2.1), consistent with a methoxy analogue of 4.01.The analysis 
of 1D and 2D NMR (DMSO-d6) data (Figure 4.20 - 4.22) confirmed the presence of four aromatic 
protons along with an extra methoxy moiety (dH 3.72 , s, H- 2¢-OMe), which showed correlation to 
C-2¢ (dC 157.0) in the HMBC spectrum. Based on that the structure for 4.05 was assigned as shown, 
a new methoxy analogue spiromastixone P. 
 
 
 
Figure 4.20: 1H NMR (600 MHz, DMSO-d6) spectrum of spiromastixone P (4.05). 
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Figure 4.21: 13C NMR (150 MHz, DMSO-d6) spectrum of spiromastixone P (4.05). 
 
 
 
 
 
 
 
   Table 4.6:  1D and 2D NMR (DMSO-d6) data for spiromastixone P (4.05). 
Position δC δH, mult, J in Hz COSY HMBC 
1 111.6    
2 163.2    
3 105.1 6.58, d (2.3)  1, 2, 5 
4 163.0    
5 115.4 6.61, d (2.3)  1, 3, 7 
6 149.2    
7 35.3 2.67, m 8 1, 5, 6, 8, 9, 
8 24.6 1.48, tq (7.5, 7.3) 7, 9 6, 7, 9 
9 14.2a 0.86, t (7.3) 8 7, 8 
10 162.4    
1¢ 112.3 6.66, d (3.0)  2¢, 3¢, 5¢  
2¢ 157.0    
3¢ 104.0 6.76, d (3.0)  1¢, 2¢, 4¢, 5¢ 
4¢ 144.8    
5¢ 142.7    
6¢ 136.0    
7¢ 31.4 2.72, m 8¢ 1¢, 5¢, 6¢, 8¢, 9¢ 
8¢ 23.8 1.61, tq (7.5, 7.3) 7¢, 9¢ 6¢, 8¢ 
9¢ 14.2a 0.98, t (7.3) 8¢ 7¢, 8¢ 
2¢-OMe 56.1 3.72, s  2¢ 
       a = assignments for resonances (within the column) are interchangeable.  
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4.2.6.6 Spiromastixone Q (4.06) 
 
 
 
 
 
 
 
HRESI(-)MS analysis of 4.06 returned a de-protonated molecular ion ([M-H]-) indicative of 
molecular formula C19H18Cl2O5 (Dmmu + 0.9), requiring the presence of two chlorine atoms in the 
structure of 4.06.  Analysis of 1D and 2D NMR (DMSO-d6) data (Figure 4.23 – 4.25 and Table 4.7) 
of 4.06 also supported the substitution of two protons from ring A by two chlorine atoms, while 
confirmed the presence of two meta-coupled aromatic protons (dH 6.48, d, J = 2.8, H-1¢ and dH 6.53, 
d, J = 2.8, H-3¢) in ring C. The HMBC correlation from H-1¢ to C-2¢ (dC 155.0), C-3¢ (dC 105.0), C-
5¢ (dC 141.3), C-7¢  (dC 31.7) and from H-3¢ C-1¢ (dC 113.3), C-2¢ (dC 155.0), C-5¢  (dC 141.3) also 
confirmed the position of the aromatic protons. Thus, the structure of 4.06 was proposed as a 3, 5-
dichlorinated analogue of 4.01. There are a number of spiromastixone analogues with various number 
of chlorine atoms substituted at different positions, but literature search returned 3, 5-dichlorinated 
4.06 as a new analogue, spiromastixone Q,  
 
 
Figure 4.23: 1H NMR (600 MHz, DMSO-d6) spectrum of spiromastixone Q (4.06). 
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Figure 4.24: 13C NMR (150 MHz, DMSO-d6) spectrum of spiromastixone Q (4.06). 
 
 
 
 
 
 
 
  
Table 4.7: 1D and 2D NMR (DMSO-d6) data for spiromastixone Q (4.06). 
Position dC dH, mult (J in Hz) COSY HMBC 
1 113.3a    
2 154.2    
3 110.6    
4 156.8    
5 120.3    
6 142.5    
7 33.2 2.76, dd, (7.3, 7.3) 8 1, 5, 6, 8, 9 
8 22.2 1.56c 7, 9 6, 7, 9 
9 13.8b 0.88, t (7.2) 8 7, 8 
10 161.8    
1¢ 113.3a 6.48, d (2.8)           2¢, 3¢, 5¢, 7¢ 
2¢ 155.0    
3¢ 105.0 6.53, d (2.8)  1¢, 2¢, 5¢ 
4¢ 143.7    
5¢ 141.3    
6¢ 135.7    
7¢ 31.7 2.81, dd, (7.5, 7.5) 8¢ 1¢, 5¢, 6¢, 8¢, 9¢ 
8¢ 23.9 1.56c 7¢, 9¢ 6¢, 7¢, 9¢ 
9¢ 13.8 b 0.93, t (7.3) 8¢ 7¢, 8¢ 
2¢ - OH/ 4-OH  9.81, br s   
      a -b = assignments for resonances (within the column) are interchangeable; c = assignments are overlapping 
resonances.  
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4.2.6.7 Spiromastixone R (4.07) 
 
 
 
 
 
 
 
HRESI(+)MS analysis of 4.07 revealed a sodiated molecular ion ([M+Na]+) indicative of  molecular 
formula C21H19Cl3O7 (Dmmu - 3.8), consistent with an acetoxy analogue of 4.02. The analysis of 1D 
NMR (DMSO-d6) data showed the presence of one aromatic proton (dH 6.78, s, H-3¢) and an acetoxy 
moiety (dH 2.07, s). The HMBC correlation from H-3¢ to C-1¢  (dC 117.2), C-2¢  (dC 152.4) and C-5¢  
(dC 142.4) confirmed the position of the aromatic proton. Further analysis of 2D NMR (DMSO-d6) 
data of 4.06 also confirmed the substitution of one methylene proton by an acetoxy group (dH 2.07, 
s, H-7; dC 74.8, C-7). The structure elucidation of 4.07 was further supported by 2D NMR data 
including HSQC, HMBC and COSY as outlined in the Figure 4.26, Figure 4.28 and Table 4.8. On 
searching the literature with molecular formula, 4.07 revealed as a new depsidone analogue, 
spiromastixone R.   
 
 
 
Figure 4.26: 1H NMR (600 MHz, DMSO-d6) spectrum of spiromastixone R (4.07). 
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Figure 4.27: 13C NMR (15 MHz, DMSO-d6) spectrum of spiromastixone R (4.07). 
 
 
 
 
 
 
 
Table 4.8: 1D and 2D NMR (DMSO-d6) data for spiromastixone R (4.07). 
Position δC δH, mult, (J in Hz) COSY HMBC 
1 116.0    
2 162.5    
3 116.5    
4 158.1    
5 119.5    
6 140.5    
7 74.8 5.76, dd (9.0, 2.0) 8 1, 5, 6, 8, 7-OCOCH3 
8 27.0 a 2.33, m;  b 1.91, m 7, 9 7, 9 
9 11.3 0.96a 8 7, 8 
10 170.2    
1¢ 117.2    
2¢ 152.4    
3¢ 105.4 6.78, s   1¢, 2¢, 5¢ 
4¢ 143.4    
5¢ 142.4    
6¢ 134.6    
7¢ 30.1 3.00, m 8¢, 9¢ 1¢, 5, ¢6¢, 8¢, 9¢ 
8¢ 22.7 a 1.55, m; b 1.44, m 7¢, 9¢ 7¢, 9¢ 
9¢ 14.4 0.96a 8¢ 7¢, 8¢ 
7-OCOCH3 170.3    
7-OCOCH3 20.8 2.07, s  7-OCOCH3 
4-OH/ 2¢-OH  10.61, br s   
   a = assignments for overlapping resonances. 
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Figure 4.28: Selected 2D NMR (DMSO-d6) correlations for spiromastixone R (4.07). 
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4.2.6.8 Spiromastixone S (4.08) 
 
 
 
 
 
 
 
HRESI(+)MS analysis of 4.08 returned a sodiated pseudo-molecular ion ([M+Na]+) indicative of  
molecular formula C22H21Cl3O7 (Dmmu - 3.9), consistent with the methoxy analogue of 4.07.  The 
analysis of 1D NMR (DMSO-d6) data of 4.08 (Figure 4.29) confirmed the presence of one aromatic 
proton (dH 7.18, s, H-3¢) and an acetoxy moiety (dH 2.07, s, H-7), related to the structure of 4.07. 
Further analysis of 2D NMR (DMSO-d6) data (Figure 4.31 and Table 4.9) of 4.08 showed the 
presence of an methoxy moiety (dH 3.83, s; dC 57.4, C-2¢), also showed correlation to C-1¢ (dC 118.4) 
and C-3¢ (dC 103.0) in the HMBC spectrum. Based on the analysis, the structure for 4.08 was assigned 
as shown, a new depsidone analogue spiromastixone S. 
 
 
 
Figure 4.29: 1H NMR (600 MHz, DMSO-d6) spectrum of spiromastixone S (4.08). 
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Figure 4.30: 13C NMR (150 MHz, DMSO-d6) spectrum of spiromastixone S (4.08). 
 
 
 
 
 
 
 
 
 Table 4.9: 1D and 2D NMR (DMSO-d6) data for spiromastixone S (4.08). 
Position δC δH, mult, (J in Hz) COSY HMBC 
1 112.0    
2 158.4    
3 113.2    
4 157.5    
5 119.0    
6 141.0    
7 74.6 5.79, dd (9.0, 2.0) 8 1, 5, 6, 8, 7-OCOCH3 
8 26.8 a 2.32, m  b 1.92, m 7, 9 7, 9 
9 11.3 0.98a 8 7, 8 
10 161.4    
1¢ 118.4    
2¢ 153.6    
3¢ 103.0 7.18, s  1¢, 2¢, 5¢ 
4¢ 143.1    
5¢ 142.9    
6¢ 134.8    
7¢ 30.0 3.03, m 8¢ 1¢, 5¢, 6¢, 8¢, 9¢ 
8¢ 22.6 a 1.56, m; b 1.44, m 7¢, 9¢ 6¢, 7¢, 9¢ 
9¢ 14.3 0.98a 8¢ 7¢, 8¢ 
7-OCOCH3 20.9 2.07, s  7-OCOCH3 
7-OCOCH3 170.3    
2¢-OMe 57.4 3.83, s  2¢, 3¢ 
  a = assignments for overlapping resonances. 
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4.2.6.9 Spiromastixone T (4.09) 
 
 
 
 
 
 
 
HRESI(+)MS analysis of 4.09 returned a sodiated pseudo-molecular ion ([M+Na]+) indicative of a 
molecular formula C22H22Cl2 O7 (Dmmu + 0.1) consistent with the dichlorinated analogue of 4.08. 
The analysis of 1D NMR (DMSO-d6) data showed the presence of two aromatic proton (dH 6.87, s, 
H-3; dH 7.09, s, H-3¢), an acetoxy moiety (dH 2.06, s, H-7) and a methoxy moiety (dH 3.82, s) in the 
structure of 4.09 (Figure 4.32). Detailed 2D NMR (DMSO-d6) data analysis also confirmed the 
presence of two aromatic protons, H-3 (dH 6.87, s) and H-3¢ (dH 7.09) connected to C-3 (dC 106.3) of 
ring A and C-3¢  (dC 102.8) of ring B respectively (Figure 4.33 and Table 4.10). Based on the 2D 
NMR (DMSO-d6) analysis, the structure for 4.09 was assigned as a new depsidone spiromastixone 
T.  
 
 
 
 
Figure 4.32: 1H NMR (600 MHz, DMSO-d6) spectrum of spiromastixone T (4.09). 
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Table 4.10: 1D and 2D NMR (DMSO-d6) data for spiromastixone T (4.09). 
Position δC δH, multi, (J in Hz) COSY HMBC 
1 a    
2 160.2    
3 106.3 6.87, br s  2, 5 
4 a    
5 118.3    
6 141.9    
7 74.9 5.81, dd (9.0, 2.0) 8 5, 6, 8, 7-OCOCH3 
8 26.6 a 2.35, m  b 1.91, m 7, 9 7, 9 
9 11.4 0.98, t (7.1) 8 7, 8 
10 a    
1¢ 117.7    
2¢ 152.7    
3¢ 102.8 7.09, s  1¢, 2¢, 5¢ 
4¢ 143.0    
5¢ 142.8    
6¢ 134.3    
7¢ 29.8 a 2.87, m  b 2.82, m 8¢ 1¢, 5¢, 6¢, 8¢, 9¢ 
8¢ 22.5 a 1.56, m  b 1.50, m 7¢, 9¢ 6¢, 7¢, 9¢ 
9¢ 14.5 1.03, t (7.1) 8¢ 7¢, 8¢ 
7-OCOCH3 21.0 2.06, s  7-OCOCH3 
7-OCOCH3 170.3    
2¢-OMe 57.2 3.82, s  2¢, 3¢ 
  a  =  signal not observed 
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4.2.6.10 Spiromastixone U (4.10) 
 
 
 
 
 
 
 
HRESI(+)MS analysis of 4.10 returned a sodiated pseudo-molecular ion ([M+Na]+) suggestive of  
molecular formula C21H20Cl2O7 (Dmmu  + 0.4), indicative of dichlorinated analogue of 4.07. The 
analysis of 1D and 2D NMR (DMSO-d6) data indicated the presence of two meta-coupled aromatic 
protons (dH 6.46, d, J = 1.7, H-1¢ and dH 6.54, d, J = 1.7, H-3¢) connected to C-1¢  (dC 113.5) and C-
3¢  (dC 105.0) respectively, confirmed their presence in the same ring B. Detailed analysis of 2D NMR 
(DMSO-d6) data confirmed the structure of 4.10, as a new depsidone analogue, spiromastixone U 
(4.10).  The analysis of 2D NMR data including HSQC, HMBC and COSY outlined in the (Figure 
4.35 and Table 4.11).  
 
 
 
Figure 4.34: 1H NMR (600 MHz, DMSO-d6) spectrum of spiromastixone U (4.10). (x = impurities) 
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Table 4.11: 1D and 2D NMR (DMSO-d6) data for spiromastixone U (4.10). 
Position δC δH, multi, J in Hz COSY HMBC 
1 119.0    
2 143.1    
3 103.0    
4 153.6    
5 113.2    
6 141.1    
7 74.7 5.76, dd (10.0, 3.0) 8, 9 1, 5, 6, 8, 7-OCOCH3 
8 26.7 a 2.32, m  b 1.90, m 7, 9 7, 9 
9 11.3 0.96, t (7.2) 8 7, 8 
10 161.4    
1¢ 113.5 6.46, d (1.7)  2¢, 3¢, 5¢ 
2¢ 155.6    
3¢ 105.0 6.54, d (1.7)  2¢, 4¢, 5¢ 
4¢ 144.4    
5¢ 142.0    
6¢ 136.4    
7¢ 32.2 a 2.88, m  b 2.69, m 8¢, 9¢ 1¢, 5¢, 6¢, 8¢, 9¢ 
8¢ 24.0 a 1.57, m b 1.52, m 7¢, 9¢ 7¢, 9¢ 
9¢ 14.3 0.93, t (7.2) 8¢ 7¢, 8¢ 
7-OCOCH3 20.9 2.02, s  7-OCOCH3 
7-OCOCH3 170.2    
2¢-OH/4-OH  9.83, br s    
     . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.35: Selected 2D NMR (DMSO-d6) correlations for spiromastixone U (4.10). 
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4.2.6.11 Spiromastixone V (4.11) 
 
 
 
 
 
 
 
 
 
HRESI(+)MS analysis of 4.11 revealed a sodiated pseudo-molecular ion ([M+Na]+) consistent with 
a molecular formula C22H24O7 (Dmmu +1.6). Analysis of 1D NMR (DMSO-d6) data revealed the 
presence of three aromatic protons (dH 6.60, d, J = 2.3, H-3; dH 6.63, d, J = 2.3, H-5; dH 7.01, s, H-
3¢) with two methoxy moieties (dH 3.80, s and dH 3.74, s) in the structure of 4.11 (Figure 4.36 and 
4.37). Detailed 2D NMR (DMSO-d6) data analysis confirmed the structure of 4.11 consisting the two 
n-propyl substituted depsidone core structure with two methoxy moieties. However, the presence of 
an extra carbonyl C-1¢-COOH (dC 163.1) indicated the substitution of one aromatic proton by a 
carboxy moiety. The position of the carboxy group confirmed based on the HMBC correlations from 
H-1¢-COOH (dH 10.77, s) to C-1¢-COOH (dC 163.1).  The structure elucidation was further supported 
by 2D NMR data, including HSQC, HMBC and COSY, as outlined in the Figure 4.38 and Table 
4.12. Therefore, 4.11 was assigned as a new depsidone analogue, spiromastixone V. 
 
 
 
 
Figure 4.36: 1H NMR (600 MHz, DMSO-d6) spectrum of spiromastixone V (4.11). 
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Figure 4.37: 13CNMR (150 MHz, DMSO-d6) spectrum of spiromastixone V (4.11). 
 
 
 
 
 
 
Table 4.12: 1D and 2D NMR (DMSO-d6) data for spiromastixone V (4.11). 
Position δC δH, mult, (J in Hz) COSY HMBC 
1 111.2    
2 162.7    
3 105.1 6.60, d (2.3)  1, 2, 5 
4 167.2    
5 115.6 6.63, d (2.3)  1, 3, 7 
6 149.7    
7 35.6 2.67, m 8 1, 5, 6, 8, 9 
8 24.7 1.51a 7, 9 6, 7, 9 
9 14.3 0.86, t (7.3) 8 7, 8 
10 162.4    
1¢ 121.2    
2¢ 153.4    
3¢ 103.3 7.01, s  1¢, 2¢, 4¢, 5¢ 
4¢ 145.7    
5¢ 142.6    
6¢ 133.3    
7¢ 29.8 2.62, m 8¢ 1¢, 5¢, 6¢, 8¢, 9¢ 
8¢ 24.1 1.51a 7¢, 9¢ 9¢ 
9¢ 14.8 0.97, t (7.3) 8¢ 7¢, 8¢ 
2¢-OMe 53.3 3.74, s  2¢ 
4-OMe 57.5 3.80, s  4 
10¢-COOH 163.1    
10¢-COOH  10.77, br s  1¢ 
   a = assignments for overlapping resonances. 
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Figure 4.38: Selected 2D NMR (DMSO-d6) correlations for spiromastixone V (4.11). 
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4.2.6.12 Spiromastixone W (4.12) 
 
 
 
 
 
 
 
HRESI(-)MS analysis of 4.12 returned a de-protonated molecular ion ([M-H]-) indicative of a 
molecular formula C22H22Cl2O7 (Dmmu + 2.3), consistent with a chlorinated analogue of 4.11. 
Analysis of 1D and 2D NMR (DMSO-d6) data for 4.12 (Figure 4.39, Figure 4.40 and Table 4.13) 
showed the presence of only one aromatic proton (dH 7.07, s, H-3¢), supported the absence of two 
protons that were substituted with two chlorine atoms. The HMBC correlation from H-3¢  (dH 7.07, 
s) to C-¢ (dC 120.9) and C-5¢ (dC 142.1) also confirmed position of the only aromatic proton. Based on 
the above analysis, 4.12 was assigned as shown, a new depsidone molecule spiromastixone W. 
 
 
 
 
 
Figure 4.39: 1H NMR (600 MHz, DMSO-d6) data of spiromastixone W (4.12). 
 
 
1.01.52.02.53.03.54.04.55.05.56.06.57.0 ppm
2.
97
2.
79
2.
24
2.
01
4.
00
2.
24
2.
43
0.
80
2.8 ppm 1.501.551.60 ppm
0.900.95 ppm
3'
7, 7' 88'
9'
9
4-
O
M
e
2'
-O
M
e
H
2O
D
M
SO
-d
6
O
O
O
MeO
OMe1
3
5
7
9
10
1'
3'4'
5'
7'
9'
CO2H
Cl
Cl
spiromastixone W (4.12)
Chapter 4: Chemical investigation of fungal isolate Spiromastix sp. (CMB-NB162) 
 
 
144 
Table 4.13: 1D and 2D NMR (DMSO-d6) data for spiromastixone W (4.12). 
Position δC δH, multi, J in Hz  COSY HMBC 
1 110.6    
2 156.7    
3 a    
4 166.4    
5 120.9b    
6 143.2    
7 29.8 2.76d 8 5, 6, 8, 9 
8 23.9 1.51, tq (7.5, 7.2) 7, 9 6, 9 
9 13.9c 0.92, t (7.2) 8 7, 8 
10 161.2    
1¢ 120.9b    
2¢ 153.4    
3¢ 103.0 7.07, s   1¢, 2¢, 4¢, 5¢ 
4¢ 144.8    
5¢ 142.1    
6¢ 133.1    
7¢ 33.5 2.76d 8¢ 1¢, 5¢, 6¢ 8¢, 9¢ 
8¢ 22.3 1.58, tq (7.5, 7.2) 7¢, 9¢ 6¢,  9¢ 
9¢ 13.9c 0.90, t (7.2) 8¢ 7¢, 8¢ 
2¢-OMe 52.4 3.79, s  2¢ 
4-OMe 56.5 3.76, s  4 
10¢-COOH 167.4    
  a = signal nor observed, b-c = assignments for overlapping resonances (same superscript within a column) are 
interchangeable; d = assignments for overlapping resonances. 
 
 
 
 
 
 
 
 
 
 
4.3 Plausible biosynthetic pathway for chlorinated depsidones 
The biosynthetic pathways for fungal depsidones have already been described.1  The literature 
proposed the biosynthetic pathways for depsidones from A. unguis, which formed from orsellinic acid 
and orcinol derivatives derived from PKS pathways and post-PKS modifications.6 Here we proposed 
the plausible biosynthetic pathways of compounds 4.01 – 4.12 (Figure 4.41). The analysis of HPLC-
MS profile of the untreated crude extract of CMB-NB162 also confirmed the presence of proposed 
precursor molecules of depsidones (Figure 4.42, A and B). 
 
Figure 4.40: Selected 2D NMR (DMSO-d6) correlations for spiromastixone W (4.12). 
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Figure 4.41: Plausible biosynthetic pathways for depsidones 4.01 – 4.12. KS = ketosynthase, AT = acyltransferase, ACP 
= acyl carrier protein 7. Highlighted the precursor molecule A and B. 
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Figure 4.42: Single-ion extraction (SIE) analysis of the untreated EtOAc extract of CMB-NB162 cultured on ISP2 agar 
medium, (a) HPLC-DAD (210 nm) chromatogram, (b) SIE profile corresponding to the precursor molecule B [m/z = 211 
(M+H)+], (c) SIE profile corresponding to the precursor molecule A [m/z = 167 (M+H)+] 
 
4.4 Bioassay results  
4.4.1 Antimicrobial assay 
The biological activities of compounds 4.01 – 4.12 were evaluated. All the pure depsidones showed 
activity against Gram-positive bacterial strains Bacillus subtilis (ATCC 6633) and against the fungal 
strain C. albicans (ATCC 90028) (MIC 0.2 – 1.0 μM) (Figure 4.43). 
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Figure 4.43: Antimicrobial assay screening graphs of compounds 4.01 – 4.12, ampicillin and nystatin served as controls 
for both bacteria and fungi respectively, while DMSO served as positive control. 
4.4.2 Cytotoxicity (MTT) assay 
In cytotoxicity assay (MTT method), the compounds were tested against two cell lines, human lung 
cancer (NCI-H460) and   human colon adenocarcinoma (SW 620). All compounds exhibited 
cytotoxic activity against both cell lines (Table 4.14 and Figure 4.44).  
Table 4.14: Cytotoxic activity (IC50 μM) of compounds 4.01 – 4.12. 
Cell line 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 
             
NCI-
H460 
0.6 1.3 2.7 0.3 0.5 2.6 1.9 1.7 0.5 0.7 0.7 0.7 
 
SW620 
 
0.3 2.1 0.3 2.5 1.3 10 3.0 0.7 0.3 0.7 1.2 1.3 
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Figure 4.44: Screening of compounds 4.01 – 4.12 cytotoxicity against human cancer cells. 
4.5 Precursor directed biosynthesis of brominated depsidones from CMB-NB162 
The production of chlorinated depsidones by CMB-NB162 indicated the presence of specific 
enzymes e.g. FADH2-dependent halogenase and haloperoxidases.8 It is known that these 
halogenation enzymes can incorporate halogens other than chloride in the natural products.9 For 
example, the enzyme haloperoxidases can utilize halogen substrate including chloride, bromide and 
iodide while FADH2-dependent halogenase can utilize chlorine and bromine only.10 Literature also 
reported that the biological activity of the depsidones was associated with the presence of halogen 
atoms in their structure; for example, aromatase inhibitory activity of aspergillusidones D – F 
(brominated depsidone analogues).10  Therefore we performed the precursor directed biosynthesis for 
the production of new brominated depsidones by culturing the fungus CMB-NB162 in the ISP2 agar 
media supplemented with KBr salt (5%). After analytical scale cultivation, agar plate was extracted 
by EtOAc and analyzed using HPLC-DAD-MS (Figure 4.45). Detailed analysis of the HPLC(-)MS 
and HR(-)MS profile with the generated molecular formula of the metabolites confirmed the 
production of brominated and chlorinated metabolites by CMB-NB162 (Table 4.15). Further 
isolation and identification of brominated depsidones from CMB-NB162 may result in the 
identification of new depsidones for the evaluation of biological properties.  
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Figure 4.45: HPLC-DAD (210 nm) profiles of crude extracts of CMB-NB162 cultured on (A) ISP2 agar, (B) ISP2 agar 
supplemented with KBr salt (5%). Peaks highlighted in pink = chlorinated metabolites, blue = brominated metabolites, 
red and yellow = non-halogenated metabolite, green = internal standard.  
Table 4.15: MS profile of the brominated and chlorinated metabolites of CMB-NB162 and molecular formula of 
corresponding metabolites 
Peak no. Retention time (tR) (min) 
HR(-) MS 
[(M-H) -] MW Molecular formula 
Dppm Diff. 
a 10.120 525.4100 526.0 C28H38N4O6 + 0.01 
b 11.540 327.1232 328.1 C19H20O5 + 0.12 
c 12.399 361.0843 362.0 C19H19ClO5 + 0.51 
d 13.090 395.0453 396.0 C19H18Cl2O5 - 0.08 
e 13.817 341.1389 342.1 C20H22O5 - 0.90 
f 14.831 501.0275 502.0 C22H21Cl3O7 + 0.10 
g 15.572 443.0220 444.0 C20H19Cl3O5 - 0.31 
h 12.488 405.0410 406.0 C19H19Br1O5 - 1.20 
i 13.133 482.9521 483.9 C19H18Br2O5 - 1.02 
j 13.273 482.9521 483.9 C19H18Br2O5 + 0.52 
k 13.861 560.8626 561.8 C19H17Br3O5 - 1.01 
l 14.250 419.0572 420.0 C20H21Br1O5 - 0.98 
m 14.926 496.9677 497.9 C20H20Br2O5 + 1.42 
n 15.066 496.9677 497.9 C20H20Br2O5 - 0.88 
o 15.794 574.8783 575.8 C20H19Br3O5 - 0.12 
p 15.935 530.9288 531.9 C20H19Br2Cl1O5 + 0.20 
 
4.6 Conclusion and future directions 
This chapter summarizes the isolation, identification and biological profiling of chlorinated 
depsidone metabolites from fungus Spiromastix sp. CMB-NB162. Depsidones was first isolated from 
fungus Aspergillus nidulans as niduluns in 1953.11 Literature suggested that the depsidones are 
mainly produced by lichens and fungi and exhibit a wide range of biological activities including 
antitumor, antimicrobial, antiviral, pesticidal etc.4,9,12 It has also been reported that the incorporation 
of halogens in depsidone increases the activity against some enzymes, such as aromatase (a 
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therapeutic target for the treatment of breast cancer).1 It is also been noted that some isolated 
depsidones with no chiral center exhibited certain specific rotations, suggesting the seven-membered 
ring with planar chirality.2 A report published by Niu et al.,2 reported the known molecules (4.01 - 
4.04), exhibited positive specific rotations. The report also mentioned that the negative CD effects of 
compounds reflects M-helicity of the lactone ring (B) decided on the basis of benzene sector and 
benzene chirality rules.2 That suggested the presence of atropoisomerism in depsidone molecules, has 
been overlooked throughout the past decades. The phenomena of atropisomerism has the potential of 
serious impact on the biological activity, as atropoisomers can be present as distinct enantiomers or 
diastereoisomers with their attendant different properties.13 As for example, abyssomicin C, a 
promising antimicrobial for tuberculosis, whose atropoisomeric potential was not recognized until 
the total synthesis which produced both abyssomicin C and atrop-abyssomicin C. And the atrop-
abyssomicin C was the main active compound whereas abyssomicin C was only a minor product of 
atrop-abyssomicin C under mild acidic conditions.12,13  
 
In our study, we attempted to apply the time-dependent chirality and heat treatment to enhance the 
axial rotation to overcome the energy barriers, but all our trials were unsuccessful. According to the 
literature, analytical separation of atropoisomers can assist to count the biological activity of 
depsidones (4.01 - 4.12). 
 
4.7 Experimental 
4.7.1 Isolation, purification and taxonomic identification of CMB-NB162 
The sheep faecal sample supplied from research farm, Australia was processed and inoculated onto 
the ISP2 and M1 agar plate. The fungus Spiromastix sp. CMB-NB162 was obtained as a white single 
colony onto ISP2 agar plate and then transferred onto another fresh ISP2 agar plate and incubate at 
29 °C for 10 days. A single colony was transferred onto a microscopic slide to observe the spore and 
hyphae pattern. Colonies from fresh agar culture were transferred on to the cryovials containing 15% 
aqueous glycerol and kept into - 80 °C freezer for preservation. 
Genomic DNA from CMB-NB162 was extracted from the mycelia using a DNeasy plant and tissue 
DNA kit (QIAGEN). The18s rRNA genes were amplified by PCR using both the ITS1 (5ʹ′-
TCCGTAGGTGAACCTGCGG-3ʹ′) and ITS4 (5ʹ′-TCCTCCGCTTATTGATATGC-3ʹ′) primers 
purchased from Sigma-Aldrich. The PCR mixture (50 μL) contained genomic DNA (1 μL, 20–40 ng), 
four deoxynucleoside triphosphates (dNTP, 200 μM each), MgCl2 (1.5 mM), primer (0.3 μM each), 
1 U of Taq DNA polymerase (Fisher Biotec) and PCR buffer (5 μL, 10X). PCR was performed using 
the following conditions: initial denaturation at 95 °C for 3 min, 30 cycles in series of 94 °C for 30 s 
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(denaturation), 55 °C for 60 s (annealing) and 72 °C for 60 s (extension), followed by one cycle at 
72 °C for 6 min.  
ITS gene sequence of CMB-NB162 
GCGGCTCCCTCTCCGGGGGGTTCGTTTCGGCGCCGCGTCCGGCCCAACCGTGTCTATCTGTACCTG
TTGCTTCGGCGGGCCTGCGGGCCTCGCTCGCTGCCGGGGGCCCCCTGGGGCTCCGGGCTCGTGCCC
GCCGGAGACACCTGGAACTACTGTCGAAGTTGGCGGTCTGAGTAAACTTGATAATCATCAAAACTT
TCAACAACGGATCTCTTGGTTCCGGCATCGATGAAGAACGCAGCGAAATGCGATAAGTAATGTGAA
TTGCAGAATTCCGTGAATCATCGAATCTTTGAACGCACATTGCGCCCCCTGGTATTCCGGGGGGCA
TGCCTGTCCGAGCGTCATTGCAACCCCTTCAAGCCCGGCTTGTGTGTTGGGCGTCGTCCCCGCTGG
ACGCGCCCGAAAGGCAGTGGCGGCTCCGTGTCCGGTGCCCGAGCGTATGGGCTTTATCACCCGCTC
CAGAGGCCCGGCCGGCGCTGGCCCCGCGAGCCTTGACTGAACTCCAGTTAAGGTCTCAACTAAAAC
TTTTCGTGGTTGACCTCGGATCAGGTAGGGATACCCGCTGAACTTAAGCATATCAAAACGGAGG 
 
BLAST search (closest match)  
 
 
4.7.2 MATRIX cultivation of CMB-NB162 
To investigate the wider secondary metabolite production of CMB-NB162, fungus was cultivated in 
24-well plate microbioreactors that generate extracts across a range of culture media (´11) including 
solid, broth static and broth shaken. Briefly, from the well-grown fungal culture on petri dish, 
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mycelia/ spores were transferred using a sterile loop to micro-bioreactor deep well plates (2.5 mL 
agar or 1.5 ml of broth). The micro-bioreactor cultures were incubated at 29 °C, for 10 days, with 190 
rpm for shaken broth. The resulting (´ 33) cultures were extracted in situ with EtOAC (2.0 mL per 
well) followed by filtering to 2 mL vial and dried under N2. The secondary metabolite production 
across the different culture media and culture conditions were analyzed by UHPLC-DAD and 
UHPLC-QTOF-MS/MS analysis. 
 
4.7.3 Global Natural Product Social Molecular Networking (GNPS) 
For GNPS analysis, aliquots (1 μL) of all the MATRIX extracts were subjected to Agilent 6545 Q-
TOF LC/MS (equipped with an Agilent 1290 infinity II UPLC system), using Agilent SB-C8 1.8 μm, 
2.1 × 50 mm column, with a 0.5 mL/min, 4.5 min gradient elution from 90% H2O/MeCN to MeCN, 
followed by isocratic elution with MeCN for 1 min, with a constant isocratic 0.1% formic acid 
modifier. The source parameters were: electrospray negative ionisation; mass range of m/z 100-1700; 
scan rate 10 ´ per sec; MS/MS scan rate 3 ´ per sec; fixed collision energy 40 eV; source gas 
temperature 325° C; gas flow 10 L/min; and nebulizer 20 psig. The scan source parameters were: 
VCap 4000; fragmentor 100; skimmer 45; and octopoleRFPeak 750. The QTOF-LC- (-) MS/MS 
data was then converted to .mzXML format using the Agilent MassHunter Qualitative Analysis 
software and MS converter. Molecular networking was performed in the GNPS data analysis 
workflow (https://gnps.ucsd.edu) using the spectral clustering algorithm, and a cosine score of 0.7 
and a minimum of 3 matched peaks. The resulting spectral networks were imported into Cytoscape 
version 3.5.1, where nodes represented parent (-) m/z and edge thickness corresponded to cosine 
scores. 
 
4.7.4 Purification, isolation and characterization of 4.01 – 1.12 
The MeOH soluble fraction (100 mg) was subjected to SPE fractionation (Agilent C18, 10% stepwise 
gradient elution from 10% MeOH to 100% MeOH) to yield fractions -1-2-1 to -1-2-7. Fraction -1-2-
2 (5.0 mg) subjected to semipreparative HPLC fractionation (Zorbax C18 column, 250 ´ 9.4 mm, 5 
μm, 3 mL/min gradient elution from 50% to 60% MeCN/H2O over 20 min, with constant 0.1% TFA 
modifier) to yield 4.12 (2.3 mg). Fraction -1-2-3 (7.5 mg) was subjected to semipreparative HPLC 
fractionation (Zorbax C18 column, 250 ´ 9.4 mm, 5 μm, 3 mL/min gradient elution from 50% to 60% 
MeCN/H2O over 20 min, with constant 0.1% TFA modifier) to yield 4.01 (2.4 mg). Fraction -1-2-4 
(10.9 mg) was subjected to semipreparative HPLC fractionation (Zorbax C18 column, 250 ´ 9.4 mm, 
5 μm, 3 mL/min gradient elution from 50% to 70% MeCN/H2O over 20 min, with constant 0.1% 
TFA modifier) to yield 4.02 (0.8 mg), 4.04 (1.5 mg), 4.05 (3.2 mg) and 4.14 (2.6 mg). Fraction -1-2-
5 (12.3 mg) was subjected to semipreparative HPLC fractionation (Zorbax C18 column, 250 ´ 9.4 
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mm, 5 μm, 3 mL/min gradient elution from 60% to 80% MeCN/H2O over 20 min, with constant 0.1% 
TFA modifier) to yield 4.06 (1.1 mg), 4.07 (3.3 mg), 4.08 (3.2 mg), 4.09 (1.0 mg), 4.11 (0.9 mg). 
Fraction -1-2-6 (12.5 mg) was subjected to semipreparative HPLC fractionation (Zorbax C18 column, 
250 ´ 9.4 mm, 5 μm, 3 mL/min gradient elution from 70% to 90% MeCN/H2O over 20 min, with 
constant 0.1% TFA modifier) to yield 4.03 (10.3 mg) (Scheme 4.01 in supporting information). 
Spiromastixone A (4.01): A light yellowish oil, [a]D 21.8 + 24 (c 0.05, MeOH), 1D and 2D NMR 
(600 MHz, DMSO-d6) see table 4.2 and figures 4.8 to 4.10; HRESI(+)MS m/z  351.1217 [M+Na]+ 
(calcd for C19H20NaO5, 351.1203). 
Spiromastixone F (4.02): A light yellowish oil, [a]D24 + 34.6 (c 0.025, MeOH), 1D and 2D NMR 
(600 MHz, DMSO-d6) see table 4.3 and figures 4.11 to 4.13; HRESI(-)MS m/z  429.0029 [M-H]- 
(calcd for C19H16Cl3O5, 429.0069). 
Spiromastixone G (4.03): A light yellowish oil, [a]D 21.8  + 25 (c 0.05, MeOH), 1D and 2D NMR 
(600 MHz, DMSO-d6) see table 4.4 and figures 4.14 to 4.16 ; HRESI(-)MS m/z  443.0274 [M-H]- 
(calcd for C20H18Cl3O5, 443.0225). 
Spiromastol D (4.04): A light yellowish oil, 1D and 2D NMR (600 MHz, DMSO-d6) see table 4.5 
and figures 4.17 to 4.19; HRESI(-)MS m/z  345.1387 [M-H]- (calcd for C19H21O6, 345.1344). 
Spiromastixone P (4.05): A light yellowish oil, [a]D22 + 46 (c 0.025, MeOH), 1D and 2D NMR (600 
MHz, DMSO-d6) see table 4.6 and figures 4.20 to 4.22; HRESI(+)MS m/z 365.1380 [M+Na]+ (calcd 
for C20H22NaO5, 365.1359). 
Spiromastixone Q (4.06): A light yellowish oil, [a]D22 + 25.6 (c 0.02, MeOH), 1D and 2D NMR 
(600 MHz, DMSO-d6) see table 4.7 and figures 4.23 to 4.25; HRESI(-)MS m/z 395.0468 [M-H]- 
(calcd for C19H17Cl2O5, 395.0459). 
Spiromastixone R (4.07): A light yellowish oil, [a]D22 – 60.5 (c 0.05, MeOH), 1D and 2D NMR 
(600 MHz, DMSO-d6) see table 4.8 and figures 4.26 to 4.28; HRESI(+)MS m/z 511.0051 [M+Na]+ 
(calcd for C21H19Cl3NaO7, 511.0089). 
Spiromastixone S (4.08): A light yellowish oil, [a]D21.5 – 40.0 (c 0.05, MeOH), 1D and 2D NMR 
(600 MHz, DMSO-d6) see table 4.9 and figures 4.29 to 4.31; HRESI(+)MS m/z 525.0206 [M+Na]+ 
(calcd for C22H21Cl3O7Na, 525.0245). 
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Spiromastixone T (4.09): A light yellowish oil, [a]D21.5 - 31.9 (c 0.05, MeOH), 1D and 2D NMR 
(600 MHz, DMSO-d6) see table 4.10 and figures 4.32 to 4.34; HRESI(+)MS m/z 491.0636 [M+Na]+ 
(calcd for C22H22Cl2O7Na, 491.0635). 
Spiromastixone U (4.10):  A light yellowish oil, [a]D24.4 - 58.7 (c 0.02, MeOH), 1D and 2D NMR 
(600 MHz, DMSO-d6) see table 4.11 and figures 4.34 to 4.35; HRESI(+)MS m/z 477.0482 [M+Na]+ 
(calcd for C21H20Cl2NaO7, 477.0478). 
Spiromastixone V (4.11): A light yellowish oil, [a]D21.8 + 21.4 (c 0.05, MeOH), 1D and 2D NMR 
(600 MHz, DMSO-d6) see table 4.12 and figures 4.36 to 4.38; HRESI(+)MS m/z 423.1430 [M+Na]+ 
(calcd for C22H24NaO7, 423.1414). 
Spiromastixone W (4.12): A light yellowish oil, [a]D21.5 + 32.1 (c 0.05, MeOH), 1D and 2D NMR 
(600 MHz, DMSO-d6) see table 4.13 and figures 4.39 to 4.40; HRESI(-)MS m/z 467.0693 [M-H]- 
(calcd for C22H21Cl2O7, 467.0670). 
4.7.5 Bioassays 
See Appendix I: General Experimental page 261-262. 
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5 Chapter 5: Isolation of new cyclic tetrapeptides from MATRIX cultivation of 
fungus Spiromastix sp. CMB-NB162 
5.1 Introduction 
This chapter describes the continued investigation of Spiromastix sp. CMB-NB162, cultured under 
different media conditions according to the MATRIX approach as discussed earlier in Chapter 4. 
Additional analysis of UHPLC-QTOF-MS/MS(+) data followed by GNPS analysis revealed the 
presence of distinct clusters belonging to novel metabolites. This chapter focuses on the isolation, 
structure elucidation and bioactivity profiling of these additional metabolites. 
Scaled-up cultivation of CMB-NB162 under sabouraud broth (SDB) static conditions, followed by 
isolation and purification, yielded five new cyclic tetrapeptides, spiromastides A - E (5.1 - 5.5). The 
structure elucidation of 5.1 - 5.5 was achieved by detailed spectroscopic (NMR, HRESI(+)MS, 
QTOF-MS/MS) and C3 Marfey’s analysis. Bioactivity profiling of spiromastides A - E (5.1 - 5.5) 
revealed no cytotoxic or anti-microbial properties.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Structures of spiromastides A- E (5.1 – 5.5). 
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5.2 Chemical profiling of Spiromastix sp. CMB-NB162  
5.2.1 MATRIX cultivation of CMB-NB162 
As mentioned in Chapter 4, the secondary metabolic profile of CMB-NB162 was explored according 
to the MATRIX approach, by cultivating across a range of culture media (´ 11) under solid agar, 
broth static and broth shaking condition, in 24-well plate microbioreactors at 29 °C over 10 days with 
necessary shaking at 190 rpm. The resulting cultures (´ 33) were extracted in situ with EtOAc (2 mL) 
with the decantated organic phases individually dried down under N2. The crude extracts were then 
redissolved in MeOH (1 mg/mL) and subjected to UHPLC-DAD and UHPLC-QTOF-MS/MS 
analysis. Detailed analysis of the HPLC-DAD-MS and UHPLC-QTOF-MS/MS data for CMB-
NB162 grown under SDB static condition revealed the presence of series of putative peptides (Figure 
5.2), with molecular weights assigned on the basis of HPLC-DAD-ESIMS and UHPLC-QTOF-
MS/MS analysis (Table 5.1). A search for these metabolites in the molecular network revealed a 
separate noteworthy cluster (Figure 5.3, B), contained the target peptides. Scale-up cultivation and 
extraction was carried out for the isolation of metabolites (v – x). However, the UHPLC-QTOF-
MS/MS analysis of other the metabolites (i – iv) suggested to be diketopiperazines (DKPs) and need 
further identification. 
 
 
Figure 5.2: HPLC-DAD (210 nm) chromatogram of (a) crude extract of CMB-NB162 obtained from SDB static 
condition (b) SDB media blank.  
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Table 5.1: LC-MS data and their corresponding molecular formula for the highlighted peaks in figure 5.2. 
Peak tR (min) LRESI(+)MS HRESI(+)MS MW Molecular formula 
Dppm 
(Diff) 
i 4.150 261.0 261.1235 260.1162 C14H16N2O3 + 0.1 
ii 4.220 285.2       285.1102 --- --- --- 
iii 4.867 221.0 --- --- --- --- 
iv 5.315 245.0 245.1297 244.1212 C14H16N2O2 + 1.2 
v 5.500 545.0 545.2984 544.2795 C28H40N4O7 - 1.89 
vi 5.988 501.1 501.2718 500.2715 C26H36N4O6 + 0.2 
vii 7.080 521.1 521.3130 520.3050 C30H40N4O4       + 0.8 
viii 7.192 471.0 471.2968 470.2893 C26H38N4O4 + 0.2 
ix 7.512 527.1 527.1203 526.1190 C28H38N4O6 + 1.3 
x 8.103 485.0 485.1322 484.3059 C27H40N4O4 + 0.9 
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Figure 5.3: Molecular network of the crude extracts obtained from the MATRIX cultivation of CMB-NB162. The GNPS 
analysis was performed using UHPLC-QTOF-MS/MS (positive polarity) fragments with minimum matched fragment 
ions 2. The size of the nodes indicates the sum ion abundance. (A) Whole molecular network, (B) cluster containing the 
targeted peptides. Metabolites numbered in red (5.1 – 5.5) are discussed in this chapter.   
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5.2.2 Scale-up cultivation of CMB-NB162 and isolation of spiromastides A-E (5.1 – 5.5) 
A seed culture of CMB-NB162 prepared by inoculating a single colony into SDB culture medium 
(80 mL) in a culture flask (250 mL) followed by incubation at 29 °C for 7 days. Aliquots (100 µL) of 
the seed culture transferred into 2L (´ 4) culture flask containing SDB culture medium (400 mL) 
were incubated at 29 °C for 10 days under static conditions. After incubation, the liquid broth was 
extracted with EtOAc (4 ´ 400 mL) and concentrated in vacuo to yield crude extract (150 mg). The 
crude extract was then subjected to liquid-liquid partitioning using n-hexane (100 mL) and aqueous 
methanol (100 mL).  Based on the HPLC-MS analysis, the methanol fraction (130 mg) was subjected 
to further separation using solid phase flash chromatography (SPE, C8) followed by semi-preparative 
reversed phase chromatographic separation and purification to yield 5.1 to 5.5 (Figure 5.4 and 
Scheme 5.1). The purification of highly abundant metabolites of cluster B was not successful due to 
their co-elution with other metabolites.  
 
 
Figure 5.4: HPLC-DAD (210 nm) chromatogram of (a) crude extract of CMB-NB162 obtained under SDB static culture 
(b) SDB media blank. 
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(a) Liquid-liquid partitioning (n-hexane and aqueous methanol). 
(b) C8 SPE fractionation [ combined 10% - 40% MeOH/H2O (-1-2-1), 50%- 80% MeOH/H2O (-1-2- 2), and 100% MeOH 
(-1-2-3)]. 
(c) Semi-preparative HPLC: Z-C8, 5% - 60% MeCN/H2O over 30 min, 3 mL/min. 
(d) Semi-preparative HPLC: Z-C3, 3% - 20% MeCN/H2O over 30 min, 3 mL/min. 
(e) Semi-preparative HPLC: Z-C3, 0% - 30% MeCN/H2O over 30 min, 3 mL/min. 
 
Scheme 5.1: Fractionation and purification scheme for CMB-NB162, SDB extract. 
 
5.2.3 Structure elucidation of spiromastides A – E (5.1 – 5.5) 
5.2.3.1 Spiromastide A (5.1) 
HRESI(+)MS analysis of 5.1 returned a sodiated molecular ion 
[(M+Na)+] attributed to a molecular formula (C30H40N4O4, Dmmu 
– 0.2) requiring ´  13 double bond equivalent. The presence of only 
13 signals in the 13C NMR (DMSO-d6) resonances required that 
5.1 possesses an element of symmetry. The 1D NMR (DMSO-d6) 
data for 5.1 (Figure 5.5 and 5.6) also revealed resonances 
attributed to two amino acid a-protons (dH 3.46 and  dH 4.16) and 
two amide carbonyls (dC 166.5 and  dC 167.8).  
Further analysis of the 2D NMR data (Figure 5.8 and Table 5.2) confirmed the peptidic molecule 
and identified phenylalanine and leucine residues. Combining all of the above observations required 
L-Phe
L-Phe
L-Leu
L-Leu NH
NHHN
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O
O
O
O
(5.1)
CMB-NB162
(SDB, Broth static)
1.2 L, 150 mg
n - hexane (1-1) methanol (-1-2)
14.0 mg 130.0 mg
-1-2-1 -1-2-2 -1-2-3
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that 5.1 was a cyclic tetrapeptide. A C3 Marfey’s analysis of 5.1 confirmed the presence of L-Phe and 
L-Leu residues (Figure 5.9). 
With the four amino acid residues for 12 DBE, 5.1 must be a symmetric cyclic tetrapeptide comprised 
of two L-Leu and two L-Phe residues. There is only one possible sequence that fits these requirements. 
Thus, the structure of spiromastide A (5.1) is as shown. 
A 2008 study by Rungprom et al.1 reported the isolation of a cyclic tetrapeptide with the same planner 
structure as 5.1, as a mixture with cyclo-(Leu-Ile-Leu-Ile), from a Thai marine sponge-derived 
bacteria. Significantly these authors did not assign the amino acid configurations, while these 
metabolites were isolated as a mixture precluded the measurement of an [a]D.  Curiously, these 
authors also failed to run a Marfey’s analysis, even though such an experiment would have assigned 
absolute configuration to both components in the mixture. They did confirm the planner structure by 
total synthesis. Our comparison of the [a]D for 5.1 ( - 51.0, c 0.01, CHCl3) with that reported for 
synthetic material (- 92.2, c 0.57, CHCl3) confirmed the amino acid residues, as exhibited by 
Marfey’s analysis. We report, the first time, the fully characterised naturally occurring cyclic 
tetrapeptide spiromastide A (5.1), isolated from a sheep faeces derived fungus Spiromastix sp. CMB-
NB162. 
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Figure 5.5: 1H NMR (600 MHz, DMSO-d6) spectrum of spiromastide A (5.1). 
 
 
 
 
 
Figure 5.6: 13C NMR (150 MHz, DMSO-d6) spectrum of spiromastide A (5.1). 
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Table 5.2: NMR (DMSO-d6) data of spiromastide A (5.1). 
    a = assignments with the same superscript are overlapping signals. 
 
 
Figure 5.7: Expanded HSQC NMR (600 MHz, DMSO-d6) spectrum of spiromastide A (5.1). 
 
 
 
F2 [ppm] 6  4  2 
F1
 [p
pm
]
 1
20
 
 1
00
 
 8
0 
 6
0  
 4
0 
5,6,7,8,9-L-Phe
3b-L-Leu3a-L-Leu
6-L-Leu
5-L-Leu4-L-Leu
3a-L-Phe 3b- L-Phe
2-L-Leu
2-L-Phe
Pos. δH, mult, (J in Hz) δC COSY HMBC  
L-Leu 
1  167.8   
2 3.46, m 52.6 3, N-H 1, 1 (L-Phe) 
3 a 0.75, ddd (13.7, 9.0, 4.7) 
b 0.10, ddd (13.7, 9.0, 4.7) 
 
44.0 2, 4 2, 5, 6 
4 1.41, m 23.3a 3a, b; 5, 6 3 
5 0.62, d (6.5) 21.8 4 3, 4, 6 
6 0.59, d (6.6) 23.3a 4 3, 4, 5 
N-H 8.12, d (1.9)  2 1 (L-Phe) 
L-Phe 
1  166.5   
2 4.16, m 55.8 3, N-H 1, 3, 4 
3 a 3.12, dd (13.3, 3.7) 
b 2.82, dd (13.3, 3.7) 
38.8 2 1, 4, 5/9  
4  136.5   
5/9 7.14, m 130.8 6/8 3, 6/8, 7 
6/8 7.28, m 128.5 7, 5/9 4, 5/9 
7 7.21, m 127.1 6/8 5/9 
N-H 8.06, d (1.9)  2  
L-Phe
L-Phe
L-Leu
L-Leu NH
NHHN
HN
O
O
O
O
1
9
3
7
5
1
6
3
5
 Chapter 5: Isolation of new cyclic tetrapeptides from MATRIX cultivation of fungus Spiromastix sp. (CMB-NB162 
 
 
 
164 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9: C3 Marfey’s analysis of spiromastide A (5.1). (a) C3 HPLC-DAD (340 nm) chromatogram revealing D-FDAA 
amino acid derivatives. (b-c) C3 HPLC-MS-SIE chromatograms for D-FDAA derivatives of authentic standards (broken 
lines) and the acid hydrolysate of 5.1 (shaded peaks) (b) D-Leu and L-Leu (SIE m/z 384), (c) D-Phe  and L-Phe (SIE m/z 
418). * Marfey’s reagent 
 
!"
"
*
D-Leu L-Leu
(a)
(b)
(c)
L-Phe
D-Phe
15 20 25 30 35 40 45
Retention time (min)
Figure 5.8: Key 2D NMR (600 MHz, DMSO-d6) correlations for spiromastide A (5.1). 
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5.2.3.2 Spiromastide B (5.2) 
HRESI(+)MS analysis of 5.2 returned a protonated molecular ion [(M+H)+] attributed to a molecular 
formula (C26H38N4O4, Dmmu - 0.8) requiring ´ 10 double bond 
equivalent (DBEs). The presence of four ‘N’ and four ‘O’ atom in 
the molecular formula suggested the presence of four amino acid 
residues in the structure of 5.2.  A C3 Marfey’s analysis of 5.2 also 
revealed the presence of L-Phe, D-Pro, L-Leu amino acid residues 
(Figure 5.10). Further analysis of 1D and 2D NMR (DMSO-d6) 
data for 5.2 showed the presence of four a-protons (dH 3.61, 3.75, 
4.07 and 4.34) and four amide carbonyls (dC 165.1, 168.4, 169.0 and 166.8) (Figure 5.11 and 5.12). 
Detailed analysis of 2D NMR (HSQC, HMBC, COSY) data for 5.2 confirmed the presence of the 
amino acid residues as phenylalanine (L-Phe), proline (L-Pro) and two leucine (L-Leu) in the structure 
of 5.2. (Table 5.3). Combining all of the above observations required that 5.2 was a cyclic 
tetrapeptide. Further HMBC correlations from the N-H of L-Phe1 (dH 7.98) to its carbonyl (C-1, dC 
165.1) and the carbonyl of L-Leu4 (C-1, dC 168.4), confirmed the sequence of L-Leu4-L-Phe1. 
UHPLC-QTOF-MS/MS fragmentation also showed the clear fragment series as L-Phe- L-Leu- D-Pro-
L-Leu and unambiguously confirmed the structure for 5.2 (Figure 5.15).  
A series of study 2, 3 reported the isolation of cyclic tetrapeptides from both fungal and bacterial 
strains, but the literature data search returned spiromastide B (5.2) as a new cyclic tetrapeptide 
isolated from fungal strain belongs to the Spiromastix sp.       
 
Figure 5.10: C3 Marfey’s analysis of spiromastide B (5.2). (a) C3 HPLC-DAD (340 nm) chromatogram revealing D-
FDAA amino acid derivatives. (b - d) C3 HPLC-MS-SIE chromatograms for D-FDAA/L-FDAA derivatives of authentic 
standards (broken lines) and the acid hydrolysate of 5.2 (shaded peaks) (b) D-Leu and L-Leu (SIE m/z 384), (c) D-Phe  
and L-Phe (SIE m/z 418), (c) L-Pro  and D-Pro (SIE m/z 368). * Marfey’s reagent 
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Figure 5.11: 1H NMR (600 MHz, DMSO-d6) spectrum of spiromastide B (5.2). 
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Figure 5.12: 13C NMR (150 MHz, DMSO-d6) spectrum of spiromastide B (5.2). 
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Figure 5.13: Expanded HSQC NMR (600 MHz, DMSO-d6) spectrum of spiromastide B (5.2). 
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Table 5.3: 2D NMR (DMSO-d6) data of spiromastide B (5.2). 
  a - e = assignments for overlapping resonances. 
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Figure 5.14: Key 2D NMR (DMSO-d6) correlations for spiromastide B (5.2). 
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Figure 5.15: Diagnostic MS/MS spectrum for spiromastide B (5.2). 
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and 5.4 considered as minor metabolite. A C3 Marfey’s analysis also revealed the presence of L-Leu 
and L-Val as the major amino acid residues and D-Leu and D-Val as the minor residues belongs to 
the structure of 5.3 and 5.4 respectively (Figure 5.19). 
 
The presence of only 11 signals in the 13C NMR (DMSO-d6) (Figure 5.17, black coloured peaks) 
resonances required that 5.3 possesses an element of symmetry. Further analysis of the 1D and 2D 
(DMSO-d6) data for 5.3 confirmed the resonances attributed to ´ 2 amino acid a-protons (dH 3.68 
and 3.75, dC 58.8 and 58.2) (Table 5.4 for major metabolite) and confirmed the presences of leucine 
(Leu) and valine (Val) residues. With the four amino acid residues accounting for ´ 4 DBEs, 5.3 must 
be a symmetric cyclic tetrapeptide composed of two L-Leu and two L-Val residues. Detailed analysis 
of the 1D and 2D NMR (DMSO-d6) data corresponding to the minor metabolites (Figure 5.17, red 
coloured peaks; Table 5.4, minor metabolite) also confirmed the presence of leucine (D-Leu) and 
valine (D-Val) residues in the structure of 5.4. Literature data search returned spiromastide C/D 
(5.3/5.4) as new cyclic tetrapeptide isolated from fungal strain belongs to the Spiromastix sp. CMB-
NB162. 
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Figure 5.16: 1H NMR (600 MHz, DMSO-d6) spectrum of spiromastide C/D (5.3/5.4). (x = impurities) 
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Figure 5.17: 13C NMR (150 MHz, DMSO-d6) spectrum of spiromastide C/D (5.3/5.4). 
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Table 5.4: 1D and 2D NMR (600 MHz, DMSO-d6) data for spiromastide C/D (5.3/5.4). 
   a - b = assignments for overlapping resonances. 
 
 
 
 
 
 
 
 
Pos. δH, mult, (J in Hz) δC COSY HMBC  
Major compound 
L-Leu 
1  167.2   
2 3.75a 58.2 3, N-H 1, 3, 4 
3 a 1.52, m 
b 1.51, m 
24.2 2, 4 2, 4, 5, 6 
4 1.87, m 37.6 3, 5, 6 2, 3, 5, 6 
5 0.83b 14.7 4 3, 6 
6 0.84b 11.6 4 3, 5 
N-H 7.92, br s  2  
L-Val 
1  167.1   
2 3.68, m 58.8 3, N-H 1, 3, 4, 5 
3 2.19, m 30.6 2, 4, 5 2, 4, 5 
4 0.96, d (7.2) 18.3 3 2, 3, 5 
5 0.92, d (7.0) 17.0 3 2, 3, 4 
N-H 7.91, br s  2  
Minor compound 
D/L-Leu 
1  166.6   
2 3.75a 52.2 3, N-H 1, 3 
3 a 1.61, m 
b 1.60, m 
23.3 2, 4 2, 4 
4 1.82, m 43.7 3, 5, 6 2, 3 
5 0.82b 17.1 4 3, 6 
6 0.85b 21.5 4 3, 5 
N-H 8.03, br s  2  
D/L-Val 
1  168.2   
2 3.61, m 59.2 3, N-H 1, 3,  
3 2.10, m 31.3 2, 4, 5 2,  
4 0.94c 18.5 3  3  
5 0.87, d (7.0) 22.9 3 3 
N-H 8.16, br s  2  
Figure 5.18: Key 2D NMR (600 MHz, DMSO-d6) correlations of spiromastide C/D (5.3/5.4). 
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Figure 5.19: C3 Marfey’s analysis of spiromastide C/D (5.3/5.4). (a) C3 HPLC-DAD (340 nm) chromatogram revealing 
D-FDAA amino acid derivatives. (b - c) C3 HPLC-MS-SIE chromatograms for D-FDAA derivatives of authentic standards 
(broken lines) and the acid hydrolysate of 5.3/5.4 (shaded peaks), (b) D-Leu and L-Leu (SIE m/z 384), (c) D-Val and L-
Val (SIE m/z 370). * Marfey’s reagent. 
 
5.2.3.4 Spiromastide E (5.5) 
HRESI(+)MS analysis of 5.5 returned a sodiated molecular ion 
[(M+Na)+] attributed to a molecular formula (C24H44N4O4,  
Dmmu - 0.2) requiring ´ 5 double bond equivalent (DBEs). But 
the presence of only 12 corresponding signals in the 13C NMR 
(DMSO-d6) (Figure 5.21) resonances required that 5.5 also 
possessed an element of symmetry. Additionally, C3 Marfey’s 
analysis also confirmed the presence of L-Leu and L-allo-Ile in 
the structure of 5.5 (Figure 5.24). 
 Further analysis of the 1D and 2D NMR (DMSO-d6) data for 5.5 (Figure 5.23, Table 5.5) revealed 
the resonances attributed to two amino acid a-protons (dH 3.68 and 3.75) and two amide carbonyls 
(dC 167.3 and 168.8) and confirmed the presence of L-Leu and L-allo-Ile residues Additionally, the 
HMBC spectrum showed the correlation of H-2 of L-allo-Ile (dH 3.68, m) to C-1 (dC 167.3) and C-1 
(dC 168.8) of L-Lue and confirmed the presence of L-allo-Ile next to L-Leu.  
With the four amino acid residues accounting for ´ 4 DBEs, 5.5 must be a symmetric cyclic 
tetrapeptide composed of two L-Leu and two L-allo-Ile residues. Comparing the NMR data of the 
reported synthetic cyclic tetrapeptide cyclo-(Leu-Ile-Leu-Ile), which comprised of same molecular 
formula,1 returned spiromastide E (5.5) as a new cyclic tetrapeptide isolated from fungal strain 
belongs to the Spiromastix sp. CMB-NB162. 
*
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However, the Marfey’s analysis showed the presence of traces of D-allo-Ile as a co-metabolite with 
5.5, that signifies the presence of the extra signals in the 1H and 13C NMR (DMSO-d6) spectrum of 
5.5. Due to the very poor signals, we were unable to confirm the structure of co-metabolite of 5.5. 
 
 
 
 
 
Figure 5.20: 1H NMR (600 MHz, DMSO-d6) spectrum of spiromastide E (5.5). 
 
Figure 5.21: 13C NMR (150 MHz, DMSO-d6) spectrum of spiromastide E (5.5). 
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Table 5.5: 1D and 2D NMR (600 MHz, DMSO-d6) data for spiromastide E (5.5). 
 a = assignments for overlapping resonances. 
 
 
 
   Figure 5.22: Expanded 2D HSQC NMR (600 MHz, DMSO-d6) spectrum of spiromastide E (5.5). 
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Pos. δH, mult, (J in Hz) δC COSY HMBC  
L-Leu 
1  168.8   
2 3.75, m 52.8 3, N-H 1, 3, 4 
3 a 1.61, m  
b 1.43, m 
44.1 2, 4 2, 4, 5, 6 
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Figure 5.24: C3 Marfey’s analysis of spiromastide E (5.5). (a) C3 HPLC-DAD (340 nm) chromatogram revealing D-
FDAA amino acid derivatives. (b) C3 HPLC-MS-SIE chromatograms for D-FDAA derivatives of authentic standards 
(broken lines) and the acid hydrolysate of 5.5 (shaded peaks in red), D-Leu and L-Leu (SIE m/z 384), D-Ile and L-Ile (SIE 
m/z 384), D-allo-Ile and L-allo-Ile (SIE m/z 384). 
 
5.2.4 Biological assays 
All the isolated cyclic tetrapeptides (5.1 – 5.5) were tested against Gram-negative bacteria 
Escherichia coli (ATCC 25922) and Gram-positive bacteria Bacillus subtilis (ATCC 6633) and 
fungus Candida albicans (ATCC 90028) and none of the metabolites (up to 30 µM) showed anti-
microbial activities against the tested organisms (Figure 5.25). As other sets of depsidone metabolites 
obtained from the ISP2 medium extract of CMB-NB162 showed anti-microbial potential, both the 
crude extracts of CMB-NB162 obtained from both ISP2 and SDB media were tested against some 
MDR strains. The results showed strong growth inhibition by the extract of CMB-NB162 from ISP2 
medium while extract from SDB medium showed none to moderate activity (Figure 5.26). 
All pure metabolites (5.1 – 5.5) were also been evaluated as non-toxic (up to 30 µM) when tested 
against human lung cancer cells (NCI-H460) and human colon cancer cells (SW 620) (Figure 5.27).  
*
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Figure 5.23: Key 2D NMR (600 MHz, DMSO-d6) correlations of spiromastide E (5.5). 
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Figure 5.25: Antimicrobial assay screening graphs of compounds 5.1 – 5.5, ampicillin and amphotericin B served as 
controls for both bacteria and fungi respectively, while DMSO served as positive control. 
 
 
 
Figure 5.26: Anti-MDR assay screening graphs of crude extract of CMB-NB162 obtained from different media 
constituents, vancomycin and methicillin served as standard, while DMSO served as positive control. (VRE = 
vancomycin resistant Enterococcus faecalis, MRSA = methicillin resistant Staphylococcus aureus). 
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Figure 5.27: Screening of compounds 5.1 – 5.5 cytotoxicity against human cancer cells. 
 
5.3 Conclusion 
This chapter presents an example of exploration of chemical diversity under different media 
conditions. The cultivation of CMB-NB162 in SDB culture showed the production of new cyclic 
tetrapeptides spiromastides (A - E) (5.1 - 5.5). Cyclic tetrapeptides belong to a very uncommon family 
of microbial metabolites. Only fewer than 30 analogues have been reported till date and they 
displayed diverse pharmacological properties including antibacterial, phytotoxic peptides, inhibitors 
of lipopolysaccharide-induced nitric oxide production and cardiac calcium channel blocker.4 5 
 
The structure of cyclic tetrapeptides spiromastides A – E (5.1 - 5.5) inclusive of their absolute 
configuration were assigned based on the detailed spectroscopic data and C3 Marfey’s analysis. The 
structure of 5.1, 5.2, 5.3/5.4 and 5.5 also showed the presence of repeated number of same amino acid 
residues. While all the depsidone analogues, isolated from same CMB-NB162 fungus on ISP2 agar, 
showed antimicrobial and cytotoxic potential (described in Chapter 4); all the cyclic tetrapeptides 
(5.1 - 5.5) exhibited no antimicrobial or cytotoxic potential. The further evaluation of the 
antimicrobial potential against MDR strains, the crude extract of CMB-NB162 obtained from SDB 
media remained less potent compare to the crude extract obtained from ISP2 agar. As the literature 
reported a wide range of pharmacological properties of cyclic tetrapeptides, further investigations are 
encouraged to unfold the pharmacologic potential of the cyclic tetrapeptides spiromastides A- E (5.1 
- 5.5).  
5.4 Experimental 
See Appendix I: General Experimental, page 260. 
 
5.4.1.1 Isolation and taxonomy of Spiromastix sp. CMB-NB162 
Refer to experimental section, Chapter 4, page 154. 
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5.4.1.2 GNPS analysis 
Refer to experimental section, Chapter 4, page 156. 
 
5.4.1.3 Scale-up cultivation on SDB medium 
A seed culture was prepared by inoculating a single colony of Spiromastix sp. CMB-NB162 in SD 
broth medium (80 mL in a 250 mL Schott flask) containing 0.5% peptic digest of animal tissue, 0.5% 
pancreatic digest of casein and 4.0% dextrose and incubated at 29 °C for 10 days. Aliquots of the 
seed culture (1 mL) were transferred to 2 L flasks (´ 4) containing SDB medium (400 mL), and the 
flasks were incubated at 29 °C for 10 days. The resulting cultures were extracted with EtOAc (4 ´ 
400 mL), shaken at 150 rpm overnight, followed by filtration. The organic layer concentrated in vacuo 
to yield a crude extract (150 mg) which was sequentially triturated with solvents of increasing 
polarities viz., n-hexane (2 ´ 50 mL) and MeOH (2 ´ 50 mL) to afford 10 and 130 mg, respectively, 
after concentration in vacuo. 
The methanol fraction (130 mg) was subjected to solid phase chromatography (SPE, C8), followed 
by semi-preparative reversed phase chromatographic separation and purification. Four pure 
metabolites were obtained: spiromastide A (5.1) (2.2 mg), spiromastide B (5.2) (2.5 mg), 
spiromastide C/D (5.3/5.4) (1.5 mg) and spiromastide E (5.5) (0.6 mg).   
 
Spiromastide A (5.1): yellowish powder, UV (EtOH) lmax (log e) 290 (2.53) nm; 1D and 2D NMR 
(600 MHz, DMSO-d6) see Table 5.2 and Figures 5.5 - 5.8; HRESI(+)MS m/z 543.2940 [M+Na]+ 
(calcd for C30H40N4O4Na 543.2942). 
 
Spiromastide B (5.2): yellowish powder, UV (EtOH) lmax (log e) 290 (2.53) nm; 1D and 2D NMR 
(600 MHz, DMSO-d6) see Table 5.3 and Figures 5.11 - 5.14; HRESI(+)MS m/z 471.2958 [M+H]+ 
(calcd for C26H39N4O4 471.2966). 
 
Spiromastide C/D (5.3/5.4): yellowish powder; 1D and 2D NMR (600 MHz, DMSO-d6) see Table 
5.4 and Figures 5.16 - 5.18; HRESI(+)MS m/z 447.2952 [M+Na]+ (calcd for C22H40N4O4Na 
447.2942). 
 
Spiromastide E (5.5): yellowish powder; 1D and 2D NMR (600 MHz, DMSO-d6) see Table 5.5 and 
Figures 5.20 - 5.23; HRESI(+)MS m/z 475.3253 [M+Na]+ (calcd for C24H44N4O4Na 475.3255). 
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5.4.1.4 Marfey’s analysis 
A sample of spiromastides (50 μg) in 6 M HCl (100 μL) was heated to 100 °C in a sealed vial for 12 
h, after which the hydrolysate was concentrated to dryness at 40 °C under a stream of dry N2. The 
hydrolysate was then treated with 1 M NaHCO3 (20 μL) and L/D-FDAA (1-fluoro-2,4-dinitrophenyl-
5-L/D-alanine amide) as a 1% solution in acetone (40 μL) at 40 °C for 1 h, after which the reaction 
was neutralized with 1 M HCl (20 μL) and filtered (0.45 μm PTFE) prior to analysis. 
 
C3 Marfey’s analysis – An aliquot (10 μL) of analyte was subjected to HPLC-DAD-MS analysis 
(Agilent Zorbax SB-C3 column, 5 μm, 4.6 ´ 150 mm, 50 °C, with a 1 mL/min, 55 min linear gradient 
elution from 15% to 60% MeOH/H2O, with a 5% isocratic modifier of 1% formic acid in MeCN) 
with amino acid content assessed by UV (340 nm) and ESI(±)MS monitoring, supported by single 
ion extraction (SIE) methodology, with comparison to authentic standards. 
 
5.4.2 Bioassays 
 
5.4.2.1 Antimicrobial assays 
See Appendix I: General Experimental, page 261. 
 
5.4.2.2 Cytotoxicity assay 
See Appendix I: General Experimental, page 262. 
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6 Chapter 6: Identification and characterization of metabolites involved in 
defensive mechanism of microbes during co-cultivation 
6.1 Introduction 
Over the last decades, genomic analyses have revealed the presence of a wide array “silent” secondary 
metabolite gene clusters in microbes, that are believed to be responsive to some natural stimuli, 
including chemical stimuli. Among all kind of stimuli, co-cultivation offered an attractive natural 
stimulus that significantly enhanced (>100-fold) the production of some natural products, that are 
either well-known, rare or new to science.1 This chapter describes the application of microbial co-
cultivation to explore the microbial chemical diversity by activating silent secondary metabolism.  
 
We demonstrated the co-cultivation of antifungal producing Streptomyces sp. CMB-NB198 with two 
co-isolated fungi (Purpureocillium sp. CMB-NF122 and Aspergillus sp. CMB-NF125). Investigation 
of the co-cultivation of CMB-NB198 with CMB-NF122 revealed a substantial upregulation of the 
fungal secondary metabolite alternariol (6.1) by the fungus CMB-NF122, followed by the scaled-up 
co-cultivation and purification of alternariol (6.1). Another scaled-up co-cultivation of CMB-NB198 
with CMB-NF125, followed by subsequent fractionation and purification of the EtOAc crude extracts 
yielded three fungal metabolites trypacidin (6.2), monomethylsulochrin (6.3), 2-(4-hydroxyphenyl) 
acetamide (6.4) and one known bacterial metabolite N-acetyl tyramine (6.5) along with a new 
metabolite pre-hazimycin (6.6). Structure elucidation was achieved by detailed spectroscopic data 
analysis. Bioactivity profiling of the isolated metabolites showed that alternariol (6.1), trypacidin 
(6.2) and monomethylsulochrin (6.3) possessed anti-bacterial potential. The study also included the 
investigation on the identification of the metabolites (chemical cues) responsible for the activation of 
secondary metabolism during co-cultivation.  
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Structures of metabolites (6.1 – 6.6). 
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6.2 Isolation, DNA taxonomy and morphology of CMB-NB198, CMB-NF122 and CMB-
NF125 
Strains CMB-NF122, CMB-NF125 and CMB-NB198 were isolated in 2015 from the same sample 
of sheep faeces supplied from a sheep farm in NSW, Australia. After processing the faeces, a single 
colony of each strain was transferred onto ISP2 agar plates and allowed to incubate at 29 °C for 10 - 
30 days. Streptomyces CMB-NB198 was developed as white colonies which become black after 
development on ISP2 agar. The fungus CMB-NF122 and CMB-NF125 grew very quickly, producing 
aerial hyphae after 7 days of cultivation on ISP2 agar. To identify taxonomically, genomic DNA 
sequencing was performed for all strains. Genomic DNA was extracted from all strains using DNeasy 
plant mini kit (QIAGEN) for the fungi and DNeasy blood and tissue kit (QIAGEN) for bacteria. After 
PCR amplification, DNA was sequenced for ITS1 and ITS4 region for fungi and FC27 and RC1492 
for bacteria at the Australian Genomic Research Facility (AGRF) based at The University of 
Queensland. The sequences were analysed using the Basic Local Alignment Search Tool (BLAST) 
of National Centre for Biotechnology Information (NCBI). The BLAST search showed that the 
amplified ITS sequence for CMB-NF122 has 98% homology with other members of the genus 
Purpureocillium; CMB-NF125 has 99% homology with other members of the genus Aspergillus; 
while CMB-NB198 belongs to the genus Streptomyces (Figure 6.2) (detailed in the experimental 
section). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: Photographs of isolated strains form sheep faecal sample on ISP2 agar. 
CMB-NF122 (Purpureocillium sp.) CMB-NF125 (Aspergillus sp.) 
CMB-NB198 (Streptomyces sp.) 
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6.3 Case study 1: 
During isolation of pure strains from their mixed culture plate, a clear zone of inhibition was observed 
around the colony of CMB-NB198. Later, the purified strains from the same mixed culture plate were 
allowed to grow together in one agar plate. The result showed a noticeable interaction between co-
isolated Streptomyces CMB-NB198 and Purpureocillium sp. CMB-NF122, where the growth of the 
fast-growing fungus CMB-NF122 was inhibited by slow growing Streptomyces CMB-NB198 
(Figure 6.3).  
 
 
 
 
 
 
 
While checking the selectivity of this interaction, Streptomyces CMB-NB198 was co-cultured with 
other fungus obtained from the same faecal sample. The result showed that the antifungal activity of 
CMB-NB198 was not selective to CMB-NF122, as it exhibited an antifungal response toward fungus 
CMB-NF115 (Figure 6.4; a  and b).   
  
 
 
 
 
 
 
 
 
6.4 Case study 2: 
The co-culture of Aspergillus sp. CMB-NF125 and Streptomyces CMB-NB198 showed obvious 
fungal-bacterial interaction on ISP2 agar plate, where the growth of the fast-growing fungus CMB-
NF125 was inhibited by the Streptomyces CMB-NB198.  Moreover, development of a red colour 
band in the fungal interface was noticed during co-cultivation (Figure 6.5).  
 
 
(a) 
front side back side  
(b) 
front side back side 
Figure 6.3: Photographs of purified mono-cultured and co-cultured strains on ISP2 agar.  
Figure 6.4: Investigation on the specificity of CMB-NB198 with other fungi. Co-cultivation of CMB-NB198 with (a) 
CMB-NF115 and (b) CMB-NF125 on ISP2 agar.  
CMB-NF122 CMB-NB198 Co-culture
CMB-NF122
CMB-NB198
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6.5 Case study 1: 
6.5.1 Analytical cultivation and chemical profiling 
Both the fungus Purpureocillium sp. CMB-NF122 and the Streptomyces CMB-NB198 were co-
cultured in one ISP2 agar plate and incubated at 29 °C for 7 days. The co-culture plate was then sliced 
into three parts, comprising (a) CMB-NF122, (b) CMB-NB198, (c) the interface of co-culture as 
shown in the Figure 6.6. The EtOAc extract of each slice was then analysed by UHPLC-DAD 
(Zorbax SB-C8 column, 50 ´ 2.1 mm, 1.8 µm, 0.417 mL/min gradient elution from 90% H2O/MeCN 
to 100% MeCN, containing 0.01% TFA as modifier, for 5 min) and HPLC-DAD-MS (Zorbax SB-C8 
column, 150 ´  4.6 mm, 5 µm, 1 mL/min gradient elution from 90% H2O/MeCN to 100% MeCN over 
15 min with isocratic 0.05% formic acid modifier). This analysis revealed that the co-cultivation had 
activated the production of a fungal metabolite 6.1, eluting at tR = 1.823 min (m/z = 259 [M+H]+) 
(Figure 6.6), which was completely absent in the pure fungal culture (Figure 6.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CMB-NF125CMB-NB198
CMB-NF125CMB-NB198
Figure 6.5: Photographs of co-cultivated Streptomyces sp. CMB-NB198 and Aspergillus sp. CMB-NF125 on ISP2 agar.  
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Figure 6.6: UHPLC-DAD chromatogram (254 nm) of crude extract of co-cultured CMB-NB198 and CMB-NF122 and 
the corresponding UV-Vis spectrum of the activated metabolite (highlighted in red) (a) the fungus CMB-NF122, (b) 
interface of the two strains, (c) the bacterium CMB-NB198. Peak in green is an internal standard. 
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To better understand the nature of the activation process, the fungus was allowed to grow in the 
presence of the extract of Streptomyces CMB-NB198. A 24 well microbioreactor plate loaded with 
the ISP2 broth medium (1470 μL) and inoculated with the culture broth (15 μL) was treated with an 
aliquot (15 μL) of serially diluted solution from an aqueous stock solution of crude extract of CMB-
NB198 (1 mg/mL), then incubated at 27 °C at 190 rpm for 7 days. After extraction with EtOAc (2.5 
mL), the extract was subjected to UHPLC-DAD analysis followed by HPLC-DAD-MS analysis. 
After careful scrutiny, the presence of 6.1 was obserevd (tR=1.823 min) in the crude extract of CMB-
NF122 treated with bacterial extract at concentration ³ 100 µg/mL (Figure 6.7).  
 
Figure 6.7: UHPLC-DAD chromatogram (254 nm) of crude extract of (a) CMB-NF122 mono-culture (b) CMB-NF122 
cultured in the presence of the extract of CMB-NB198 (100 mg/mL). Peak highlighted in red is the activated metabolite 
6.1 and green is the internal standard. 
 
6.5.2 MATRIX study 
To determine if 6.1 could be activated by a simple change in the cultivation media and conditions, 
CMB-NF122 was cultured in ´ 11 different media under ´ 3 different culture conditions according 
to the MATRIX approach. UHPLC-DAD analysis of the all ´ 33 extracts confirmed the absence of 
6.1 across all media conditions, except in the extract of CMB-NF122 co-cultivated with CMB-NB198 
(Figure 6.8). 
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Figure 6.8: UHPLC chromatograms of crude extracts of CMB-NF122 cultivated in different agar media. Peak highlighted 
in red is the activated metabolite 6.1 and in green is the internal standard. 
 
6.5.3 Preparative cultivation and fractionation of co-culture crude extract 
A scaled-up co-cultivation of both CMB-NF122 and CMB-NB198 on ISP2 agar (´ 25) plates was 
incubated at 29 °C for 7 days. The agar culture was sliced into pieces and extracted with EtOAc (200 
mL). The decanted organic layer was then dried down in vacuo to obtain the crude extract (100.1 
mg). The crude extract was then triturated to afford n-hexane (60.3 mg), DCM (20.7 mg) and MeOH 
(5.2 mg) soluble fractions. The DCM soluble fraction was then subjected to preparative HPLC to 
purify the activated compound 6.1 (2.5 mg) (Scheme 6.1).  
 
 
Scheme 6.1: Isolation scheme for the crude extract obtained from co-cultivated CMB-NF122 and CMB-NB198. 
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6.5.4 Structure elucidation of alternariol (6.1) 
 
 
 
 
 
HRESI(+)MS analysis of 6.1 returned as a sodiated molecular ion ([M+Na]+) indicative of a 
molecular formula C14H10O5 (Dmmu +3.6). Analysis of 1H NMR (methanol-d4) data showed the 
presence of resonances attributed to one methyl group (dH 2.76, s) and two pairs of meta coupled 
aromatic methine (dH 6.37, d, J = 1.9, H-3; dH 7.26, d, J= 1.9, H-5; dH 6.70, d, J = 2.5, H-9; dH 6.61, 
d, J = 2.5, H-11) (Figure 6.9). The 13C NMR (methanol-d4) data (Figure 6.10) revealed resonances 
attributed to four oxygenated sp2 quaternary carbons (C-2, dC 164.1; C-4, dC 166.3; C-10, dC 154.5; 
C-12, dC 159.9), one carbonyl (C-13, dC 167.0) and a tertiary methyl (C-8, dC 140.1). Literature data 
search confirmed that 6.1 was a known fungal mycotoxin alternariol, known to be produced by the 
endophytic fungi.2,3 The structure elucidation of 6.1 was further supported by 2D NMR (methanol-
d4) data, including HSQC, HMBC and COSY, as outlined in Figure 6.11 and Table 6.1. 
 
 
 
 
 
Figure 6.9: 1H NMR (600 MHz, methanol-d4) spectrum of alternariol (6.1). 
3.03.54.04.55.05.56.06.57.07.5 ppm
2.
81
0.
96
0.
96
0.
98
0.
96
6.656.70 ppm 6.38 ppm7.26 ppm
5 9
11
3
m
et
ha
no
l-d
4
14H
2O
X
O
OH
O
OH
HO
1
3
4
6
9
11
13
14
O
OH
O
OH
HO
(6.1)
Chapter 6: Identification and characterization of metabolites involved in defensive mechanism of microbes during co-cultivation  
 
 
 
191 
 
Figure 6.10: 13C NMR (150 MHz, methanol-d4) spectrum of alternariol (6.1). 
 
 
 
 
 
 
 
 Table 6.1: 1D and 2D NMR (methanol-d4) data for alternariol (6.1). 
Position dC dH, mult (J in Hz) experimentala HMBC 
δH, mult, (J in Hz) 
literature4,b 
dC, literature4, c 
1 99.7    97.7 
2 164.1    164.7 
3 102.0 6.37, d (1.9) 1, 2, 4, 5 6.38, d (1.9) 100.5 
4 166.3    165.4 
5 105.6 7.26, d (1.9) 1, 3, 4, 7 7.27, d (2.0) 104.0 
6 139.9    138.4 
7 111.1    109.5 
8 140.1    138.6 
9 118.7 6.70, d (2.5) 7, 11 6.71, d (2.6) 117.1 
10 154.5    153.0 
11 102.9 6.61, d (2.5) 7, 9, 10, 12 6.32, d (2.6) 101.3 
12 159.9    158.4 
13 167.0    165.5 
14 25.9 2.76, s 7, 8, 9  2.77, s 24.3 
    a = 600 MHz, b = 500 MHz, c = 125 MHz,   
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Figure 6.11: Key 2D NMR (600 MHz, methanol-d4) correlations for alternariol (6.1). 
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6.5.5 Investigation into the possible elicitor triggering the activation of alternariol (6.1) 
biosynthesis during co-cultivation 
In order to identify the possible underlying causes (i.e., chemical cues) responsible for the activation 
of 6.1, a series of experiments were designed. 
Alternariol (6.1) was first isolated from Alternaria sp.5 Later it was described as a mycotoxin 
produced by fungal species.5 There is evidence that fungi produce defensive metabolites against 
antifungal producing bacteria.6 In relation to the search of cue chemicals responsible for activation 
and considering the literature data, we assumed that the presence of any antifungal agent in the extract 
of CMB-NB198 might trigger the activation of alternariol (6.1).  
 
Experiment 1 
To test this hypothesis, the fungus CMB-NF122 was cultivated in the presence of some standard 
antifungal agents that included naturally occurring amphotericin B and nystatin, synthetic 
ketoconazole, using a 24-well microbioreactor. The fungus CMB-NF122 was cultivated in a 
microbioreactor containing ISP2 liquid media (1485 µL) containing an aliquot (15 µL) solution of 
antifungal agents (six different concentrations starting from 50 µM to 1.86 µM), with incubation at 
190 rpm, 29 °C for 7 days. The EtOAc extracts were then analysed using UHPLC-DAD and HPLC-
MS analysis. This analysis showed that both naturally occurring antifungal agents, amphotericin B 
and nystatin, stimulated CMB-NF122 to produce alternariol (6.1), whereas the synthetic antifungal 
ketoconazole showed no capacity for activation (Figure 6.12). That attributed to the differences in 
the mechanism of action of synthetic ketoconazole to the natural anti-fungal agents. Literature also 
reported that the mode of fungicidal activity of both amphotericin B and nystatin is apparently similar 
as they both possessed the ergosterol binding mechanisms, whereas the synthetic azoles completely 
inhibit the biosynthesis of ergosterol from lanosterol by inhibiting fungal cytochrome P450 as their 
fungicidal activity.7  
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Figure 6.12: UHPLC profile of the crude extract of (a) CMB-NF122 + amphotericin B, (b) CMB-NF122 + nystatin, (c) 
CMB-NF122 + ketoconazole and (d) pure alternariol (6.1). Peak highlighted in red is alternariol and green is the internal 
standard. 
 
6.6 Experiment 2 
In addition to the above experiment, the antifungal assay by disc diffusion method also performed 
using the same standard amphotericin B, nystatin, ketoconazole (15 µM/disc) and the extract of 
CMB-NB198 (the bacteria involved in the co-cultivation studies), (100 µg/disc). The result showed 
that the tested concentration of natural antifungal drugs and the extract of CMB-NB198 could not 
inhibited the growth of CMB-NF122. However, careful investigation revealed that in the case of 
amphotericin B, nystatin and the extract of CMB-NB198, the culture of CMB-NF122 turned brown, 
consistent with the production of alternariol (6.1). Of note, although amphotericin B, nystatin and the 
extract of CMB-NB198 failed to inhibit the growth of CMB-NF122, they did inhibit the test fungus 
CMB-NF118 and C. albicans (Figure 6.13). 
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Figure 6.13: Antifungal assay of standard amphotericin B (15 µM/disc), nystatin (15 µM/disc), ketoconazole ((15 
µM/disc) and crude extract of CMB-NB198 (100µg/disc) against (a) CMB-NF122, (b) CMB-NF118 and (c) C. albicans 
by disc diffusion method. The zone of inhibition was pictured from the opposite side of the agar plate. 
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6.6.1 Chemical profiling of the crude extract of CMB-NB198 
The result obtained from the above experiments prompted us to investigate the presence of any 
specific activator agent in the crude extract of CMB-NB198. Careful analysis of the HPLC-DAD-MS 
and UHPLC-QTOF-MS/MS profile of an EtOAc extract of CMB-NB198 confirmed the presence of 
members of the niphimycin class of compounds with m/z values 1142.7 (M+H)+, 1156.7 (M+H) +, 
1124.7 (M+H)+ (Figure 6.14 and Table 6.2). Niphimycins are potent antifungals.8 
 
Figure 6.14: HPLC-DAD-MS profile of crude extract of CMB-NB198 cultured on ISP2 agar. 
Table 6.2: LC-MS profile of the crude extract of CMB-NB198. 
Peak 
No. 
HPLC 
tR (min) 
(M+H)+/ 
(M+Na)+ (M-H)
- Molecular weight 
Molecular 
formula 
D ppm 
(Diff) 
Reference 
compounds 
a 4.227 137.0 --- --- --- ---  
b 5.382 174.0 172.0 173 C10H7NO2 -2.79  
c 6.037 478.0 --- --- --- ---  
d 6.450 247.0 245.0 246 C15H6N2O2 2.72  
e 6.464 247.0 245.0 246 C15H6N2O2 2.72  
f 7.163 285.0 283.0 284 C15H12 N2O2 1.37  
g 7.210 397.2 395.2 396 C16H28O11 -0.14  
h 7.393 306.0 304.0 305 C14H11NO7 0.57  
i 8.007 364.0 362.0 363 C17H29N7O2 0.74  
j 8.452 496.2 494.2 495 C23H9N7O7 0.34  
k 9.469 569.4 567.4 568 C29H52N12 -0.82  
l 9.512 --- 838.4 --- --- ---  
m 9.748 1142.7 --- --- C59H103N3O18 1.02 niphimycins 
n1 9.965 1156.7 --- --- C60H105N3O18 -0.96 niphimycins 
n2 10.125 1124.7 --- --- C60H105N3O16 -1.84 niphimycins 
o 10.538 387.0 --- --- --- ---  
p 11.201 1047.2 --- --- --- ---  
q 11.568 --- --- --- --- ---  
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6.6.2 Effect of alternariol (6.1) on the production of antifungal niphimycins by CMB-NB198 
To reveal any effect of alternariol (6.1) in the production of antifungal niphimycins by the bacteria 
CMB-NB198, aliquot (15 μL) of alternariol (6.1) was added to culture of CMB-NB198 using 24 well 
microbioreactor. The 24 well microbioreactor plate was first loaded with the ISP2 broth medium 
(1470 μL) and inoculated with the culture broth (15 μL) of CMB-NB198. After that alternariol (15 
μL) (concentration ranging from 50 μM to 1 μM) was added in duplicate across the 24 wells of a 
microbioreactor. The microbioreactor was then incubated at 27 °C at 190 rpm for 7 days. After 
extraction with EtOAc (2.5 mL), aliquots (1 μL) of the extracts were subjected to UHPLC-DAD 
analysis followed by HPLC-DAD-MS analysis. After careful scrutiny of the HPLC profile, it was 
revealed that the production of metabolites belongs to niphimycins cluster (highlighted in red) by the 
bacteria CMB-NB198 was increased when cultivated in the presence of alternariol (6.1) (Figure 
6.15). 
 
 
 
 
 
 
 
 
 
 
 
 
6.6.3 Biological profile of 6.1 
As alternariol (6.1) and its derivatives is been reported as mycotoxins, the potency of 6.1 was 
evaluated against Gram (+)ve bacteria B. subtilis (ATCC 6633) and Gram (-)ve bacteria E. coli 
(ATCC 11775) and fungus C. albicans (ATCC 90028). Alternariol (6.1) showed potent growth 
inhibition against Gram (+)ve B. subtilis  (MIC 3.2 µM) and the fungus C. albicans  (MIC 2.9 µM) 
but no growth inhibition in case of Gram (-)ve E. coli (Figure 6.16). Alternariol (6.1) also exhibited 
strong cytotoxic effect when tested against human colon cancer cell (SW620) (IC50 0.9 µM) and 
human lung cancer cell (NCI-H460) (IC50 2.2 µM) (Figure 6.17). 
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Figure 6.15: HPLC profile (210 nm) of crude extract of (a) CMB-NB198 and (b) CMB-NB198+ alternariol (6.1) (12.5 
µM). Peak highlighted in red are the antifungal metabolites, green is the internal standard. 
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Figure 6.16: Antimicrobial assay screening graph of alternariol (6.1), rifampicin and amphotericin B served as controls 
for both bacteria and fungi respectively, while DMSO served as positive control. 
 
 
Figure 6.17: Screening of alternariol (6.1) cytotoxicity against human cancer cell lines. 
 
6.6.4 Conclusion 
Other studies also detected the complex interaction between fungi and Streptomyces. For example, 
Oh et al.9 reported a co-cultivation study of two marine microorganisms, the fungus Emericella sp. 
and the actinomycete Salinispora arenicola, that enhanced the expression of emericellamides 
biosynthesis by 100-fold. Another study by Schroeckh et al.10 reported a co-cultivation study 
involving a bacterium, S. rapamycinicus and fumgus A. nidulans, where the bacterium elicited a 
fungal defensive strategy.  
This study showed that the production of alternariol (6.1) by Purpureocillium sp. CMB-NF122, was 
activated when co-cultured with Streptomyces sp. CMB-NB198, isolated from the same sheep faecal 
sample. We demonstrated that an anti-fungal agent produced by the bacterium CMB-NB198 and an 
anti-bacterial agent produced by the fungus CMB-NF122, acted as chemical cues that changed 
(increased) each other’s transcriptional levels, respectively.   
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During co-culture condition, low levels of antifungal niphimycins produced by the bacteria CMB-
NB198 activated the transcription of silent alternariol (6.1) by the fungus CMB-NF122. The latter 
activation can be replicated by challenging the fungus CMB-NF122 with either an EtOAc extract of 
CMB-NB198 or by treated with the known natural antifungal agent amphotericin B or nystatin (both 
of which act on the fungal cell wall by binding with ergosterol). Of note, the synthetic antifungal 
ketoconazole shown no such transcriptional activation of 6.1, possibly as ketoconazole has a different 
mode of action as antifungal where they inhibit the total biosynthesis of ergosterol from lanosterol.  
Based on the above observations, further investigation on the chemical communication between these 
two strains is necessitated to better understand the molecular mechanisms behind this shared chemical 
ecology. Recently introduced advanced analytical tools, such as mass spectroscopic analysis of living 
microbial colonies11 could be useful to elaborate the interaction between these two strains. 
 
6.7 Case study 2: 
6.7.1 Analytical scale agar-based co-cultivation of CMB-NB198 and CMB-NF125 
The co-culture agar plate of CMB-NF125 and CMB-NB198 was sliced into three parts, comprising 
(a) the fungus CMB-NF125, (b) the Streptomyces CMB-NB198 and (c) the interface of co-culture, 
as shown in the Figure 6.18. Each part was then extracted with EtOAc separately followed by drying 
the organic layer under N2 to yield the crude extract. Crude extracts in MeOH (5 mg/mL) were 
analysed by HPLC-DAD-MS (Zorbax SB-C8 column, 150 ´ 4.6 mm, 5 µm, 1 mL/min gradient 
elution from 90% H2O/MeCN to 100% MeCN over 15 min with isocratic 0.05% formic acid 
modifier). Chemical investigation of the co-cultured extracts (Figure 6.18) with comparison to mono-
culture (Figure 6.19 and 6.20) revealed a significant enhancement in the production of two CMB-
NF125 metabolites 6.2 (tR 9.525, m/z 443.8, [M+H]+) and 6.4 (tR 3.954, m/z 152, [M+H]+), and 
activation of production of two CMB-NB198 metabolites 6.5 (tR 6.512, m/z 180, [M+H]+) and  6.6 
(tR 5.210 (m/z 415, [M+H]+). To identify the chemistry involved in this co-cultivation, a scale-up co-
cultivation of CMB-NB198 and CMB-NF125 was performed. 
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Figure 6.18: HPLC chromatogram of crude extract of (a) CMB-NF125, (b) CMB-NB198 (c) Interface. Peaks highlighted 
in red, orange and yellow = enhanced/activated peaks, green = internal standard. 
 
 
Figure 6.19: HPLC chromatogram of crude extract (a) CMB-NF125 mono-culture, (b) CMB-NF125 co-cultured with 
CMB-NB198, (c) ISP2 media only. Red peak (6.2) and orange peak (6.4) were enhanced during co-cultivation. Green 
peak is the internal standard. 
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Figure 6.20: HPLC chromatogram of crude extract (a) CMB-NB198 mono-culture, (b) CMB-NB198 co-cultured with 
CMB-NF125, (c) ISP2 media only. Yellow peak (6.5 – 6.6) was enhanced during co-culture. Green peak is the internal 
standard. 
 
6.7.2 Preparative co-cultivation and fractionation of co-culture extract 
CMB-NF125 and CMB-NB198 were carefully inoculated on the opposite edges of petridishes (´ 80) 
containing ISP2 agar and incubated for 12 days at 29 °C under static conditions. After the incubation, 
the agar plates were separated into part A (CMB-NB198) and part B (CMB-NF125), which were 
separately extracted with EtOAc (500 mL) to yield two crude extracts, A (100 mg) and B (120 mg).  
The crude extracts were then subjected to partitioning with n-hexane (-1-1) and aqueous MeOH (-1-
2) separately. HPLC-DAD-MS analysis localized the desired metabolites in the MeOH fractions, 
which were subjected to preparative HPLC fractionation to afford trypacidin (6.2) and 
monomethylsulochrin (6.3) from the fungus CMB-NF125 (part B), 2-(4-hydroxyphenyl) acetamide 
(6.4), N-acetyl tyramine (6.5) and pre-hazimycin (6.6), from the bacterium CMB-NB198 (part A) 
(Scheme 6.2).  
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(a) n-hexane/MeOH solvent partitioning 
(b) Preparative HPLC: Zorbax-C8 column, 21.2 ´ 150 mm, 5 µm, 20 mL/min gradient over 30 min, from 0 % – 100 %   
MeCN inclusive of 0.01 % TFA as modifier.                                                                                                                                                                                                                    
(c) Preparative HPLC: Zorbax-C8 column, 21.2 ´ 150 mm, 5 µm, 20 mL/min gradient over 30 min, from 20 % – 100 % 
MeCN inclusive of 0.01 % TFA as modifier. 
 
Scheme 6.2: Isolation scheme for CMB-NF125 co-culture with CMB-NB198 on ISP2 agar 
6.7.3 Structure elucidation 
6.7.3.1 Trypacidin (6.2) 
HRESI(+)MS analysis of 6.2 returned as a  sodiated molecular ion 
([M+Na]+) consistent with a molecular formula C18H16O7 (Dmmu + 1.1). 
Detailed analysis of the 1H NMR (DMSO-d6) data for 6.2 (Figure 6.21) 
revealed the presence of resonances attributed to three O-methyls (dH 
3.88, s; dH 3.63, s and dH 3.67, s); one aromatic methyl (dH 2.40, s); two 
aromatic protons (dH 6.61, br s, H-4; dH 6.68, br s, H-6) along with one pair of  meta-coupled proton 
(dH 6.96, d, J = 1.4, H-4¢ and dH 5.97, d, J = 1.4, H-6¢). The 13C NMR (DMSO-d6,) data for 6.2 
(Figure 6.22) revealed resonances for three carbonyl carbon (dC 189.9, C-1¢; dC 163.5, C-3¢-
COOCH3; dC 185.3, C-5¢) and three oxygenated quaternary carbon (dC 158.3, C-1; dC 152.9 C-5; dC 
169.5, C-7¢). Detailed analysis of 2D (HSQC, COSY, HMBC) NMR data (DMSO-d6 ) (Figure 6.23 
and Table 6.3) and literature search of the molecular formula identified 6.2 as a trypanocidal 
antibiotic trypacidin, first isolated from A. fumigatus  in 1965.12,13 Though the absolute configuration 
of trypacidin has not been confirmed yet, but our experimental optical rotation for trypacidin (6.2) 
([α]22D - 85.3, c 0.025, MeOH) was comparable to the reported value  ([α]22D -166, c 0.1, MeOH).14 
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Figure 6.21: 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, MeCN/H2O with formic acid at 210 nm) spectra 
of trypacidin (6.2). 
 
Figure 6.22: 13C NMR (150 MHz, DMSO-d6) spectrum of trypacidin (6.2). 
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Figure 6.23: Key 2D NMR (600 MHz, DMSO-d6) correlations of trypacidin (6.2). 
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Table 6.3: 1D and 2D NMR data for trypacidin (6.2) and comparison with the literature data. 
Position dC dH, mult (J in Hz)a HMBC 
dH, mult 
(J in Hz)b 
dH, mult 
(J in Hz)c 
1 158.3 --- --- --- --- 
2 107.7 --- --- --- --- 
3 174.0 --- --- --- --- 
4 106.3 6.61, br s 2, 6, 1¢ 6.52, br s 6.55, d (2.1) 
5 152.9 --- --- --- --- 
6 105.7 6.68, br s 2, 4 6.34, br s 6.37, d (2.1) 
1¢ 189.9 --- --- --- --- 
2¢ 84.1 --- --- --- --- 
3¢ 138.7 --- --- --- --- 
4¢ 136.3 6.96, d (1.4) 2¢, 6¢ 3¢-COOCH3 7.08, d (1.4) 7.10, d (1.4) 
5¢ 185.3 --- --- --- --- 
6¢ 104.2 5.97, d (1.4) 2¢, 4¢, 5¢ 5.74, d (1.4) 5.77, d (1.4) 
7¢ 169.5 --- --- --- --- 
5-Me 22.9 2.40, s 5, 6 2.41, s 2.44, s 
1-OMe 56.4 3.88, s 1 3.92, s 3.95, s 
7¢-OMe 57.8 3.63, s 7¢ 3.63, s 3.66, s 
3¢-COOCH3 163.5 --- --- --- --- 
3¢-COOCH3 53.3 3.67, s 3¢-COOCH3 3.66, s 3.69, s 
    1H NMR measured in a = 600 MHz, DMSO-d6, b = 600 MHz, CDCl3, c = literature data for 6.2, 400 MHz, CDCl312 
 
6.7.3.2 Monomethylsulochrin (6.3)  
HRESI(–)MS analysis of 6.3 returned a  molecular ion ([M–H]–) 
consistent with a molecular formula C18H18O7 (Dmmu + 0.9). The 
1H NMR (DMSO-d6) data for 6.3 (Figure 6.24) showed the 
presence of resonances attributed to three O-methyls (dH 3.62, s; 
dH 3.62, s and dH 3.33, s); one methyl (dH 2.25, s); two meta-
coupled aromatic protons (dH 6.90, d, J = 3.6, H-4¢; dH 6.70, d, J = 3.6, H-6¢); two aromatic protons 
(dH 6.38, br s, H-4; dH 6.26, br s, H-6) along with two hydroxy protons (dH 10.05, s and dH 12.96, s). 
The 13C NMR (DMSO-d6) data for 6.3 (Figure 6.25) revealed the presence of two carbonyl carbon 
(dC 199.3, C-1¢; dC 160.8, C-3¢-COOCH3) and four oxygenated quaternary carbon (dC 163.3, C-1; dC 
156.6, C-3; dC 158.0, C-5¢; dC 165.7, C-7¢). HMBC correlation from H-4¢ to C-2¢ (dC 125.8) and C-6¢ 
(dC 103.2), and from H-6¢ to C-2¢ (dC 125.8), C-4¢ (dC 107.2) and C-7¢ (dC 165.7) confirmed the 
presence of both these protons on the same aromatic ring. Likewise, HMBC correlations from H-4 to 
C-2 (dC 110.1) and C-6 (dC 103.4), and from H-6 to C-2 (dC 110.1) and C-4 (dC 110.1) confirmed 
their presence in the same aromatic ring. Detailed analysis of the 2D NMR data (HSQC, COSY, 
HMBC) for 6.3 (Table 6.4 and Figure 4.26) and literature search of the molecular formula, supported 
by structure fragments, confirmed that 6.3 was the known fungal metabolite monomethylsulochrin,14 
O CO2Me
OH
OMe
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OHMeO
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Monomethylsulochrin (6.3) was first isolated from A. fumigatus  in 1965,  is a common metabolites 
of fungi of the genera Aspergillus, Penicillium and Oospora.13 
 
 
 
 
 
Figure 6.24: 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, MeCN/H2O with formic acid at 210 nm) spectra 
of monomethylsulochrin (6.3). (x = impurities) 
 
Figure 6.25: 13C NMR (150 MHz, DMSO-d6) spectrum of monomethylsulochrin (6.3). 
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Figure 6.26: Key 2D NMR (600 MHz, DMSO-d6) correlations of monomethylsulochrin (6.3). 
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Table 6.4: 1D and 2D NMR data for monomethylsulochrin (6.3) compared with the reported compound. 
Pos. dC dH, mult (J in Hz)a HMBC dH, mult (J in Hz)
b dH, mult (J in Hz)c 
1 163.3 --- --- --- --- 
2 110.1d --- --- --- --- 
3 156.6 --- --- --- --- 
4 110.1d 6.38, br s  2, 6 6.09, br s 6.06, br s 
5 147.8 --- --- --- --- 
6 103.4 6.26, br s 2, 4, 1¢ 6.49, br s 6.45, br s 
1¢ 199.3 --- --- --- --- 
2¢ 125.8 --- --- --- --- 
3¢ 127.9 --- --- --- --- 
4¢ 107.2 6.90, d (2.5) 2¢, 6¢ 7.06, d (2.2) 7.02, d (2.1) 
5¢ 158.0 --- --- --- --- 
6¢ 103.2 6.70, d (2.5) 2¢, 4¢, 5¢ 6.65, d (2.2) 6.62, d (2.1) 
7¢ 165.7 --- --- --- --- 
5-Me 21.9 2.25, s 3, 4, 5 2.32, s 2.29, s 
1-OMe 52.1 3.62f 1 3.72, s 3.68, s 
7¢-OMe 55.9e 3.62f 7¢ 3.73, s  3.70, s  
3¢-COOCH3 55.9e 3.33, s 3¢-COOCH3 3.40, s 3.37, s 
3¢-COOCH3 160.8 --- --- --- --- 
3-OH  12.96, s 3, 4 13.01, s 12.98, s 
5¢-OH  10.05, s 4¢, 5¢, 6¢   
   1H NMR measured in a = 600 MHz, DMSO-d6; b = 600 MHz, CDCl3; c = literature data for 6.3, 400 MHz, CDCl313; 
   d - e = assignments for resonances (same superscript) are interchangeable; f = assignments for overlapping resonances. 
 
. 
 
 
6.7.3.3 2-(4-hydroxyphenyl) acetamide (6.4) 
HRESI(+)MS analysis of 6.4 returned a pseud-molecular ion ([2M+Na]+) consistent with a molecular 
formula (C8H9NO2, Dmmu + 0.9), requiring five double bond equivalent (DBE). The 1H NMR 
(DMSO-d6) data for 6.4 (Figure 6.27) showed the presence of resonances for one disubstituted 
aromatic ring (dH 7.04, d, J = 8.4; dH 6.67, d, J = 8.4). The 13C NMR (DMSO-d6) data for 6.4 (Figure 
6.28) showed the presence of one carbonyl (dC 173.2, C-1), one oxygenated carbon (dC 156.2, C-6), 
while HSQC data revealed one methylene (dH 3.22, s, H-2). Analysis of the 2D NMR (600 MHz, 
DMSO-d6) data for 6.4 (Figure 6.29 and Table 6.5) supported the presence of a p-substituted phenyl 
moiety. On searching the literature, it was determined that 6.4 was identical to the known fungal 
metabolite 2-(4-hydroxyphenyl) acetamide, first isolated from P. oxalicum  in 1998.15  
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Figure 6.27: 1H NMR (600 MHz, DMSO-d6) spectrum of 2-(4-hydroxyphenyl) acetamide (6.4). 
 
Figure 6.28: 13C NMR (150 MHz, DMSO-d6) spectrum of 2-(4-hydroxyphenyl) acetamide (6.4). 
Table 6.5: 1D and 2D NMR (DMSO-d6) data for 2-(4-hydroxyphenyl) acetamide (6.4) compared to the reported 
compound. 
Position dC dH, mult (J in Hz) a COSY HMBC dH, mult (J in Hz) b 16 
1 173.2 --- --- --- --- 
2 41.9 3.22, s --- 1, 3, 4/8 3.21, s 
3 127.0  --- ---  
4/8 130.3 7.04, d (8.4) 5/7 2, 6 7.03, d (8.4) 
5/7 115.3 6.67, d (8.4) 4/8 3, 6 6.66, d (8.4) 
6 156.2 --- --- --- --- 
6-OH --- 9.19, s --- 5/7, 6 9.24, s 
NH2 --- 7.32, br s --- 1, 2 7.33, br s 
NH2 --- 6.77, br s --- 1, 2 7.33, br s 
  1H NMR measured in a = 600 MHz, b = 400 MHz 
 
 
 
 
 
 
 
 
 
2.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5 ppm
6.76.86.97.0 ppm
6-OH
NH2 NH2
4/8
5/7
2
D
M
SO
-d
6
H
2O
405060708090100110120130140150160170 ppm
D
M
SO
-d
6
1 6
4/8
3
5/7
2
HO
OH2N
1
2
46
8
Figure 6.29: Key 2D NMR (600 MHz, DMSO-d6) correlations of 2-(4-hydroxyphenyl) acetamide (6.4). 
HO
OH2N
1
2
46
8
COSYHMBC
Chapter 6: Identification and characterization of metabolites involved in defensive mechanism of microbes during co-cultivation  
 
 
 
206 
6.7.3.4 N-acetyl tyramine (6.5) 
HRESI(+)MS analysis of 6.5 returned a sodiated molecular ion 
([2M+Na]+) consistent with a molecular formula C10H13O2N (Dmmu 
+1.2). The 1H NMR (DMSO-d6) data for 6.5 (Figure 6.30) showed the 
presence of resonances attributed to a p-disubstituted aromatic ring (dH 
6.97, d, J = 8.4, H- 5/9;  dH 6.66, d, J = 8.4, H-6/8) and an acetyl methyl (dH 1.77, s). The 13C NMR 
(DMSO-d6) data for 6.5 (Figure 6.31) showed the presence of one carbonyl (dC 169.4, C-1) and an 
oxygenated carbon (dC 156.0, C-7), while HSQC data revealed two methylenes (dH 3.16, dd, J = 13.0, 
6.5; H-2 and dH 2.56, dd, J = 7.6, 7.3; H-3). Analysis of the 2D NMR (HSQC, HMBC, COSY) data 
for 6.5 together with the literature search, identified 6.5 as the common bacterial metabolite N-acetyl 
tyramine.17,18 
 
 
 
 
Figure 6.30: 1H NMR (600 MHz, DMSO-d6) spectrum of N-acetyl tyramine (6.5). 
 
Figure 6.31: 13C NMR (150 MHz, DMSO-d6) spectrum of N-acetyl tyramine (6.5). 
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 Table 6.6: 1D and 2D NMR data for N-acetyl tyramine (6.5) compared to the reported compound. 
Pos. dC dH, mult (J in Hz)a COSY HMBC dH, mult (J in Hz)b dH, mult (J in Hz)c 
1 169.4 --- --- --- --- --- 
2 40.9 3.16, dd (13.0, 6.3) 3, NH 1, 3 3.32e 3.33, t (7.5) 
3 34.8 2.56, dd (7.6, 6.3) 2 2, 5/9 2.67, dd (7.6, 7.3) 2.69, t (7.5) 
4 d --- --- --- --- --- 
5/9 129.8 6.97, d (8.4) 6/8 3, 6/8, 7 7.01, d (8.4) 7.02, d (9.2) 
6/8 115.3 6.66, d (8.4) 5/9  7 6.70, d (8.4) 6.71, d (8.5) 
7 156.0 --- --- --- --- --- 
1-Me 23.0 1.77, s --- 1 1.89, s 1.89, s 
NH --- 7.86, br s 2 1, 2   
7-OH --- 9.16, s --- 6, 8   
 1H NMR measured in a = 600 MHz, DMSO-d6; b = 600 MHz, methanol-d4; c = literature (400 MHz, methanol-d4) data 
18; d = signal not observed, e = assignments overlapped with solvent signal. 
 
6.7.3.5 Pre-hazimycin (6.6) 
HRESI(+)MS analysis of 6.6 returned a sodiated molecular ion 
([M+Na]+) consistent with a molecular formula C20H22O6N4, 
(Dmmu 0.0). The 1H NMR (600 MHz, DMSO-d6) data for 6.6 
(Figure 6.33) showed the presence of only 11 proton resonances, 
while the 13C NMR (DMSO-d6) (Figure 6.34) data showed only 
10 carbon resonances, requiring that 6.6 possesses an element of 
symmetry. 
Further analysis of the 1D and 2D NMR data for 6.6 revealed 
resonances attributed to a 1,2,4-trisubstututed benzene ring (dH 
7.02, d, J = 2.1; dH 6.77, d, J = 8.1; dH 7.00, dd, J = 2.2, 8.1), a 
diastereotopic methylene (dH 2.92, dd, J = 13.8, 4.8; dH 2.68, dd, J = 14.0, 9.0; dC 37.0) and a 
deshielded methine (dH 4.45, ddd, J = 11.5, 8.7, 4.8; dC 52.6). HMBC correlation between amide 
CONH2 (dH 7.49/7.07, s) and an amide CONH2 (dC 172.8); COSY correlations between NHCOCH 
(dH 8.17) and NHCOCH (dH 4.45, m), and HMBC correlation between NHCHO (dH 8.17) and an 
amide NHCHO (dC 160.8) confirmed the presence of CONH2 and NHCHO moieties in the structure 
of 6.6.  
Figure 6.32: Key 2D NMR (600 MHz, DMSO-d6) correlations of N-acetyl tyramine (6.5). 
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Assignments of all 2D NMR data (Figure 6.35 and Table 6.7) revealed HMBC correlation from H-
2 (dH 4.45) to C-1 (dC 172.8), C-3 (dC 37.0), C-4 (dC 127.9) and C-10 (dC 160.8), as well as COSY 
correlations between H-3 (a, dH 2.92; b, dH 2.68) and N-H (dH 8.17). Further HMBC correlations from 
the aromatic methine H-9 (dH 7.02) to C-3 (dC 37.0), C-7 (dC 152.7) and C-5 (dC 128.7) confirmed the 
position of H-9. The dimerization of metabolite 6.6 was determined to be a C-8 to C-8¢, based on the 
ortho disposition of H-5/5¢ and H-6/6¢, and meta disposition of H-9/9¢. Thus 6.6 was identified as 2-
2¢-N-N-diformyl-dityrosine-diamide for which we assigned the trivial name pre-hazimycin. Online 
database searching indicated the basic skeleton of 6.6 was similar to hazimycins (a group of 
compounds isolated from Pseudomonas sp.), possessed a dihydroxydiaryl skeleton (a cross linked 
dityrosine) contained isonitrile group (Figure 6.35).19  
 
 
 
 
 
 
 
 
 
 
Figure 6.33: 1H NMR (600 MHz, DMSO-d6) spectrum of pre-hazimycin (6.6). 
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Figure 6.34: 13C NMR (150 MHz, DMSO-d6) spectrum of pre-hazimycin (6.6). 
 
 
 
 
 
 
 
 
 
 
 
  Table 6.7: 1D and 2D NMR (600 MHz, DMSO-d6) data for pre-hazimycin (6.6). 
Position dC dH, mult (J in Hz) COSY HMBC 
1/1¢ 172.8 --- --- ---- 
2/2¢ 52.6 4.45, ddd (11.5, 8.7, 4.8) 3, NH 1, 3, 4, 10 
3/3¢ 37.0 a, 2.92, dd (14.0, 4.8) b, 2.68, dd (14.0, 9.5) 2 
1, 2, 4, 5, 9 
4/4¢ 127.9 --- --- --- 
5/5¢ 128.7 7.00, dd (8.1, 2.2) 6 7, 9 
6/6¢ 115.5 6.77, d (8.1) 5 4, 7, 8 
7/7¢ 152.7 --- --- --- 
8/8¢ 125.5 --- --- --- 
9/9¢ 132.2 7.02, d (2.1)  3, 5, 7, 8 
10/10¢ 160.8 7.94, s NH 2 
NH/NH¢ --- 8.17, d (8.6) 2 2, 3, 10 
NH2/NH2¢ --- 7.07, s --- 1, 2 
NH2/NH2¢ --- 7.49, s --- 1, 2 
7-OH/7-OH¢ --- 9.00, br s --- --- 
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Figure 6.35: Key 2D NMR (600 MHz, DMSO-d6) correlations of pre-hazimycin (6.6). 
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Wright et al.19 was first isolated hazimycin factor 5 (6.7) and hazimycin factor 6 (6.8) from 
Pseudomonous sp. SCC 1411 in 1982, as a new class of antifungal antibiotic. Stereochemical detail 
was revealed by the X-ray crystallographic analysis of hazimycin factor 5, which existed as equal 
number of molecules with R,R and S,S stereochemistry. Experiments also suggested that in the 
presence of water, hazimycin factors 5 can be interconverted to hazimycin factor 6, consisting of 
equal number of molecules with R,S and S,R stereochemistry (Figure 6.36).19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Later in 1983 Marquez et al.20 reported the taxonomy and biological properties of hazimycins and in 
1985, same research group Puar et al.21 reported that hazimycins are biosynthesized from tyrosine 
and methionine, where methionine are the origin of isonitrile carbon. But both the authors group 
misspelled hazimycins as hazimicins, but indicated the same structures. 
A 2015 study by Nobuhiro et al. isolated three other hazimycin congeners, hazimycin B, C and D 
(6.9 – 6.11) form another actinomycete kitasatospora sp., and mentioned hazimycin factors 5 and 6 
as hazimycin A.22 
The absolute stereochemistry at 2 and 2¢ of hazimycins were defined as S, S as the optical rotation of 
hazimycins ([α]D – 10.6, c 0.1, MeOH) were comparable to synthetic L,L-dityrosine ([α]D – 2.6, c 
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Figure 6.36: Interconversion of hazimycin factor 5 (6.7) and 6 (6.8). 
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0.08, 1M HCl).22 But our experimental optical rotation of 6.6 was obtained as [α]D + 97.0, c 0.025, 
MeOH, opposite to that for hazimycins, so the absolute stereochemistry at 2 and 2¢ of 6.6 was 
suggested as R, R. Here we suggested the isolation of more 6.6 to perform the conversion to dityrosine 
by mild acid hydrolysis, to further confirm the absolute stereochemistry, and also chemical 
derivatization (e.g. C3 Marfey’s analysis) of the dityrosine to confirm the enantiopurity of 6.6. 
 
 
 
Cross linked dityrosine, a tyrosine dimer, is a natural component of protein structure, have a wide 
range of natural occurrence such as elastic ligament of insects, the ascopore cell walls of 
Saccharomyces cerevisiae, the cell wall of C. albicans, the cuticles of Haemonchus contortus, the 
cross linked fertilization envelope of sea urchin egg Stronglycocentrotus purpuratus etc.23  In most 
of these cases, the formation of dityrosine is believed to possess a defensive and/or strengthening  
role to the proteins. Cross-linked tyrosine residues are also common as biologically active cyclic 
peptides, for example, the cyclo-isodityrosine containing bouvardins.24, 25 A number of conditions 
have been mentioned regarding the diverse conditions associated with generation of dityrosine in 
proteins. Most common are the peroxidase catalysed reactions leading formation of tyrosyl radicals, 
formation of superoxide dismutase etc. But literature reported the formation of dityrosine 
simultaneously under the condition of nitrative stress. Van der Vliet et al., reported the formation of 
dityrosine by reacting phenylalanine and tyrosine with peroxynitrite.23  
 
6.7.4 Biological properties of isolated metabolites 
All the isolated metabolites were tested for their antimicrobial and cytotoxic properties. In micro-
broth dilution assay, trypacidin (6.2) and monomethylsulochrin (6.3) showed substantial activity 
against B. subtilis (ATCC 6051) and C. albicans (ATCC 10231), while displaying a potent activity 
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against tested cancer cell lines. Other activated metabolites 6.4, 6.5 and 6.6 did not shown any 
inhibitory activities with the concentration up to 30 µM (Table 6.8, Figure 6.37 and Figure 6.38). 
 
Table 6.8: Antibacterial, antifungal and cytotoxic properties of 6.2 – 6.6  
 B. subtilis 
(ATCC 6051) 
(MIC µM) 
C. albicans 
(ATCC 10231) 
(MIC µM) 
Human colon 
cancer cell 
(SW620) 
(IC50 µM) 
Human lung 
cancer cell 
(NCI-H460) 
(IC50 µM) 
trypacidin (6.2) 0.82 0.60 0.72 2.8 
monomethylsulochrin (6.3) 1.2 1.1 0.81 1.02 
2-(4-hydroxyphenyl)acetamide (6.4) > 30 > 30 > 30 > 30 
N-acetyl tyramine (6.5) > 30 > 30 > 30 > 30 
pre-hazimycin (6.6) > 30 > 30 > 30 > 30 
 
 
Figure 6.37: Antimicrobial assay screening graph of 6.2 – 6.6, rifampicin and amphotericin B served as controls for both 
bacteria and fungi respectively, while DMSO served as positive control. 
 
 
Figure 6.38: Cytotoxicity activity of 6.2 – 6.6 against human cancer cell lines  
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6.7.5 Investigation on the possible elicitor triggering the activation of metabolites 6.5 and 6.6 
by CMB-NB198 
A series of experiments were designed to understand the possible mechanisms or cues responsible 
for the activated production of 6.5 and 6.6 by the Streptomyces CMB-NB198 during co-cultivation 
with CMB-NF125. 
Experiment 1 
CMB-NB198 was allowed to culture in the presence of mono-culture extracts of CMB-NF125 and 
extract of CMB-NF125 co-cultured with CMB-NB198 (100 µg/mL). The results of UHPLC-DAD 
analysis revealed that the production of both 6.5 and 6.6 was only induced by the extract prepared 
from co-cultivated CMB-NF125 and CMB-NB198 (Figure 6.39). This result lead to the hypothesize 
that one or more metabolites present in the co-cultured extract of CMB-NF125 and CMB-NB198 was 
responsible for activating the production of 6.5 and 6.6 in CMB-NB198 culture.  
 
 
Figure 6.39: UHPLC profile of crude extract of (a) CMB-NB198, (b) CMB-NB198 with CMB-NF125 mono extract and 
(c) CMB-NB198 with CMB-NF125 co-culture extract. Peaks highlighted in yellow are activated metabolite peak 6.5 and 
6.6, green is the internal standard. 
 
To test this hypothesis, CMB-NB198 cultured in the presence of metabolites 6.2 and 6.4, each 
produced by CMB-NF125 during co-cultivation with CMB-NB198. The analysis of the UHPLC-
DAD data revealed that both the metabolites 6.5 and 6.6 was activated when treated with 6.2 at 
concentration £ 12.5 µM, where higher concentrations of 6.2 completely inhibited the growth of 
CMB-NB198. (Figure 6.40). The addition of compound 6.4 to the culture of CMB-NB198 did not 
show any effect. Thus 6.2 can be viewed as both antibacterial toward CMB-NB198 at high 
concentrations and a stimulant of the CMB-NB198 defensive agents 6.5 and 6.6 at lower 
concentrations. 
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Figure 6.40: UHPLC profile of crude extract of CMB-NB198 cultivated in the presence of different concentrations of 
pure metabolite 6.2. Peaks highlighted in yellow are activated metabolite peak 6.5 and 6.6, green is the internal standard. 
 
Experiment 2 
To investigate the possibility that anti-bacterial metabolites produced by the fungus CMB-NF125 
activated the production of 6.5 and 6.6 by CMB-NB198, monoculture of CMB-NB198 was treated 
with the pure metabolites 6.2, 6.3 and 6.4 (up to 30 µM concentration). Both the metabolites 6.2 and 
6.3 revealed as anti-bacterial against CMB-NB198 (MIC 1.0 – 3.0 µM) (Figure 6.41). Another disc 
diffusion assay also proved the anti-bacterial activity of both 6.2 and 6.3 (30 µM per disc) (Figure 
6.41).   
 
 
 
 
 
 
 
 
 
Experiment 3 
It has been reported that, the fungal metabolite trypacidin (6.2) is a toxic metabolite isolated from A. 
fumigatus.26 A literature evaluated the toxicity of trypacidin (6.2) against the human cell lines 
(alveolar lung cells and bronchial epithelial cells), related to the induction of nitric oxide (NO) by 
trypacidin with in the first hour of exposure, leading to cell death.26 In independent studies Capon et 
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al. established the use of sodium nitroprusside (SNP) as an excellent donor of NO in microbial 
culture, leading to the transcriptional activation of silent defence mechanism of microbes. We 
hypothesized that the induced production of metabolites 6.5 and 6.6 in CMB-NB198 cultures exposed 
to trypacidin (6.2) was associated with induction of NO by activating the bacterial nitric oxide 
synthase (bNOS) enzyme. To investigate the possibility of induction of bNOS by trypacidin in the 
bacterial culture, SNP (5 µM/mL) was added to the culture of CMB-NB198. Analysis of the UHPLC-
DAD data showed the activation of both 6.5 and 6.6 metabolites by CMB-NB198 in the presence of 
SNP, as previously observed in the presence of fungal metabolite trypacidin (6.2) (12.5 µM) (Figure 
6.42).  
 
Figure 6.42: UHPLC profile of crude extract of CMB-NB198 cultivated in the presence of 6.2 and SNP. Peaks 
highlighted in yellow are activated metabolite peak 6.5 and 6.6, green is the internal standard. 
 
Future directions 
To prove the involvement of bacterial nitric oxide synthase (bNOS) mediated activation of 6.5 and 
6.6, the follow-up experiment would be the culture of bacteria CMB-NB198 in the presence of 
trypacidin (6.2) and the bNOS inhibitor such as aminoguanidine (AG). If 6.2 trigger the bNOS to 
produce NO, then AG would quench the NOs and shut down the activation of 6.5 and 6.6. 
 
 
 
 
 
 
 
 
 
CMB-NB198
CMB-NB198 + 6.2 (12.5 µM)
CMB-NB198 + SNP (5 µM)
A
bs
or
ba
nc
e 
(2
54
 n
m
) m
A
U
Retention time (min)
1.0 1.4 1.8 2.2 2.6
6.6 6.5
Chapter 6: Identification and characterization of metabolites involved in defensive mechanism of microbes during co-cultivation  
 
 
 
216 
6.7.6 Investigation on the possible elicitor triggering the upregulation of metabolites 6.2 and 
6.4 by fungus CMB-NF125 
Experiment 1 
Fungus CMB-NF125 was allowed to culture in the presence of EtOAc extract of CMB-NB198 (at 
concentration 12.5 µg/mL to 100 µg/mL) in 24-well microbioreactor at 29 °C, 190 rpm for 10 days. 
HPLC-DAD-MS analysis confirmed that none of these treatments induced the production of 6.2 and 
6.4 except the co-cultivation of both CMB-NF125 and CMB-NB198. This study suggested the 
production of 6.2 and 6.4 by fungus CMB-NF125 was induced only by the presence of live 
Streptomyces CMB-NB198. Same result obtained when the culture of CMB-NF125 was treated with 
EtOAc extracts of co-cultured CMB-NF125 and CMB-NB198 (Figure 6.43). 
 
Figure 6.43: HPLC profile of crude extract of CMB-NF125 (a) mono culture, (b) cultured with crude extract of co-
cultured CMB-NB198, (c) cultured in the presence of 6.5, (d) cultured in the presence of 6.6, (e) cultured with live CMB-
NF125.  Peak highlighted in red/orange is upregulated metabolite peak 6.2 and 6.4 respectively, green is the internal 
standard.  
 
Experiment 2 
To further confirm the above assumption, EtOAc crude extracts both from the mono-culture and co-
culture of CMB-NB198 (100 µg/disc) were screened against the fungus CMB-NF125 by agar disc 
diffusion assay. Results showed that, both the crude extracts obtained from the (a) mono-culture of 
CMB-NB198 and (b) co-culture of CMB-NB198 and CMB-NF125 showed growth inhibition of 
fungus CMB-NF125, but none of the cases induced the production of red colour compound (6.2) 
except the (c) live Streptomyces CMB-NB198 (Figure 6.44).  
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The inhibition of the growth of the fungus by the extract of CMB-NB198 may be due to the presence 
of antifungal agents (niphimycin class) in the extract of CMB-NB198 (as discussed in case study 1). 
To explore this interaction, two of commercially available polyol macrolide antifungals 
(amphotericin B and nystatin) were screened against CMB-NF125. The result proved that none them 
can activate the production of the red coloured compound 6.2 (Figure 6.45).  
 
 
 
 
 
 
 
 
 
 
Further taking into consideration, the anti-fungal activity of the metabolites 6.5 and 6.6 was also 
evaluated against CMB-NF125 and they retained as non-active (Figure 6.46).  
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Figure 6.44: Disc diffusion assay against CMB-NF125 to investigate the chemical cues involved in the upregulation of 
trypacidin (6.6) (a) EtOAc extract of CMB-NB198 mono-culture, (b) EtOAc extract of CMB-NB198 co-culture with 
CMB-NF125 (c) live CMB-NB198. The red colour on the interface of the CMB-NF125 and CMB-NB198 indicated the 
enhanced production of 6.2. 
Figure 6.45: Disc diffusion assay against CMB-NF125 to investigate the chemical cues involved in the upregulation of 
trypacidin (6.6) (a) amphotericin B, (b) nystatin (c) live CMB-NB198. The red colour on the interface of the CMB-NF125 
and CMB-NB198 indicated the enhanced production of 6.2. 
 
Figure 6.46: Disc diffusion assay against CMB-NF125 to investigate the chemical cues involved in the upregulation of 
trypacidin (6.2) (a) pure metabolite 6.5, (b) pure metabolite 6.6 (50 µM/well). 
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Experiment 3 
Literatures reported the production of volatile organic compounds (VOCs) by Streptomyces sp. and 
their involvement in the interspecies communication. The VOCs produced by Sterptomyces are also 
responsible for the alterations in the morphology in several fungi, inhibit the spore germination along 
with their antifungal activity.27,28 Thus, the involvement of volatile organic compounds was 
investigated to further figure out the underlying relationship between CMB-NF125 and CMB-
NB198. To perform this experiment, both the strains were allowed to grown in one ISP2 agar plate 
where the intersection between the strains were removed to inhibit any chemical interactions. Results 
showed that only co-cultivation without any physical barrier can upregulate the production of 
metabolite by fungus (Figure 6.47).  
 
 
 
 
 
 
 
 
 
6.7.7 Conclusion and future directions 
Here we demonstrated a unique interaction between Aspergillus sp. CMB-NF125 and the 
Streptomyces CMB-NB198. Several experiments helped to prove that the production of trypacidin 
(6.2) by the fungus CMB-NF125 was upregulated only when competing with Streptomyces CMB-
NB198 during co-cultivation. On the other hand, the activated production of N-acetyl tyramine (6.5) 
and pre-hazimycin (6.6) by CMB-NB198 was stimulated by the co-cultivated fungal metabolite 
trypacidin (6.2). The study also suggested that the activation of 6.5 and 6.6 might be due to the strong 
anti-bacterial activity of trypacidin (6.2), as the production of the later one was upregulated during 
co-cultivation.   
A recent study by Khalil et al.,29 demonstrated the involvement of NO mediated transcriptional 
activation during co-culture of Aspergillus sp. and Streptomyces. Therefore, we demonstrated that 
NO could replicate the transcriptional activation effect of trypacidin (6.2) as the biosynthesis of pre-
hazimycin (6.6) by the bacteria CMB-NB198. This hypothesis can be tested by addition of SNP to 
the mono-culture of CMB-NB198 followed by the fluorescence microscopy-based detection of NO 
in live cells. Moreover, the powerful desorption electrospray ionization imaging mass spectrometry 
front side front side back side back side 
(a) (b) 
Figure 6.47: Co-cultivation of CMB-NF125 and CMB-NB198 (a) with a physical border to inhibit any chemical 
interaction, (b) without any physical barrier. 
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(DESI-IMS) or matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI-IMS) 
will be used to spatially map the distribution of metabolic exchange in situ in the co-culture of CMB-
NF125 and CMB-NB198, which would help to reveal the real activation mechanism of co-culture 
and biological functions of 6.2–6.6. 
 
6.8 Experimental 
6.8.1 Isolation and Taxonomy of CMB-NF122, CMB-NF125 and CMB-NB198 
Strains CMB-NF122, CMB-NF125 and CMB-NB198 were isolated from fecal material sourced from 
a sheep, by cultivation on ISP2 agar plates at 30 °C for 7 days. Genomic DNA was extracted from 
the mycelia using the DNeasy Plant Mini Kit (QIAGEN) for fungi and DNeasy blood and tissue kit 
(QIAGEN) for bacteria, as per the manufacturer’s protocol. The 18S rRNA and 16sRNA genes were 
amplified by PCR using the universal primers ITS 1 (5¢ TCCGTAGGTGAACCTGCGG 3¢) and ITS 
4 (5¢ TCCTCCGCTTATTGATATGC 3¢) for fungi and FC27 (5¢ AGAGTTTGATCCTGGCTCAG 
3¢) and RC1492 (5¢ TACGGCTACCTTGTTACGACTT 3¢) for bacteria purchased from Sigma-
Aldrich. The PCR mixture (50 μL) contained genomic DNA (2 μL, 20–40 ng), EmeraldAmpn GT 
PCR Master Mix (2X Premix) (25 μL), primer (0.2 μM, each), and H2O (up to 50 μL). PCR was 
performed using the following conditions: initial denaturation at 95 °C for 2 min, 40 cycles in series 
of 95 °C for 20 s (denaturation), 56 °C for 20 s (annealing) and 72 °C for 30 s (extension), followed 
by one cycle at 72 °C for 5 min. The PCR products were purified with PCR purification kit (QIAGEN) 
and sequenced. The sequences were analyzed using BLAST search to calculate the closest homology. 
 
CMB-NF122 
18sRNA sequence 
CCACTGTGACCTTACCTCAGTTGCCTCGGCGGGAACGCCCCGGCCGCCTGCCCCCGCGCCGGCGCC
GGACCCAGGCGCCCGCCGCAGGGACCCCAAACTCTCTTGCATTACGCCCAGCGGGCGGAATTTCTT
CTCTGAGTTGCACAAGCAAAAACAAATGAATCAAAACTTTCAACAACGGATCTCTTGGTTCTGGCA
TCGATGAAGAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATC
TTTGAACGCACATTGCGCCCGCCAGCATTCTGGCGGGCATGCCTGTTCGAGCGTCATTTCAACCCT
CGAGCCCCCCCGGGGGCCTCGGTGTTGGGGG 
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Blast search (closest match) 
 
 
CMB-NF125 
18sRNA sequence 
CTGGGTCACCTCCCACCCGTGTCTATCGTACCTTGTTGCTTCGGCGGGCCCGCCGTTTCGACGGCC
GCCGGGGAGGCCTTGCGCCCCCGGGCCCGCGCCCGCCGAAGACCCCAACATGAACGCTGTTCTGAA
AGTATGCAGTCTGAGTTGATTATCGTAATCAGTTAAAACTTTCAACAACGGATCTCTTGGTTCCGG
CATCGATGAAGAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAG
TCTTTGAACGCACATTGCGCCCCCTGGTATTCCGGGGGGCATGCCTGTCCGAGCGTCATTGCTGCC
CTCAAGCACGGCTTGTGTGTTGGGCCCCCGTCCCCCTCTCCCGGGGGACGGGCCCGAAAGGCAGCG
GCGGCACCGCGTCCGGTCCTCGAGCGTATGGGGCTTTGTCACCTGCTCTGTAGGCCCGGCCGGCGC
CAGCCGACACCCAACTTTATTTTTCTAAGGTTGACCTCGGATCAGGTAGGGAGACCCGCGAA 
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Blast search (closest match) 
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CMB-NB198 
16sRNA sequence 
AGTCGAACGATGAACCGGTTTCGGCCGGGGATTAGTGGCGAACGGGTGAGTAACACGTGGGCAATC
TGCCCTGCACTCTGGGACAAGCCCTGGAAACGGGGTCTAATACCGGATATGACACGCTCCCGCATG
GGATGCGTGTGGAAAGCTCCGGCGGTGCAGGATGAGCCCGCGGCCTATCAGCTTGTTGGTGGGGTG
ATGGCCTACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGCGACCGGCCACACTGGGACTGAGAC
ACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGAAAGCCTGATGCAG
CGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCAGCAGGGAAGAAGCGAGAGT
GACGGTACCTGCAGAAGAAGCGCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGCGCA
AGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGGCTTGTCGCGTCGGATGTGAAAGCC
CGGGGCTTAACCCCGGGTCTGCATTCGATACGGGCAGGCTAGAGTTCGGTAGGGGAGATCGGAATT
CCTGGTGTAGCGGTGAAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGATCTCTGGGC
CGATACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGC
CGTAGACGTTGGGAAACTAGGGTGTGGGGCGACA 
 
Blast search (closest match) 
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6.8.2 Scale-up cultivation and isolation of metabolites  
Scale-up cultivation was carried out as described in section 6.5.3 and section 6.6.2 of this chapter. 
 
Alternariol (6.1): Yellowish amorphous powder; UV (MeOH) lmax (log e) 258 (4.13), 330 (4.50), 
338 (4.35) nm; 1D and 2D NMR (600 MHz, methanol-d4) see Table 6.1 and Figures 6.8 – 6.10; 
HRESI(+)MS m/z 281.0456 [M+H]+ (calcd for C14H10NaO5 281.0420). 
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Trypacidin (6.2): Red powder; UV (MeOH) lmax (log e) 284 (3.20), 328 (3.10) nm; [α]D - 85.3, c 
0.025, MeOH); 1D and 2D NMR (600 MHz, DMSO-d6) see Table 6.3 and Figures 6.20 – 6.22; 
HRESI(+)MS m/z 367.0799 [M+Na]+ (calcd for C18H16NaO7 367.0788). 
 
Monomethylsulochrin (6.3): Yellowish powder, UV (MeOH) lmax (log e) 230 (5.10), 284 (4.80), 
328 (5.35) nm; [α]D - 31.3, c 0.025, MeOH); 1D and 2D NMR (600 MHz, DMSO-d6) see Table 6.4 
and Figures 6.23 – 6.25; HRESI(-)MS m/z 345.0989 [M-H]-  (calcd for C18H17O7 345.0980). 
 
2-(4-hydroxyphenyl) acetamide (6.4): White powder; [α]D - 4.6, c 0.025, MeOH); 1D and 2D NMR 
(600 MHz, DMSO-d6) see Table 6.5 and Figures 6.26 – 6.28; HRESI(+)MS m/z 325.1168 [2M+Na]+  
(calcd for C16H18N2NaO4 325.1159). 
 
N-acetyl tyramine (6.5): White powder; 1D and 2D NMR (600 MHz, DMSO-d6) see Table 6.6 and 
Figures 6.29 – 6.31; HRESI(+)MS m/z 381.1797 [2M+Na]+  (calcd for C20H26N2NaO4 381.1785). 
 
Pre-hazimycin (6.6): Yellowish powder; [α]D + 97.0, c 0.025, MeOH); 1D and 2D NMR (600 MHz, 
DMSO-d6) see Table 6.7 and Figures 6.32 – 6.34; HRESI(+)MS m/z 437.1432 [M+Na]+  (calcd for 
C20H22N4NaO6 437.1432). 
 
6.8.3 Bioassays 
6.8.3.1 Antimicrobial assay 
See Appendix I: General Experimental, page 261. 
6.8.3.2 Cytotoxicity assay 
See Appendix I :General Experiments, page 262. 
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7 Chapter 7: Rearrangement of structures of hydrazones by total synthesis and 
precursor selection  
7.1 Part 1: Rearrangement of structures of hydrazones by total synthesis 
Hydrazones, nitrogen-nitrogen bond containing compounds, are relatively scarce in nature but have 
been reported from a variety of sources including plants, marine organisms and microorganisms. 
Examples of some naturally occurring hydrazones includes katorazone (7.1), the first isolated 
hydrazone from Streptomyces sp.1; yoroopyrazone (7.2), a naphthopyridazone from Streptomyces sp.1 
and leucoagaricone (7.3) from the fungus Agaricus xanthoderma3 (Figure 7.1). Both natural and 
synthetic hydrazones possess a wide range of biological activities including antimicrobial, 
anticonvulsant, analgesic, anti-inflammatory, anti-platelet, antitubercular and anti-tumor properties. 
Particular attention has been paid to acyl hydrazones with an azomethine proton (-NHN=CH-) as 
prominent candidates for drug discovery.4 
Despite considerable advances in understanding of biosynthetic pathways for many classes of natural 
product, knowledge of the  biosynthetic origin of nitrogen-nitrogen bonds is still limited.3 While 
reading the literature data, we took note of  penipacids A - E (7.4 – 7.8), isolated from marine derived 
fungus P. paneum (Figure 7.2).5 Close scrutiny of the structures for penipacids A – E (7.4 – 7.8) 
raised the possibility that they are derived from anthranilic acid. To test the hypothesis, we decided 
to synthesize penipacids A - E along with other Schiff’s base derived hydrazones, and possibly revise 
the structures. This chapter describes the synthesis and characterization of anthranilic acid derived 2-
hydrazino benzoic acid (7.10) and hydrazones (7.11 – 7.16) (Figure 7.3).  
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Figure 7.1: Structures of natural hydrazones (7.1 – 7.3). 
Figure 7.2: Structures of penipacids A – E (7.4 – 7.8).  
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7.2 Synthesis and structure revision of hydrazones 
7.2.1 Synthesis of anthranilic acid (7.9) 
Anthranilic acid (7.9) was prepared by reacting Na-phthalimide with sodium hypochlorite followed 
by neutralization with conc. HCl. Briefly, phthalimide (15 g) was dissolved in conc. NaOH (9 g) at 
10 °C. Sodium hypochlorite (7 g) was added to the cold mixture and stirred for 15 min, after which 
it was heated to 50 °C for 15 min and cooled back to 30 °C. Conc. HCl (30-40 mL) was then added 
to neutralize the pH followed by the slow addition of glacial acetic acid (30-40 mL) leading to 
crystallization. The crystal was filtered and washed with cold water to yield anthranilic acid (7.9) 
(Scheme 7.1). 
 
 
 
 
 
 
 
Scheme 7.1: Synthesis of anthranilic acid (7.9). (i) NaOH, 10 °C, 10 min; (ii) NaClO, stirring 15 min, 50 °C, cooled to 
30 °C; (iii) conc. HCl, 30 °C, 10 min; glacial acetic acid, 5 min; 90% yield. 
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Figure 7.3: Structures of synthesized 2-hydrazino benzoic acid (7.10) and hydrazones (7.11 – 7.16). 
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7.2.1.1 Characterization of anthranilic acid (7.9) 
 
Figure 7.4: 1H NMR (600 MHz, DMSO-d6) spectrum of anthranilic acid (7.9) 
 
Figure 7.5: 13C NMR (150 MHz, DMSO-d6) spectrum of anthranilic acid (7.9) 
Table 7.1: 1D and 2D NMR (600 MHz, DMSO-d6) data for anthranilic acid (7.9) 
Position dC dH, mult (J in Hz) COSY HMBC 
1 110.2 --- --- --- 
2 151.5 --- --- --- 
3 116.9 6.70, d (8.2) 4 1, 2, 5 
4 134.4 7.18, ddd (8.3, 6.5,1.3) 3, 5 2, 6 
5 115.4 6.50, ddd (8.3, 6.5,1.3) 4, 6 1, 3 
6 131.6 7.67, dd (7.9, 1.3) 5 1, 4, 5, 1-COOH 
1-COOH 170.2 --- --- --- 
 
7.2.2 Synthesis of 2-hydrazino benzoic acid (7.10) 
7.10 was synthesised according to the method described by Kovacs et al.6 Briefly, anthranilic acid 
(7.9) (0.137 g, 1mmol, 1 eq) was suspended in HCl (6M, 2.4 mL) at - 5 °C. Sodium nitrite (0.075 g, 
1.1 mmol, 1.1 eq) was dissolved in water (1 mL) and added dropwise to the reaction mixture for over 
1 min and stirred for 1 hr at - 5 °C. Then SnCl2.2H2O (0.451 g, 2 mmol, 2 eq) dissolved in HCl (0.6 
mL of 6M HCl) was added to the mixture. The sediment was filtered and washed with water and 
dried in vacuo, to yield 7.10 (0.12 g, 87%) (Scheme 7.2).   
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Scheme 7.2: Synthesis of 2-hydrazino benzoic acid (7.10), (i) HCl (6M), NaNO2; (ii) SnCl2, ice bath, 1h; 90% yield 
7.2.2.1 Characterization of 2-hydrazino benzoic acid (7.10) 
 
Figure 7.6: 1H NMR (600 MHz, DMSO-d6) spectrum of 2-hydrazino benzoic acid (7.10) 
Table 7.2: 1D and 2D NMR (600 MHz, DMSO-d6) data for 2-hydrazino benzoic acid (7.10) 
Position dC dH, mult (J in Hz) COSY HMBC 
1 110.7 --- --- --- 
2 152.1 --- --- --- 
3 116.0 7.13, d (8.0) 4 1, 2, 5 
4 135.2 7.53, dd (8.0, 7.5) 3, 5 2, 6 
5 115.6 6.85, dd (7.5, 7.0) 4, 6 1, 3 
6 131.2 7.85, d (7.0) 5 1, 4, 5, 1-COOH 
1-COOH 169.4 --- --- --- 
 
7.2.3 Synthesis of hydrazone 7.11 
7.10 (20 mg, 0.13 mmol) was dissolved in 4-OH-4-methyl-2-pentanone (4.5 ml, 5 mg, 0.43 mmol), 
at room temperature and stirred for 10 min (Scheme 7.3). The reaction mixture was purified using 
the preparative reversed phase HPLC (column Zorbax C8, 21.5 x 150 mm, 5 µm, 10 – 100 % MeCN 
modified with 0.01% TFA, 20 mL/min, over 30 min) to yield 7.11. The HPLC-MS analysis of the 
purified fraction confirmed the purity of the synthesized hydrazone 7.11 (Figure 7.7). 
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Figure 7.7: HPLC-MS-SIE chromatogram for 7.11 [m/z = 251 (M+H)+] (column Zorbax C8, 4.6 x 150 mm, 5 µm, 10 – 
100 % MeCN modified with 0.1% TFA, 1 mL/min, over 20 min) 
7.2.3.1 Characterization of 7.11 
HRESI(+)MS analysis of 7.11 revealed a sodium adduct ([M+Na]+) indicative of the molecular 
formula C13H18N2O3 (Dmmu + 0.8), requiring ´ 6 double bond equivalents (DBEs). The 1H NMR 
(DMSO-d6) for 7.11 displayed four aromatic proton, three methyl and one N-H resonance (Figure 
7.8). The detailed analysis of 2D NMR data (Table 7.3) confirmed the structure of 7.11 that was 
reported as penipacid A.5 Additionally, the NMR (DMSO-d6) data for 7.11 showed the presence of 
two geometric isomers (mentioned as major and minor) (Figure 7.8). The ROESY correlations 
between the N-H (dH 10.72, s) to the H-1¢ (dH 1.95, s) confirmed the E-geometry of the major isomer 
(Figure 7.12). 
 
 
 
 
 
 
 
 
 
Scheme 7.3: Synthesis of 7.11, (i) 4-OH-4-methyl-2-pentanone, 10 min, rt; 90% yield 
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Figure 7.8: 1H NMR (600 MHz, DMSO-d6) spectrum of 7.11 
 
 
 
Figure 7.9: 13C NMR (150 MHz, DMSO-d6) spectrum of 7.11 
 
 
 
1.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0 ppm
2.
00
0.
50
0.
97
0.
68
0.
28
1.
07
1.
20
0.
34
0.
28
1.
08
0.
23
1.
00
0.
29
0.
01
6.76.86.97.07.17.27.37.47.57.67.77.87.9 ppm
5
3
46
1'
D
M
SO
-d
6
4'-Me
NH
H
2O
3'
5'53 46
1'
4'-Me
NH
3'
5'x
2030405060708090100110120130140150160170 ppm
114116118120122124126128130132134 ppm
148.5 ppm
5
3
4 6
1'
D
M
SO
-d
6
4'-Me
3'
5'
1
2'
1-COOH
4'
5 34 6
1'
4'-Me
3'
5'
2'
1-COOH
2 2
1
35
CO2H H
N
N OH
1′
3′
4′
5′
1
35
CO2H H
N
N OH
1′
3′
4′
5′
Chapter 7: Rearrangement of structures of hydrazones by total synthesis and precursor selection 
 
 
 
233 
Table 7.3: 1D and 2D NMR (600 MHz, DMSO-d6) data for 7.11 
Position dC dH, mult (J in Hz), COSY HMBC ROESY 
Major isomer 
1 113.0     
2 148.5     
3 113.8 7.07, d (8.0) 4 1, 2, 5 4 
4 134.9 7.85, ddd (8.1, 7.6, 1.2) 3, 5 2, 6 3, 5 
5 120.3 6.96, ddd (8.1, 7.6, 1.2) 4, 6 1, 3 4, 6 
6 132.0 7.90, dd (8.2, 1.5) 5 1, 2, 4, 1-COOH 5 
1-COOH 169.2     
NH  10.72, s  2, 3, 2¢ 1¢ 
1¢ 17.5a 1.95, s  2¢ 3¢, NH 
2¢ 148.4     
3¢ 51.9 2.39, br s  1¢, 2¢, 4¢, 5¢ 1¢ 
4¢ 70.0     
5¢ 30.1 1.15, s c  3¢, 4¢  
4¢-Me 30.1 1.15, s c  4¢  
Minor isomer 
1 e     
2 148.3b     
3 114.2 7.51, d (8.4) 4 1, 2, 5 4 
4 135.0 7.43, t (7.4) 3, 5 2, 6 3, 5 
5 117.0 6.71, t (7.4) 4, 6 1, 3 4, 6 
6 131.7 7.81, dd (8.0, 1.9) 5 1, 2, 4, 1-COOH 5 
1-COOH 170.4     
NH  11.06, s  2, 3, 2¢  
1¢ 17.5a 1.93, s  2¢ 3¢ 
2¢ 148.3b     
3¢ 52.5 2.71, br s  1¢, 2¢, 4¢, 5¢ 1¢ 
4¢ e     
5¢ 26.4 1.24, s d  3¢, 4¢  
4¢-Me 26.4 1.24, s d  4¢  
a - d = assignments with the same superscript are overlapping; e = signal not observed;  
 
 
Table 7.4: 1H NMR (600 MHz, CDCl3) data comparison of 7.11 with published data. 
Position dH, mult (J in Hz), dH, mult (J in Hz) c 
3 7.98, dd (7.8, 1.2) 7.97, dd (7.9, 0.8) 
4 6.63, ddd (8.0, 7.5, 1.2) 6.76, br t (7.9) 
5 7.20, ddd (8.0, 7.6, 1.2) 7.45, td (8.2, 1.0) 
6 7.37, dd (8.2, 1.5) 7.50, br d (8.2) 
NH a 10.63, s 
1¢ 2.06, s 2.00, s 
3¢ 2.72, br s 2.53, s 
5¢ 1.13, s b 1.35, s 
4¢-Me 1.13, s b 1.35, s 
 a = signal not observed;  b = assignments with the same superscript are overlapping; c = literature data (500 MHz, CDCl3)7 
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Figure 7.10: Expanded HSQC (600 MHz, DMSO-d6) for 7.11. 
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Figure 7.11: Key 2D NMR (600 MHz, DMSO-d6) correlations of 7.11. 
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Figure 7.12: Expanded ROESY (600 MHz, DMSO-d6) spectrum of 7.11. 
7.2.4 Synthesis of hydrazone 7.12 a/b 
According to the method described above, 7.10 (20 mg, 0.13 mmol) was dissolved in pyruvic acid 
(6.3 mL, 5 mg, 17.6 mmol), at room temperature and stirred for 10 min (Scheme 7.4). The reaction 
mixture was purified using the preparative reverse phase HPLC (column Zorbax C18, 21.5 x 150 mm, 
5 µm, 10 – 100 % MeCN modified with 0.01% TFA, 20 mL/min, over 30 min) to yield 7.12. The 
HPLC-MS analysis of the purified fraction showed the presence of two peaks of the purified 
compound (Figure 7.13). The major peak (7.12a) was further purified from the mixture using semi-
preparative HPLC (column Zorbax C18, 9.4 x 250 mm, 5 µm, 10 – 100 % MeCN modified with 0.1% 
TFA, 3 mL/min, over 30 min). 
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7.2.4.1 Structure elucidation of 7.12a 
HRESI(+)MS analysis of 7.12a revealed a sodium adduct ([M+Na]+) indicative of the molecular 
formula C10H10N2O4 (Dmmu + 0.6) requiring ´ 7 double bond equivalents (DBEs). The 1H NMR 
(DMSO-d6) for 7.12 displayed four aromatic proton, one methyl and one N-H resonance (Figure 
7.14). The detailed analysis of 2D NMR data (DMSO-d6) (Table 7.4) and comparison with the 
literature data corresponded with the reported data for penipacid C.5 The total synthesis and fully 
characterization of 7.12a helped to rearrange the structure of penipacid C. The ROESY correlation 
between the N-H (dH 11.37, s) and the methyl H-3¢ (dH 2.05, s) also confirmed the double bond 
configuration of C-2¢ as E-configuration. Earlier in 2011, Cheng et al. also isolated and characterized 
7.12a as farylhydrazone B, a fungal metabolite form Isaria farinosa.8 
 
 
 
Figure 7.14: 1H NMR (600 MHz, DMSO-d6) spectrum of 7.12a 
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Figure 7.15: 13C NMR (150 MHz, DMSO-d6) spectrum of 7.12a 
 
Table 7.5: 1D and 2D NMR (600 MHz, DMSO-d6) data for 7.12a and compared with the reported compound. 
Position dC dH, mult (J in Hz), COSY HMBC ROESY dH, mult (J in Hz)5 
1 112.2 --- --- --- --- --- 
2 146.4 --- --- --- --- --- 
3 114.2 7.82, d (8.2) 4 1, 2, 5 4 7.76, d (8.0) 
4 134.9 7.56, ddd (8.3, 7.0, 1.5) 3, 5 2, 6 3, 5 7.60, t (8.0) 
5 120.2 6.95, ddd (8.3, 7.0, 1.5) 4, 6 1, 3 4, 6 6.98, t (8.0) 
6 131.6 7.90, dd (7.0, 1.5) 5 1, 2, 4, 1-
COOH 
5 7.91, dd (8.0,1.7) 
1-COOH 170.3 --- --- --- --- --- 
NH  11.37, s  1, 2, 2¢ 3¢ 11.45, s 
1¢ 166.2 --- --- --- --- --- 
2¢ 136.6 --- --- --- --- --- 
3¢ 11.3 2.05, s  1¢, 2¢ NH 2.04, s 
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Figure 7.16: Key 2D NMR (600 MHz, DMSO-d6) correlations of 7.12a 
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Figure 7.17: Expanded ROESY (600 MHz, DMSO-d6) spectrum of 7.12a 
In 2012, Tsang et al. performed the total synthesis of farylhydrazone B, starting from ortho-nitro 
benzoic acid which require 6 days of reaction time in multiple steps (Scheme 7.5).9 But our method 
has the advantage of being simple with good yields as compared to the mentioned method.  
Additionally, the method we used, helped to prove the formation of hydrazones through the Schiff 
base condensation.  
 
 
 
 
Scheme 7.5: Synthesis of farylhydrazone B. (i) H2SO4, MeOH, 65 °C, 5 d, 90%; (ii) Zn dust (5.0 eq), NH4Cl (10.0 eq), 
acetone/water (4:1), 40 °C, 12 h, 74%; (iii) NaNO2 (0.90 eq), SnCl2.2H2O (1.80 eq), HCl, H2O. 0 °C, 1 h; (iv) pyruvic 
acid (1.7 eq), HCl, H2O, rt, 45 min, 46% (two steps); (v) NaOH (0.5 N), H2O/MeOH (1:1), reflux, 1h, 99%. 
 
7.2.5 Synthesis of 7.13 
According to the method described above, 7.10 (20 mg, 0.13 mmol) was dissolved in 2, 3-butanedione 
(5 mg, 0.05 mmol), at room temperature and stirred for 10 min (Scheme 7.6). The mixture of the 
product was purified using the preparative reverse phase HPLC (column Zorbax C18, 21.5 x 150 mm, 
5 µm, 10 – 100 % MeCN modified with 0.01% TFA, 20 mL/min, over 30 min) to yield 7.13. The 
HPLC-MS analysis and the single ion extraction for the molecular ion (m/z = 221 [M+H]+) also 
confirmed the purity of the hydrazone 7.13 (Figure 7.18).  
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7.2.5.1 Structure elucidation of 7.13 
HRESI(+)MS analysis of 7.13 revealed a sodium adduct ([M+Na]+) indicative of the molecular 
formula C11H12N2O3 (Dmmu + 0.7), requiring ´ 7 double bond equivalents (DBEs). The analysis of 
1H NMR (DMSO-d6) for 7.13 displayed four aromatic proton, two methyl and one N-H resonance 
(Figure 7.19). The detailed analysis of 2D NMR (DMSO-d6) data (Table 7.5) confirmed the structure 
of 7.13. Online database searching with the molecular formula consistent with farylhydrazone C, a 
phenylhydrazone isolated from Antarctic-derived the fungus Penicillium sp. HHDN14-431.10 As no 
ROESY correlation between the N-H (dH 11.47, s) and the methyl H-4¢ (dH 2.42, s) has been observed, 
hence the configuration of double bond remained unclear.  
 
 
Scheme 7.6: Synthesis of 7.13, (i) 2, 3-butanedione, 10 min, rt; 96% yield 
(i)
CO2H H
N
N
7.13
O
CO2H H
N
NH2
7.10
Figure 7.18: HPLC-MS-SIE chromatogram of 7.13 [ m/z = 221 (M+H)+], (column Zorbax C8, 4.6 x 150 mm, 5 µm, 10 
– 100 % MeCN modified with 0.1% TFA, 1 mL/min, over 20 min). 
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Figure 7.19: 1H NMR (600 MHz, DMSO-d6) spectrum of 7.13 
 
Figure 7.20: 13C NMR (150 MHz, DMSO-d6) spectrum of 7.13 
 
Table 7.6: 1D and 2D NMR (600 MHz, DMSO-d6) data for 7.13 and compared with the reported compound. 
Position dC dH, mult (J in Hz), experimental COSY HMBC 
dH, mult (J in Hz), 
literature10 
1 112.3 --- --- --- --- 
2 145.6 --- --- --- --- 
3 113.5 7.78, d (8.2) 4 1, 2, 5 7.76, d (8.0) 
4 134.7 7.61, ddd (8.2, 7.3, 1.5) 3, 5 2, 6 7.60, t (8.0) 
5 120.2 7.02, ddd (8.2, 7.3, 1.5) 4, 6 1, 3 6.98, t (8.0) 
6 131.3 7.93, dd (7.3, 1.5) 5 1, 3, 4, 1-COOH 7.91, dd (8.1, 7.0) 
1-COOH 169.8 --- --- --- --- 
NH  11.47, s  1, 2, 3¢ 11.45, s 
1¢ 8.3 1.95, s  2¢, 3¢ 1.94, s 
2¢ 196.1 --- --- --- --- 
3¢ 143.5 --- --- --- --- 
4¢ 24.1 2.42, s  2¢, 3¢ 2.39, s 
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7.2.6 Synthesis of 7.14a/b 
According to the method described above, 7.10 (20 mg, 0.13 mmol) was dissolved in anhydrous 
MeOH (5 mL) and treated with 2-furyldehyde (5 mg, 0.05 mmol), at room temperature and stirred 
for 10 min (Scheme 7.7) to yield 7.14a/b.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.22: HPLC-DAD chromatogram of 7.14a/b, (column Zorbax C8, 4.6 x 150 mm, 5 µm, 10 – 100 % MeCN 
modified with 0.1% TFA, 1 mL/min, over 20 min). 
 
7.2.6.1 Structure elucidation of 7.14a/b 
HRESI(+)MS analysis of 7.14a/b revealed a protonated adduct ([M+H]+) indicative of the molecular 
formula C12H10N2O3 (Dmmu + 0.1), requiring ´ 9 double bond equivalents (DBEs). The analysis of 
the 1H NMR and 13C NMR (DMSO-d6) spectra (Figure 7.23 and 7.24) for 7.14 revealed the presence 
of two geometric isomers in a ratio of about 2:1, while 7.14a was considered as the major isomer. 
Analysis of the 2D NMR (DMSO-d6) (including HSQC, HMBC and COSY) data confirmed the 
structure of 7.14a, reported as penipacid G (Table 7.6). The ROESY spectrum showed the 
CO2H H
N
N
O
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Scheme 7.7: Synthesis of 7.14, (i) 2-furaldehyde, 10 min, rt; 86% yield 
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Figure 7.21: Key 2D NMR (600 MHz, DMSO-d6) correlations of 7.13 
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correlations between N-H (dH 11.11, s) and H-1¢ (dH 8.08, s) confirmed the E-geometry of the 7.14a 
(Figure 7.26). The NMR analysis was performed in methanol-d4 according to the reported data for 
penipacid G,7 which revealed the distinctive presence of both  isomers (Figure 7.27).  
 
 
Figure 7.23: 1H NMR (600 MHz, DMSO-d6) spectrum of 7.14a. 
 
 
 
 
 
Figure 7.24: 13C NMR (150 MHz, DMSO-d6) spectrum of 7.14a/b. (x = minor isomer) 
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Table 7.7: 1D and 2D NMR (600 MHz, DMSO-d6) data for 7.14a 
Position dC dH, mult (J in Hz), COSY HMBC ROESY 
1 111.9     
2 146.8     
3 112.9 7.64, dd (8.4, 1.3) 4 1, 5 4 
4 134.5 7.48, ddd (8.0, 7.6, 1.2) 3, 5 2, 6 3, 5 
5 117.6 6.77, ddd (8.0, 7.6, 1.2) 4, 6 3, 6 4, 6 
6 131.1a 7.83, dd (8.2, 1.2) 5 4, 5, 1-COOH 5 
1-COOH 169.8     
NH  11.11, s  1, 2, 3, 1¢ 1¢ 
1¢ 131.1a 8.08, s  2¢, 3¢ NH 
2¢ 150.1     
3¢ 110.8 6.85, d (1.8) 4¢ 4¢ 1¢, 4¢, 5¢ 
4¢ 144.0 7.73, dd (3.3, 1.8) 3¢, 5¢ 2¢ 3¢, 5¢ 
5¢ 147.0 7.97, br s 4¢ 2¢, 3¢, 4¢ 3¢, 4¢ 
a = assignments for resonances (with the same superscript) are interchangabale. 
 
 
 
 
 
 
 
 
Figure 7.26: Expanded ROESY (600 MHz, DMSO-d6) spectrum of 7.14a 
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Figure 7.27: 1H NMR (600 MHz, methanol-d4) spectrum of 7.14a/b 
Table 7.8: 1H NMR (600 MHz, methanol-d4) data for 7.14a and compared with the reported compound. 
Position dH, mult (J in Hz), experimental (Major isomer) dH, mult (J in Hz), literature
5 
3 7.66, dd (8.4, 1.3) 7.66, br s 
4 7.43a 7.42, t (7.5) 
5 6.76, ddd (8.1, 8.0, 1.3) 6.77, t (7.5) 
6 7.91, dd (8.2, 1.3) 7.92, d (7.8) 
1¢ 7.83, s 7.82, s 
3¢ 6.65, d (3.3) 6.63, d (3.3) 
4¢ 6.51, dd (3.3, 1.6) 6.50, dd (2.8,1.7) 
5¢ 7.56, d (1.6) 7.55, br s 
     a = assignment for overlapping resonances 
 
7.2.7 Synthesis of 7.15 
2-hydrazino benzoic acid (7.10) (20 mg, 0.13 mmol) was dissolved in anhydrous MeOH (5 mL) and 
treated with 5-hydroxymethyl-2-furaldehyde (5 mg, 0.04 mmol), to synthesis hydrazone 7.15 through 
Schiff’s base condensation (Scheme 7.8). The reaction mixture was purified using the preparative 
reverse phase HPLC (column Zorbax C18, 21.5 x 150 mm, 5 µm, 10 – 100 % MeCN modified with 
0.01% TFA, 20 mL/min, over 30 min). The HPLC trace of 7.15 also showed a mixture of two peaks 
with 7.15a as the major peak (Figure 7.28). 
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Figure 7.28: HPLC-MS-SIE chromatogram of 7.15a and 7.15b. (column Zorbax C8, 4.6 x 150 mm, 5 µm, 10 – 100 % 
MeCN modified with 0.1% TFA, 1 mL/min, over 20 min). 
 
7.2.7.1 Structure elucidation of 7.15a/b 
HRESI(+)MS analysis of 7.15a/b revealed a sodium adduct ([M+Na]+) indicative of the molecular 
formula C13H12N2O4 (Dmmu + 0.9), requiring ´ 9 double bond equivalents (DBEs). The analysis of 
the 1H NMR and 13C NMR (DMSO-d6) spectra for 7.15a/b revealed two sets of signals, suggestive 
of the presence of two geometric isomers 7.15 a and b. Analysis of the 2D NMR (DMSO-d6) 
(including HSQC, HMBC and COSY) data confirmed the structure of major isomer 7.15a and the 
minor isomer 7.15b (red in colour) (Table 7.8). The geometry of the isomers was not established as 
no signal revealed in the ROESY spectrum.  However, the resonances of N-H (dH 11.18, s) for the 
minor isomer (7.15b) was consistent with the N-Hs of other hydrazones bearing E-geometry, while 
the major isomer (7.15a) with N-H (dH 12.23, s), was considered with Z-geometry in the double bond.  
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Scheme 7.8: Synthesis of 7.15, (i) 5-hydroxymethyl-2-furaldehyde, anhydrous methanol, 10 min, rt; 80% yield 
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Figure 7.29: 1H NMR (600 MHz, DMSO-d6) spectrum of 7.15a/b 
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Table 7.9: 1D and 2D NMR (600 MHz, DMSO-d6) data for 7.15a/b 
Position dC dH, mult (J in Hz) COSY HMBC ROESY 
Major isomer 
1 111.5     
2 147.6     
3 113.5 7.69, dd (8.2, 1.3) 4 1, 2, 5 4 
4 135.0 7.50, dd (7.5, 7.4) a 3, 5 2, 6 3, 5 
5 118.9 6.84, dd (7.5, 7.4) 4, 6 2, 3 4, 6 
6 131.9 7.88, dd (8.0, 1.3) 5 1, 4, 5, 1-COOH 5 
1-COOH 169.8     
NH  12.23, s  1, 2, 2¢  
1¢ 125.6 7.27, s  2¢  
2¢ 147.3     
3¢ 114.2 7.00, d (3.3) 4¢ 2¢, 5¢ 4¢ 
4¢ 109.5 6.55, d (3.3) 3¢ 2¢, 5¢ 3¢ 
5¢ 157.6     
6¢ 56.4 4.57, br s  4¢, 5¢  
6¢- OH      
Minor isomer 
1 110.8     
2 147.0     
3 112.9 7.59, d (8.0) 4 1, 2, 5 4 
4 134.3 6.78, t (7.7) 3, 5 2, 6 3, 5 
5 117.6 7.47a 4, 6 2, 3 4, 6 
6 131.1 7.83, d (7.7) 5 1, 4, 5, 1-COOH 5 
1-COOH 169.4     
NH  11.18, s  1, 2, 2¢  
1¢ 124.4 8.03, s  2¢  
2¢ 146.0     
3¢ 114.8 6.65, d (3.3) 4¢ 2¢, 5¢ 4¢ 
4¢ 110.1 6.40, d (3.3) 3¢ 2¢, 5¢ 3¢ 
5¢ 157.0     
6¢ 55.6 4.44, d (5.7)  4¢, 5¢  
6¢- OH      
  a = assignments for overlapping resonances. 
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Figure 7.30: Key 2D NMR (600 MHz, DMSO-d6) correlations of 7.15a 
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7.2.8 Synthesis of 7.16 
Similar to above method, 2-hydrazino benzoic acid (7.10) (20 mg, 0.13 mmol) was allowed to react 
with 2,5-furandicarboxaldehyde (5 mg, 0.04 mmol), to synthesis hydrazone 7.16 through Schiff’s 
base condensation (Scheme 7.9). The mixture of the product was purified using the preparative 
reverse phase HPLC (column Zorbax C18, 21.5 ´ 150 mm, 5 µm, 10 – 100 % MeCN modified with 
0.01% TFA, 20 mL/min, over 30 min).  
 
 
 
 
 
 
 
 
Figure 7.31: HPLC chromatogram (254 nm) of 7.16. (column Zorbax C8, 21.5 x 150 mm, 5 µm, 10 – 100 % MeCN 
modified with 0.01% TFA, 20 mL/min, over 20 min). 
7.2.8.1 Structure elucidation of 7.16 
HRESI(+)MS analysis of 7.16 revealed a sodium adduct ([M+Na]+) indicative of the molecular 
formula C13H10N2O4 (Dmmu + 0.7), requiring ´ 10 double bond equivalents (DBEs). The 1H NMR 
(DMSO-d6) for 7.16 was similar to 7.14, except the substitution of H-5¢ by a CHO group (Figure 
7.32). 2D NMR (HSQC, HMBC and COSY) data analysis also confirmed the structure of 7.16 (Table 
7.9). Additionally, the ROESY spectrum showed the correlation between N-H (dH 11.60, s) and H-1¢ 
(dH 8.20, s) that confirmed the E- geometry of 7.16 (Figure 7.35).   
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Scheme 7.9: Synthesis of 7.16, (i) 2,5-furandicarboxaldehyde, anhydrous methanol, 10 min, rt; 90% yield 
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Figure 7.32: 1H NMR (600 MHz, DMSO-d6) spectrum of 7.16 
 
Figure 7.33: 13C NMR (150 MHz, DMSO-d6) spectrum of 7.16 
Table 7.10: 1D and 2D NMR (600 MHz, DMSO-d6) data for 7.16 
Position dC dH, mult (J in Hz), COSY HMBC ROESY 
1 111.8     
2 146.0     
3 113.4 7.67, d (8.5) 4 1, 2, 5  4 
4 134.4 7.53, ddd (8.3, 7.0, 1.6) 3, 5 2, 6 3, 5 
5 118.9 6.89, ddd (8.3, 7.0, 1.6) 4, 6 1, 3 4, 6 
6 131.3 7.86, dd (7.0, 1.6) 5 2, 4, 5, 1-COOH 5 
1-COOH 169.3     
NH  11.60, s  1, 2, 1¢ 1¢ 
1¢ 129.7 8.20, s  2¢, 3¢ 3¢, NH 
2¢ 155.7     
3¢ 111.9 6.98, d (3.6) 4¢ 2¢, 5¢ 1¢, 5¢ 
4¢ 124.8 7.61, d (3.6) 3¢ 2¢, 5¢ 2¢, 5¢ 
5¢ 151.8     
5¢-CHO 177.8 9.59, s   4¢ 
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Figure 7.35: Expanded ROESY (600 MHz, DMSO-d6) spectrum of 7.16 
We herein report the total synthesis and rearranged the structure of penipacids (7.4, 7.6, 7.8) as 
hydrazones (7.11, 7.12, 7.14). In addition to this, the synthetic pathway also confirmed the possible 
biosynthetic pathways of hydrazones (7.11 – 7.15) and 2-hydrazino benzoic acid (7.10) as the 
anthranilic acid derived precursor of hydrazones. 
 
7.3 Part 2: Determination of biosynthetic precursor of hydrazones (7.11 – 7.16) 
Reviewing the literature data, we found that most of the reactant used to react with 2-hydrazino 
benzoic acid (7.10) to synthesis the hydrazones (7.11 – 7.16) are the most common aldehyde and 
ketones, that can be easily formed in the culture media. For example, pyruvic acid can be easily 
formed from glucose through glycolysis; 2-furaldehyde and 5-hydroxymethyl furfural are the thermal 
decomposed product of reducing sugars.11,12 Another reactant 2,3-butandione can be formed as a by-
product during fermentation.13 Our study also confirmed that the reactant 4-OH-4-methyl-2-
pentanone, used to synthesis hydrazone 7.11, can be easily formed from condensation of two 
molecule of acetone (called aldol-condensation). Recent study by Mohamed et al.14 detected and 
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Figure 7.34: Key 2D NMR (600 MHz, DMSO-d6) correlations of 7.16
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isolated two unprecedented Schiff’s bases, prolinimines A-B, where the structures of prolinimines 
were further confirmed by using putative biosynthetic precursor N-amino-L-proline methyl ester and 
furans. Subsequent studies confirmed that associated furans can be formed from the culture media 
composition (i.e., rice media), facilitating a rapid Schiff’s base condensation with the naturally 
derived N-amino-L-proline methyl ester, to form the prolinimines.15  
 
It was also known that the reactant 4-OH-4-methyl-2-pentanone, used to synthesis hydrazone 7.11, 
can be easily formed from condensation of two molecule of acetone (called aldol-condensation). 
Hence, acetone (10 mL) was kept in acidic environment for 12 h at room temperature, that resulted 
the formation of 4-OH-4-methyl-2-pentanone (3.2 mg) through the acid mediated aldol-condensation. 
The HPLC-MS analysis confirmed the formation of 4-OH-4-methyl-2-pentanone (Figure 7.36). This 
synthesized 4-OH-4-methyl-2-pentanone was further reacted with 2-hydrazino benzoic acid (7.10) 
according to the Scheme 7.3, that resulted the formation of hydrazone 7.11. 
 
 
Figure 7.36: HPLC-MS-SIE chromatogram of (a) aldol-condensation mediated acetone derived 4-OH-4-methyl-2-
pentanone (b) standard 4-OH-4-methyl-2-pentanone. 
 
The synthesized 4-OH-4-methyl-2-pentanone (1 mg) was further dissolved in methanol (5 mL, 0.01% 
TFA) and stirred at 40 °C for 12 h. The single ion extraction from the HPLC-MS chromatogram 
confirmed the formation of 4-methoxy-4-methyl-2-pentanone (m/z = 131) (Figure 7.37). The 
subsequent reaction of 4-methoxy-4-methyl-2-pentanone (1 mg) with 2-hydrazino benzoic acid 
(7.10) according to the scheme 7.3 resulted the formation of hydrazone (7.17) (m/z = 265) (Figure 
7.38), reported as penipacid B.6 
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Figure 7.37: HPLC-MS-SIE chromatogram of 4-OMe-4-methyl-2-pentanone. 
 
 
 
 
 
 
Figure 7.38: HPLC-MS-SIE chromatogram of 7.17. 
The above experiments confirmed the derivation of 4-OH-4-methyl-2-pentanone and 4-OMe-4-
methyl-2-pentanone from acetone. Literature data showed that the 4-OH-4-methyl-2-pentanone 
substrate containing compound penipacid A - B (7.4 – 7.5) was isolated by extracting the culture with 
acetone.5 So, we assume that the possible extraction of fungus culture with acetone could led to the 
production of hydrazone 7.11.  
 
Above study also let us to hypothesize that the reactants aldehyde and ketones used to synthesis the 
hydrazones through Schiff’s base condensation, are the biproduct of culture media (i.e., rice media) 
(Figure 7.39). To test this hypothesis, we decided to culture a number of anonymous fungus in the 
autoclaved rice media supplemented with 2-hydrazino benzoic acid (7.10) (1 mg/mL). 
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Figure 7.39: Possible source of aldehyde and ketones and formation of their corresponding hydrazones (7.11 – 7.17). 
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7.3.1 Detection of the production of hydrazones by anonymous fungus in the presence of 2-
hydrazino benzoic acid (7.10) 
According to the hypothesis, 10 different fungus from our lab were selected and allowed to grow in 
the rice medium (25 gm) for 15 days at 29 °C, with and without addition of 2-hydrazino benzoic acid 
(7.10) (25 mg) in MeOH (25 mL). The cultures were then extracted with EtOAc (50 mL), dried under 
N2 at 40 °C, suspended in MeOH (1 mg/mL), filtered and then subjected to HPLC-DAD-ESIMS 
analysis (column Zorbax C8, 4.6 x 150 mm, 5 µm, 10 – 100 % MeCN modified with 0.1% TFA, 1 
mL/min, over 20 min). Single ion extraction (SIE) successfully detected the presence of hydrazones 
7.12 [m/z = 223 (M+H)+], 7.14 [m/z = 231 (M+H)+] and 7.15 [m/z = 261 (M+H)+] by two different 
fungus treated with 2-hydrazino benzoic acid (7.10). The single ion extraction chromatograms of the 
hydrazones also confirmed with the chromatogram of synthetic standard hydrazones following the 
same HPLC-DAD-MS analysis method (Figure 7.40, 7.41 & 7.42). UHPLC-QTOF analysis of the 
extracts and generation of possible structures also confirmed the formation of hydrazones by the 
fungus in rice media supplemented with 7.10. Likewise, the absence of hydrazones in the culture of 
the fungus without 2-hydrazino benzoic acid (7.10) confirmed that 2-hydrazino benzoic acid (7.10) 
was the precursor molecule of the hydrazones.  
 
 
 
 
 
 
 
 
 
 
 
Figure 7.40: (a) Single ion extraction chromatograms at m/z = 223 (M+H)+ of the crude extract of fungus cultivated in 
rice medium in the presence of 7.10, (b) HPLC-MS chromatogram of synthetic standard hydrazone 7.12. Two peaks 
represent two isomers of 7.12. 
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Figure 7.41: (a) Single ion extraction chromatograms at m/z = 231 (M+H)+ of the crude extract of fungus cultivated in 
rice medium in the presence of 7.10, (b) HPLC-MS chromatogram of synthetic standard hydrazone 7.14. Two peaks 
represent two isomers, 7.14a and 7.14b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.42: (a) Single ion extraction chromatograms at m/z = 261 (M+H)+ of the crude extract of fungus cultivated in 
rice medium in the presence of 7.10, (b) HPLC-MS chromatogram of synthetic standard hydrazone 7.15. Two peaks 
represent two isomers of 7.15. 
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7.4 Conclusion 
In this study, we performed the synthesis and structure analysis of hydrazones 7.11 - 7.16. Further 
comparison of the NMR data of the synthetic hydrazones 7.11, 7.12 and 7.14 to the reported 
penipacids (7.4, 7.6, and 7.8) acknowledged the required rearrangements of the structure of the 
reported penipacids (7.4, 7.6, and 7.8).  
 
 
 
 
However, our study also confirmed the reactivity of 2-hydrazino benzoic (7.10) acid through the 
formation of hydrazone 7.11 and 7.17 by the acid mediated aldol-condensation of acetone, and 
hydrazones (7.12, 7.14 and 7.15) by reacting with the commonly produced aldehydes and ketones as 
the biproduct of any fungal culture in the rice medium.  
 
Literatures reported the naturally occurring anthranilic acid derived hydrazones (7.18 – 7.21),3 but 
careful analysis revealed that they are the Schiff’s base condensation product of 2-hydrazino benzoic 
acid (7.10). So, we assumed that the 2-hydrazino benzoic acid (7.10) was the only natural product, 
produced by the fungus and was converted to hydrazones by reacting with either culture media or 
naturally derived aldehyde and ketones as an artefact, during the fractionation and handling. This 
establish the fact that, any compound detected in the crude extract does not always be a natural 
product. Several examples of this phenomena are already reported, e.g. solvent-extraction mediated 
Schiff’s base formation of prolinimines.15 
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The study suggested us to search for the presence of 2-hydrazino benzoic acid (7.10) in the fungal 
crude extracts. However, the detection was not possible due to the high water solubility properties 
and small molecular weight of 7.10. A suggestive approach could be the conversion of 7.10 to be less 
polar and more visible compound. That could be possible by reacting 7.10 with a very reactive 
unnatural 2,4-dinitrobenzaldehyde that will allow the formation of Schiff base condensation product 
of 7.10 according to the proposed below (Scheme 7.10). 
 
 
 
 
7.5 Experimental 
See the Appendix I: General experimental, page 260. 
 
Anthranilic acid (7.9): Yellowish powder, UV (MeOH) lmax (log e) 215 (4.50), 278 (4.12) nm; 1H 
and 13C NMR data, see Figure 7.4 – 7.5 and Table 7.1; HRESI(+)MS m/z 138.0571 [(M+H]+ (calcd 
for C7H8NO2, 138.0550). 
 
2-hydrazino benzoic acid (7.10): Yellowish powder, UV (MeOH) lmax (log e) 215 (4.50), 278 (4.12) 
nm; 1H and 13C NMR data, see Figure 7.6 and Table 7.2; HRESI(+)MS m/z 135.0554 [(M-H2O)+H]+ 
(calcd for C7H7N2O, 135.0053). 
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Figure 7.43: Naturally occurring anthranilic acid derived hydrazones (7.18 – 7.21). 
Scheme 7.10: Synthesis of 2,4-dinitrobenzaldehyde hydrazone (7.22), (i) 2,4-dinitrobenzaldehyde, anhydrous MeOH, rt.  
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Hydrazone (7.11): Yellowish powder, UV (MeOH) lmax (log e) 215 (4.50), 278 (4.12), 340 (3.45) 
nm; 1H and 13C NMR data, see Figure 7.8 – 7.9 and Table 7.3; HRESI(+)MS m/z 273.1218 [(M+Na]+ 
(calcd for C13H18N2NaO3, 273.1210). 
 
Hydrazone (7.12): Yellowish powder, UV (MeOH) lmax (log e) 215 (4.50), 278 (4.12), 340 (3.45) 
nm; 1H and 13C NMR data, see Figure 7.14 – 7.16 and Table 7.5; HRESI(+)MS m/z 245.0539 
[(M+Na]+ (calcd for C10H10N2NaO4, 245.0533). 
 
Hydrazone (7.13): Yellowish powder, UV (MeOH) lmax (log e) 215 (4.50), 278 (4.12), 330 (3.50) 
nm; 1H and 13C NMR data, see Figure 7.19 – 7.21 and Table 7.6; HRESI(+)MS m/z 243.0747 
[(M+Na]+ (calcd for C11H12N2NaO3, 243.0740). 
 
Hydrazone (7.14): Yellowish powder, UV (MeOH) lmax (log e) 230 (3.80), 290 (5.12), 350 (4.05) 
nm; 1H and 13C NMR data, see Figure 7.23 – 7.25 and Table 7.7; HRESI(+)MS m/z 231.0765 
[(M+H]+ (calcd for C12H11N2O3, 231.0764). 
 
Hydrazone (7.15): Yellowish powder, UV (MeOH) lmax (log e) 215 (4.50), 278 (4.12), 340 (3.45) 
nm; 1H and 13C NMR data, see Figure 7.29 – 7.30 and Table 7.8; HRESI(+)MS m/z 283.0698 
[(M+Na]+ (calcd for C13H12N2NaO4, 283.0689). 
 
Hydrazone (7.16): Yellowish powder, UV (MeOH) lmax (log e) 215 (4.50), 278 (4.12), 340 (3.45) 
nm; 1H and 13C NMR data, see Figure and  7.32 -7.34 and Table 7.10; HRESI(+)MS m/z 281.0540 
[(M+Na]+ (calcd for C13H10N2NaO4, 281.0533). 
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8 Appendix I: General Experimental 
8.1 General experimental details 
8.1.1 Materials 
All the solvents used for experiments, including extraction and solvent-solvent partitioning of crude 
extracts, were of analytic grade. For HPLC use, HPLC grade solvents were used after filtering through 
0.45 µm polytetrafluoroethylelne (PTEE) filters. Deionized water filtered through Merck MilliQ 
Ultra filtration system and further filtered through 0.45 µm polytetrafluoroethylelne (PTEE) filters 
were used during purification of metabolites. Pre-prepared microbial culture media were purchased 
from BBL/Difco. Other chemicals were purchased from Sigma-Aldrich, NovaBiochem, BAChem 
Biosciences, Sigma, Fluka, or Merck. 
 
8.1.2 General experiments 
Faecal samples were in 50 mL Falcon tubes and processed under sterile conditions using a Laftech 
class II biological safety cabinet and incubated in MMM Friocell incubator or Innova 42 incubator 
shaker with temperature set between 26 °C to 30 °C as required. 24-well microbioreactor, cover clamp 
and the sandwich covers were purchased from Applikon Biotechnology. Pure strains were cryo 
preserved at -80 °C in deep freezer. During extraction and purification, solvents were evaporated 
under reduced pressure by using Buchi Rotavaps R-114, under N2 gas or Genevac EZ-2 Elite personal 
evaporator.  
 
Ultra-high-performance liquid chromatographic (UHPLC) data were obtained on an Agilent 1290 
infinity UHPLC system composed of 1290 infinity quaternary pump, thermostat, autosampler and 
diode array detector (DAD). UHPLC- QTOF analysis was performed on UHPLC-QTOF instrument 
comprising an Agilent 1290 Infinity II UHPLC equipped with a Zorbax C8 column (2.1 mm ´  50 mm, 
1.8 μm particles), running with H2O/MeCN inclusive of 0.1% formic acid coupled to an Agilent 6545 
Q-TOF. MS/MS analysis was performed on the same instrument for ions detected in the full scan at 
an intensity above 1,000 counts at 10 scans/s, with an isolation width of 4 ∼m/z using a fixed collision 
energy and a maximum of 3 selected precursors per cycle. General instrument parameters were as 
follows; Gas temperature 325 °C, Drying gas 10 L/Min, nebulizer 20 psig, sheath gas temperature 
400 °C, fragmention voltage 180 eV, skimmer 45 eV. HPLC-DAD-ESIMS data were acquired on an 
Agilent 1100 series separation module equipped with an Agilent 1100 series HPLC/MSD mass 
detector and Agilent diode array detector. Semi-preparative and preparative HPLCs were performed 
using Agilent 1100 series HPLC instruments with corresponding detectors, fraction collectors, and 
software. HRESI(+)MS spectra were obtained on a Bruker microTOF mass spectrometer by direct 
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injection in MeOH at 3 μL/min using sodium formate clusters as an internal calibrant. NMR spectra 
were acquired on a Bruker Advance 600 MHz spectrometer with either a 5 mm PASEL 1H/D–13C 
Z-Gradient probe or 5 mm CPTCI 1 H/19 F-13 C/15 N/DZ Gradient cryoprobe, controlled by 
TopSpin 4.0.2 software. In all cases, NMR spectra were acquired at 25 °C (unless otherwise specified) 
in hexadeuterated dimethylsulfoxide (DMSO-d6) and tetradeuterated methanol (methanol-d4) and 
deuterated chloroform (CDCl3) with referencing to residual [1H (δH 2.50, δH 3.31, and δH 7.24 
respectively) or 13C (δC 39.51, δC 49.15 and δC 77.23, respectively)] NMR resonances. 
Specific optical rotations ([α]D) were measured on a JASCO P-1010 polarimeter in a 100 × 2 mm cell 
at room temperature. UV of the pure compounds were measured using CARY 50 Bio UV-visible 
spectrophotometer. Crude extracts, fractions and pure compounds were preserved at -30 °C in 
SANYO biomedical freezer.  
 
8.1.3 Biological assays  
8.1.3.1 Antibacterial assays 
The bacterium to be tested was streaked onto a tryptic soy agar plate and was incubated at 37 °C for 
24 h. One colony was then transferred to fresh tryptic soy broth (15 mL) and the cell density was 
adjusted to 104-105 CFU/mL. The compounds to be tested were dissolved in DMSO and diluted with 
sterile H2O to give 600 µM stock solution (20% DMSO), which was serially diluted with 20% DMSO 
to give concentrations from 600 µM to 0.2 µM in 20% DMSO. An aliquot (10 µL) of each dilution 
was transferred to a 96-well microtiter plate and freshly prepared microbial broth (190 µL) was added 
to each well to give final concentrations of 30 – 0.01 µM in 1% DMSO. The plates were incubated 
at 37 °C for 24 h and the optical density of each well was measured spectrophotometrically at 600 
nm using POLARstar Omega plate (BMG LABTECH, Offenburg, Germany). Each test compound 
was screened against the Gram-negative bacteria Escherichia coli ATCC 25922 or ATCC 11775 and 
Pseudomonas aeruginosa ATCC 10145 and the Gram-positive bacteria Staphylococcus aureus 
ATCC 25923 and Bacillus subtilis ATCC 6633 or ATCC 6051. Rifampicin was used as a positive 
control (40 µg/mL in 10% DMSO). The IC50 value was calculated as the concentration of the 
compound or antibiotic required for 50% inhibition of the bacterial cells using Prism 8.0 (GraphPad 
Software Inc., La Jolla, CA). All experiments were performed in duplicate. 
8.1.3.2 Antifungal assays 
The fungus Candida albicans ATCC 10231 was streaked onto a Sabouraud agar plate and was 
incubated at 37 °C for 48 h. One colony was then transferred to fresh Sabouraud broth (15 mL) and 
the cell density adjusted to 104-105 CFU/mL. Test compounds were dissolved in DMSO and diluted 
with sterile H2O to give a 600 µM stock solution (20% DMSO), which was serially diluted with 20% 
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DMSO to give concentrations from 600 µM to 0.2 µM in 20% DMSO. An aliquot (10 µL) of each 
dilution was transferred to a 96-well microtiter plate and freshly prepared fungal broth (190 µL) was 
added to each well to give final concentrations of 30 – 0.01 µM in 1% DMSO. The plates were 
incubated at 37 °C for 24 h and the optical density of each well was measured spectrophotometrically 
at 600 nm using POLARstar Omega plate (BMG LABTECH, Offenburg, Germany). Each test 
compound was screened against the fungi Candida albicans (ATCC 90028 or ATCC 10231). 
Amphotericin B was used as a positive control (30 µg/mL in 10% DMSO). The IC50 value was 
calculated as the concentration of the compound or antifungal required for 50% inhibition of the 
fungal cells using Prism 8.0 (GraphPad Software Inc., La Jolla, CA). All experiments were performed 
in duplicate. 
 
8.1.3.3 Cytotoxicity (MTT) assays 
The MTT assay was performed using adherent cell lines SW620 (adherent epithelial like, human 
colorectal carcinoma) and NCI-H460 (adherent epithelial like, human lung carcinoma). All cells were 
cultured in Roswell Park memorial Institute (RPMI) 1640 medium as adherent mono-layer in flasks 
supplemented with 10% foetal bovine serum, L-glutamine (2 mM), penicillin (100 unit/mL) and 
streptomycin (100 µg/mL) in a humidified 37 °C incubator supplied with 5% CO2. Briefly, cells were 
harvested with trypsin and dispensed into 96-well microtiter assay plates at 3,000 to 4,000 cells/well, 
then incubated for 18 h at 37 °C with 5% CO2 (to allow cells to attach). Test compounds were 
dissolved in 20% DMSO in PBS (v/v) and diluted with sterile H2O to give 600 µM stock solutions. 
Aliquots (10 µL) applied to cells over a series of final concentrations ranging from 10 nM to 30 µM. 
Control wells were treated with 1% aqueous DMSO. After 48 h incubation at 37 °C with 5% CO2 an 
aliquot (20 µL) of 3-(4, 5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in 
phosphate buffer saline (PBS, 5 mg/mL) was added to each well (final concentration of 0.5 mg/mL), 
and the microtiter plates incubated for a further 4 h at 37 °C with 5% CO2. After this final incubation, 
the medium was aspirated and precipitated formazan crystals dissolved in DMSO (100 µL/well). The 
absorbance of each well was measured at 580 nm with a PowerWave XS Microplate Reader from 
Bio-Tek Instruments Inc. (Vinooski, VT). IC50 values were calculated using Prism 8.0 (GraphPad 
Software Inc., La Jolla, CA), as the concentration of analyte required for 50% inhibition of cancer 
cell growth (compared to negative controls). Negative control was 1% aqueous DMSO, while positive 
control was doxorubicin (30 µM). All experiments were performed in duplicate. 
 
 
 
